The role of priming in the regulation of cytosolic phospholipase A2 by Stewart, Allison
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
The role of priming in the regulation of cytosolic
Phospholipase A2.
Allison Stewart BSc.(Hons.)
Thesis submitted to the University of Glasgow for the 
degree of Doctor of Philosophy in the Faculty of
Science
Department of Biochemistry 
University of Glasgow 
Scotland
ProQuest Number: 10391307
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10391307
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
MlVEESm'
This thesis is dedicated to the memory of my Gran, Elizabeth Stewart, 
who was always there to talk to and who never beat about the bush with 
her opinions, and to the memory of my Di, Hugh Steel, who told me 
when very young, "Use your computer Hen, always use your
computer!".
INDEX Page No.
Contents 
List of Figures 
List of Tables 
Abbreviations 
Acknowledgements 
Summary 
Chapter 1 
Chapter 2 
Chapter 3 
Chapter 4
n
vui
xiv
XV
xvii
xix
1
53
85
115
Introduction 
Materials and Methods 
Priming of cytosolic phospholipase A%
The role of tyrosine phosphorylation in cytosolic phospholipase 
A2 priming
Chapter 5 Regulation of cytosolic phospholipase A2 by MAP kinase and 134
increased intracellular calcium concentrations 
Chapter 6 Localisation and phosphorylation state of cytosolic phospholipase 163
A2 under conditions studied 
Chapter 7 General Discussion 186
References 198
■
Î
■*/- ■ ii.
■î
CONTENTS Page No.
List of Figures vii
List of Tables xiv
List of Abbreviations xv
Acknowledgements xvü
Summary xix
CHAPTER 1 INTRODUCTION
1.1 PHOSPHOLIPID CYCLES
1.1.1 Inositolphospholipids as signalling molecules 1
1.1.1.1 The PIC-p family 2
1.1.1.2 The PlC-y family 4
1.1.1.3 The PIC-Ô family 5 I
1.1.1.4 Phosphatidyhnositol-specific 3 kinase 5 |
1.1.2 Phosphatidylcholine cycle
1.1.2.1 Synthesis of phosphatidylcholine
1.1.2.2 Hydrolysis of phosphatidylcholine
1.1.2.2.1 Agonist-stimulated PtdCho hydrolysis by PLC
1.1.2.2.2 Agonist-stimulated PtdCho hydrolysis by PLD
1.1.2.2.3 Physiollogical effects of PtdCho hydrolysis
1.2 PHOSPHOLIPASE A%
1.2.1 Secretory phospholipase A2 (SPLA2)
1.2.2 Cytosolic phospholipase A2 (CPLA2)
1.3 REGULATION OF CYTOSOLIC PHOSPHOLIPASE A2
1.3.1 Calcium
1.3.2 Phosphorylation
1.3.2.1 Protein kinase C (PKC)
1.3.2.2 Tyrosine phosphorylation
1.3.2.3 MAP kinase
i i
7 a
9 , 0.7
1 1
i
1 2 :
j
1 4 1
1
1 6
■<
1 8
%
2 1
1=
22
2 3
2 3
I
'&
4
1.3.3 GTP-binding proteins
1.3.3.1 Heterotrimeric 28
1.3.3.2 Small molecular weight 31
1.3.4 Priming 35
1.3.5 Substrate regulation 37
1.4 ROLE OF CYTOSOLIC PHOSPHOLIPASE A2 PRODUCTS
1.4.1 Lysophospholipids 38
1.4.2 Free fatty acids
1.4.2.1 From ly sophospholipase activity 40
1.4.2.2 From phospholipase A2 activity 40
1.4.3 Regulation of Protein kinase C by CPLA2 activation 43
1.5 INHIBITION OF PHOSPHOLIPASE A2 ACTIVITY 44
1.6 AGONISTS STUDIED
1.6.1 Bombesin 47
1.6.2 formyl-methyl-leucine-phenylalanine (fMLP) 48
1.6.3 Lysophosphatidic acid (LPA) 49
1.7 AIMS 52
CHAPTER 2 
2.1 
2 . 1.1 
2 . 1.2 
2.2 
2.3
2.3.1
2.3.2
2.3.3 
2.4
2.4.1
2.4.2
MATERIALS AND METHODS
CELL LINES AND MATERIALS
Cell Lines 53
Materials 53
BUFFER COMPOSITION 56
CULTURE AND PRESERVATION OF CELL LINES 
Routine culture 58
Cell passage 58
Cryogenic preservation of cell lines 59
MEASUREMENT OF ARACHIDONIC ACID GENERATION 
Preparation of samples for radioactive measurements 60
Thin Layer Chromatography 62
m
2.5 WESTERN BLOT ANALYSIS
2.5.1 cPLA2 location and phosphorylation state
2.5.1.1 Preparation of samples 63
2.5.1.2 Lysis procedure 64
2.5.1.3 TCA precipitation of samples 65
2.5.1.4 SDS-PAGE for cPLAi 65
2.5.1.5 Gel electrophoresis 66
2.5.1.6 Immunoblotting of cPLA2 66
2.5.2 MAP kinase detection and phosphorylation state
2.5.2.1 Preparation of cell lysates 67
2.5.2.2 SDS-PAGE for MAP kinase 68
2.5.2.3 Immunoblotting of SDS-PAGE gels for MAP kinase 68
2.5.3 Detection of tyrosine phosphorylated proteins
2.5.3.1 SDS -PAGE gel preparation for tyrosine phosphorylation 69
2.5.3.2 Immunoblotting of SDS-PAGE gels for Phosphotyrosine 70
2.6 MAP KINASE IN VITRO ACTIVITY MEASUREMENTS
2.6.1 Preparation of samples 70
2.6.2 MAP kinase activity measurements 71
2.7 cPLA2 in  v it r o  ACTIVITY MEASUREMENTS
2.7.1 Preparation of substrates 72
2.7.2 Assay procedure 73
2.8 MEASUREMENT OF CALCIUM RELEASE
2.8.1 Adherent cells 7 5
2.8.2 Suspension cells 75
2.9 CONFOCAL MICROSCOPY
2.9.1 Preparation of samples 76
2.9.2 Immunostaining of cells 77
2.9.3 Measurement of fluorescence intensity 7 8
2.10 CHEMICAL MEASUREMENT OF BASAL AND STIMULATED 
ARACHIDONIC ACID LEVELS
i v
2.10.1 Prep aration of samples 7 8
2.10.2 Derivatisation of free fatty acids 79
2.10.3 Gas chromatography 79
2.11 PERMEABILISATTON OF CELLS USING STREPTOLYSIN O
2.11.1 Determination of cell permeabilisation using entry of ethidium 80
bromide
2.11.2 Protocol for permeabilisation 80
2.12 MEASUREMENT OF STIMULATED INTRACELLULAR 
INOSITOL PHOSPHATE GENERATION
2.12.1 Preparation of samples 82
2.12.2 Determination of individual inositol phosphate generation 82
2.13 MISCELLANEOUS PROCEDURES
2.13.1 Activation of sodium orthovanadate 83
2.13.2 Preparation of perhydrovanadate 84
2.13.3 Analysis and presentation of results 84
CHAPTER 3 PRIMING OF CYTOSOLIC PHOSPHOLIPASE
3.1 INTRODUCTION 85
3.2 RESULTS
3.2.1 Product of cPLA2 activity 87
3.2.2 Kinetics of arachidonate release in bombesin-stimulated 88
Swiss 3T3 fibroblasts quiesced by both contact inhibition
and serum deprivation
3.2.2.1 Possible serum components which may chronically prime 89
cPLA2 in Swiss 3T3 fibroblasts
3.2.2.2 Effect of priming at the receptor-G-protein level 90
3.2.3 HL60 cells as a model to study acute priming of CPLA2 91
3.3 DISCUSSION
3.3.1 Fatty acid product of cPLA2 activation 106
3.3.2 Kinetics of arachidonate release 107
13.3.3 Possible serum components responsible for priming effect 108
3.3.4 Role of GTP-binding proteins in both chronically primed 110
and unprimed Swiss 3T3 fibroblasts
3.3.5 HL60 cells as a model of acute priming 112
CHAPTER 4 THE ROLE OF TYROSINE PHOSPHORYLATION 
IN PRIMING cPLAz
4.1 INTRODUCTION 115
4.2 RESULTS 116
4.3 DISCUSSION 129
CHAPTER 5 REGULATION OF cPLA^ BY MAP KINASE AND 
INCREASED INTRACELLULAR CALCIUM 
CONCENTRATION
5.1 INTRODUCTION 134
5.2 RESULTS
5.2.1 Manipulation of MAP kinase in Rat-1 Raf ER4 fibroblasts 135
5.2.2 Effect of acute and chronic priming upon MAP kinase 136
phosphorylation state and activity
5.2.3 Role of agonist-stimulated increased intracellular calcium 137
concentrations in the activation and priming of CPLA2
5.3 DISCUSSION
5.3.1 Activation of MAP kinase by p74^4f-I 156
5.3.2 Effect of priming upon MAP kinase phosphorylation state 158
and activity
5.3.3 Role of increased intracellular calcium concentrations 159
upon CPLA2
v i
CHAPTER 6
6.1
6.2
6.2.1
6 .2.2
6.3
6.3.1
6.3.2
CHAPTER 7
7.1
7.2
7.3
LOCALISATION AND PHOSPHORYLATION 
STATE OF CYTOSOLIC PHOSPHOLIPASE A% 
UNDER THE CONDITIONS STUDIED
INTRODUCTION
RESULTS
Localisation and phoshorylation state of cPLAi in 
chronically primed fibroblasts
Localisation and phosphorylation state of cPLA^ in acutely 
primed 5 day DMSO-differentiated HL60 cells and other human 
cells of the same lineage 
DISCUSSION
Location and phosphorylation state in fibroblasts 
Location and phosphorylation state in haemopoietic cells
GENERAL DISCUSSION  
THE IMPLICATIONS OF THE NUCLEAR LOCATION 
O FcPLA2
THE POSSIBLE PKC LOOP'
ROLE OF PHOSPHORYLATION IN THE PRIMING AND 
TRANSLOCATION OF CPLA2
REFERENCES
vu
163
165
168
180
183
186
189
192
198
LIST OF FIGURE Page No.
Fig. 1.1.1 Phosphatidylinositol cycle 3
Fig. 1.1.2 Phosphatidylcholine cycle 8
Fig. 1.1.2.2 Phosphatidylcholine hydrolysis by the phospholipases 10
Fig, 1.3.2.3 The MAP kinase cascade 25
Fig. 2.7.2 Immunoprécipitation of cPLA2 74
Fig. 2.11 Permeabilisation of Swiss 3T3 by Streptolysin O 81
Fig. 3.1(a) (i) Endothelin 1-stimulated pH]oleate release over 5min. 92
in Rat-1 fibroblasts.
(ii) Endothelin-stimulated [^Hjoleate release over 20min. 
in Rat-1 fibroblasts.
Fig. 3.1(b) Dose-dependency of Endothelin 1-stimulated [^Hjoleate
release at 30sec. stimulation.
Fig. 3.2(a) (i) Endothelin 1-stimulated pH] arachidonate release over 93
5min. in Rat-1 fibroblasts.
(ii) Endothelin 1-stimulated [^H] arachidonate release over 
20min. in Rat-1 fibroblasts.
Fig. 3.2(b) Dose-dependency of Endothelin 1-stimulated
[^H] arachidonate release at 30sec. stimulation.
Fig. 3.3(a) Bombesin-stimulated fatty acid release measured by Gas 94
Chromatography.
Fig. 3.3(b) Bombesin-stimulated arachidonate release measured by 95
Gas Chromatography.
Fig, 3.4(a) Bombesin-stimulated [^H] arachidonate release in 2% 96
quiesced Swiss 3T3 fibroblasts over 20 minutes 
Fig. 3.4(b) Bombesin-stimulated pH] arachidonate release in 10%
quiesced Swiss 3T3 fibroblasts over 20 minutes.
Fig. 3.5(a) As Fig.3.4(a) over 1 minute, 97
Fig. 3.5(b) As Fig.3.4(b) over 1 minute.
vm
,-,' r   'y':-' • ■■ -  \     r .. VV- - i - , .  „
Fig. 3.6(a) Effect of insulin upon bombesin-stimulated 98
[^H] arachidonate in 2% and 10% quiesced Swiss 3T3s
Fig. 3.6(b) Effect of LPA upon bombesin-stimulated [^H] arachidonate
release under both quiescing conditions.
Fig. 3.7 Dose-dependency of LPA-stimulated potentiation of 99
bombesin-stimulated pH] arachidonate release in 10% 
quiesced Swiss 3T3 fibroblasts.
Fig. 3.8(a) Dose-dependency of bombesin-stimulated pH] 100
arachidonate release in 2% quiesced Swiss 3T3s.
Fig. 3.8(b) Dose-dependency of this response in 10% quiesced cells.
Fig. 3.9(a) Effect of GTPyS upon bombesin (lOnM)-stimulated pH] 101
arachidonate release in 2% quiesced Swiss 3T3s.
Fig. 3.9(b) Effect of GTPyS in 10% quiesced Swiss 3T3s.
Fig. 3.10(a) Effect of GTPyS upon bombesin (lOOnM)-stimulated 102
pH] arachidonate release in 10% quiesced Swiss 3T3s.
Fig. 3.10(b) Effect of GDPpS upon bombesin-stimulated
pH] arachidonate release in 10% quiesced Swiss 3T3s.
Fig. 3.11(a) Effect of Pertussis Toxin upon bombesin-stimulated 103
pH] arachidonate release in 10% quiesced Swiss 3T3s.
Fig. 3.11(b) (i) Aluminium fluoride-stimulated [^H]arachidonate
release in permeabilised Swiss 3T3 fibroblasts quiesced in 
2% serum.
(ii) As above using 10% quiesced Swiss 3T3s.
(iii) As above using whole Swiss 3T3 fibroblasts quiesced in 
10% serum.
Fig. 3.12(a) Effect of DMSO-differentiation upon agonist- 104
stimulated [^H] arachidonate release in HL60 cells.
Fig. 3.12(b) Effect of cytochalasin B priming upon agonist-
stimulated [^H]arachidonate release in 5 day DMSO-differentiated 
HL60 cells.
IX
IF ig .3 .13(a) fMLP-stimulated pH]arachidonate release in DMSO- 105
differentiated HL60 cells.
Fig. 3.13(b) Dose-dependency of fMLP-stimulated pH]arachidonate
release in DMSO-differentiated HL60 cells.
Fig. 4.1(a) Tyrosine phosphorylation in control and cytochalasin 119
B-primed DMSO-differentiated HL60 cells.
Fig. 4.1(b) Tyrosine phosphorylation in 2% and 10% quiesced
Swiss 3T3 fibroblasts.
Fig. 4.2(a) Perhydrovanadate-stimulated pH]arachidonate release 120
in 10% quiesced Swiss 3T3 fibroblasts.
Fig. 4.2(b) Perhydrovanadate-stimulated [% ]arachidonate release
in DMSO-differentiated, cytochalasin B primed HL60 cells.
Fig. 4.3(a) Perhydrovanadate-stimulated [% ]arachidonate release 121
in primed and control DMSO-differentiated HL60 cells.
Fig. 4.3(b) fMLP-stimulated [^H]arachidonate release in
perhydrovanadate-primed DMSO-differentiated HL60 cells.
Fig. 4.4 Tyrosine phosphorylation in LPA- and Insulin-primed 122
Swiss 3T3 fibroblasts.
Fig. 4.5(a) Bombesin-stimulated tyrosine phosphorylation in 2% 123
and 10% quiesced Swiss 3T3s.
Fig. 4.5(b) Bombesin-stimulated tyrosine phosphorylation in 10%
quiesced Swiss 3T3s.
Fig. 4.6 Agonist-stimulated tyrosine phosphorylation in 2% 124
and 10% quiesced Swiss 3T3 fibroblasts.
Fig. 4.7 Effect of DMV upon bombesin-stimulated 125
tyrosine phosphorylation in 2% quiesced Swiss 3T3s.
Fig. 4.8(a) Effect of wortmannin upon baculovirus cPLAa activity. 126
Fig. 4.8(b) Effect of PtdIns-4,5-P2 upon in vitro CPLA2 activity.
Fig. 4.9 Effect of wortmannin upon in vitro CPLA2 activity, 127
immunoprecipitated from 2% quiesced Swiss 3T3 fibroblasts.
iF ig .4 .10(a) Effect of DMV upon bombesin-stimulated [^H] 128
arachidonate release in 2% quiesced Swiss 3T3 fibroblasts.
Fig. 4.10(a) Effect of DMV upon fMLP-stimulated pH]arachidonate
release in DMSO-differentiated HL60 cells.
Fig. 5.1 MAP kinase phosphorylation in control and estradiol- 140
treated Rat-1 Raf ER4 fibroblasts.
Fig. 5.2 LPA- and estradiol-stimulated tyrosine phosphorylation 141
in Rat-1 Raf ER4 fibroblasts.
Fig. 5.3(a) LPA-stimulated [% ]arachidonate release in control and 142
estradiol-treated Rat-1 Raf ER4 fibroblasts.
Fig. 5.3(b) Dose-dependency of LPA-stimulated pHjarachidonate
release in control and estradiol-treated Rat-1 Raf ER4 
fibroblasts.
Fig. 5.4 Bombesin-stimulated MAP kinase phosphorylation in 143
2% and 10% quiesced Swiss 3T3 fibroblasts.
Fig. 5.5 MAP kinase phosphorylation state in DMSO- 144
differentiated HL60 cells
Fig. 5.6 Bombesin-stimulated in vitro MAP kinase activity in 146
10% quiesced Swiss 3T3 fibroblasts.
Fig. 5.7(a) fMLP-and cytochalasin B-stimulated increased 147
calcium concentrations.
Fig. 5.7(b) Perhydrovanadate-stimulated increased calcium
concentrations.
Fig. 5.8(a) Effect of BAPTA-AM upon bombesin-stimulated 148
pH]arachidonate release in Swiss 3T3 fibroblasts.
Fig. 5.8(b) Effect of BAPTA-AM upon LPA-stimulated pH]
arachidonate release in Rat-1 Raf ER4 fibroblasts.
Fig. 5.9 Bombesin-stimulated increased calcium concentrations in 149
2% and 10% quiesced Swiss 3T3 fibroblasts.
XI
Fig. 5.10 Effect of BAPTA-AM upon bombesin-stimulated calcium 150
concentrations in 10% quiesced Swiss 3T3 fibroblasts.
Fig, 5.11(a) LPA-stimulated calcium concentrations in Rat-1 Raf ER4 151
fibroblasts.
Fig. 5 .11(b) LPA-stimulated calcium concentrations in estradiol-treated
Rat-1 Raf ER4 fibroblasts.
Fig, 5.12 Estradiol-stimulated calcium concentrations 152
Fig. 5.13 LPA-stimulated intracellular inositol phosphate
generation (a) IPi (b) IP2 153
(c) IP3 (d) IP4 154
(e) IP5/6 155
Fig. 6.1(a) Localisation of CPLA2 in Swiss 3T3 fibroblasts 169
Fig. 6.1(b) Localisation and phosphorylation state of CPLA2 in
Swiss 3T3 fibroblasts quiesced under both conditions.
Fig. 6.2(a) Localisation of CPLA2  by confocal microscopy in 2% 170
quiesced Swiss 3T3 fibroblasts.
Fig. 6.2(b) Localisation of CPLA2 by confocal microscopy in 10% 171
quiesced Swiss 3T3 fibroblasts.
Fig. 6.3(a) Phosphorylation state of CPLA2 in control and estradiol- 172
treated Rat-1 Raf ER4 fibroblasts.
Fig. 6.4(b) Localisation and phosphorylation state of CPLA2 in control
and estradiol-treated Rat-1 Raf ER4 fibroblasts.
Fig. 6.5(a) Localisation of CPLA2 by confocal microscopy in Rat-1 173
Raf ER4 fibroblasts.
Fig. 6.5(b) Localisation of CPLA2 by confocal microscopy in 174
estradiol-treated Rat-1 Raf ER4 fibroblasts.
Fig. 6.6 Qualitative measurement of immunofluorescence 176
Fig. 6,7 Polarisation of CPLA2 by confocal microscopy in estradiol- 177
treated Rat-1 Raf ER4 fibrobalsts.
xu
Fig. 6.8(a) Phosphorylation state of CPLA2 in DMSO-differentiated
HL60 cells.
Fig. 6.8(b) Localisation of CPLA2 in DMSO-differentiated HL60 cells.
Fig. 6.9(a) Detection of CPLA2 in human germinal centres.
Fig. 6.9(b) Detection of CPLA2 in B-and T-cell lines.
Fig. 7.1 Possible regulation of a nuclear associated CPLA2 .
Fig. 7.2 A possible CPLA2-PKC regulation loop.
Fig. 7.3 How CPLA2 maybe primed.
%
Ï
1
178 1
■179 ?i
1
190 1
193
196 b
1
-17
'1
■
1
,.51■1•1
>
xiu
LIST OF TABLES Page No.
Table 5.1 In vitro MAP kinase activities in control and primed cells. 145
Table 6.1 Quantitative immunofluorescence measurements 175
I
if
I
I
I
,1
XIV
\ - : .L '
ABBREVIATIONS
APS
ATP
BAPTA-AM
BCA
CaCl2
CaLB
cPLA2
CDP
CTP
DABCO
DAG
DBG
DMEM
DMSO
DMV
DTP
EOL
EDTA
EGTA
ERK
fM L P
GDPpS
GTPyS
HCl
HIPCS
HRP
10% (w/v) Ammonium persulphate 
Adenosine 5'-triphosphate
l,2-bis-(0-Aminophenoxy)-ethane-N,N,N',N'-tetraaceric acid tetra-
(acetoxymethyl)-ester
Bicinchoninic acid
Calcium chloride
Calcium-phospholipid binding site 
Cytosolic phospholipase A2 
Cysteine diphosphate 
Cysteine triphosphate 
l,4Diazabicyclo[2.2.2.] octane 
Diacylglycerol
DMEM with Hepes, glucose and BSA
Dulbecco's Modified Eagle Medium
Dimethyl Sulfoxide
Demethoxyviridine
DL-Dithiothreitol
Enhanced chemiluminescence
Ethylenediaminetetraacetic acid
Ethylene glycol-bis (p-aminoethyl ether) N, N, N', N'-tetraacetic 
acid
Extracellular regulated kinase 
formylMethylLeucinePhenylalanine 
Guanosine 5'-0-(2-thiodiphosphate)
Guanosine 5'-0-(3-thiotriphosphate)
Hydrochloric acid 
Heat-inactivated foetal calf serum 
Horseradish peroxidase
XV
■Î-.
'
. 1
IP3 Inositol-1,4,5-trisphosphate
IJP20 cyclic AMP-dependent protein kinase inhibitor :
KCl Potassium chloride Î
L ia Lithium chloride 1
LPA Lysophosphatidic acid 1
MARK Microtubule-associated protein kinase ,55:
MgQ2 Magnesium chloride 337
NaCl Sodium chloride . 7
NaF Sodium fluoride
NaOH Sodium hydroxide 13
NaPPi Sodium tetrapyrophosphate 7
3"
NaTB Sodium tetraborate 1;1
NBCS Newborn calf serum 1
NFM Non-fat milk " 'w
PAGE Polyacrylamide gel electrophoresis f
PAP Phosphatidic acid phosphohydrolase 7
PBS Phosphate buffered saline
PC-PLC Phosphatidylcholine-specific phospholipase C 1
PIC Phosphatidylinositol-specific phospholipase C
PIP2 Phosphatidylinositol-4,5-bisphosphate 1
PKC Protein kinase C i
PLD Phospholipase D
7 : :
PMSF Phenylmethylsulfonyl fluoride
RBG RPM I1640 with Hepes, glucose and BSA ■57
s.d. standard deviation 3
SDS Sodium Lauryl sulphate 1
SPLA2 secretory phospholipase A2
TCA Trichloroacetic acid -A
TEMED N, N, N', N'-Tetramethylethylenediamine 7
TPA Phorbol ester 3
xvi ,|
Acknowledgements
I would like to thank the Head of Department of the Biochemistry Department, 
University of Glasgow and the Department of Clinical Oncology, Institute for Cancer 
Studies, University of Birmingham for allowing me the bench space in order to carry out 
the work for this Ph.D. Thesis. My appreciation must be extended to my supervisor. 
Professor Micheal J.O.Wakelam for his help and advice throughout my time in the Lab. 
in both my undergraduate and graduate years. A big hug must also go to his smashing 
kids, Alexander and Patrick, who kept me amused for hours when babysitting. Thanks 
must also be sent to my industrial supervisor, Dr.Clive Jackson for his additional advice 
and use of Fison's money both for consumables and sponsership. If it wasn't for the 
anti-cPLA2 antibody, there wouldn't have been a Thesis!
I have been lucky enough to work with great people in two different parts of the 
country. My heart remains in Glasgow, where I was lucky enough to work beside 
people like Dr.Graeme 'G-protein' Milligan and Dr. Maggie Harnett. A special hug must 
go to Dr.Bill Cushley, who was a great advisor....well, hopefully I can still say this after 
my Viva, if he can get away from changing nappies! Congratulations! Before I go any 
further a great big Tm not worthy' must go to the Biochemistry Secretaries, especially 
Janet and Sadie. A great big thank you must go to all members of the Lab. in Glasgow, 
past and present. A special mention must be given to wee Sand, who kept us all in order 
in the everyday running of the group, and who was a great friend to me. Finally, there ;■
was my big brother, Andy Paul. Nothing more need be said, except thank you. To the
.■Î
original member of the 'sad gang’, Dr. Fraser MacCallum a great big hug and all the best 
for the future.
At Birmingham, I must thank Professor David Kerr for his welcome and I can't :
hold the fact that he is a Partick Thistle supporter against him. Much appreciation must 
go to Dr.Trevor Pettitt for the work on the GC Mass Spec, and for trusting me to actually
'use it. In Immunology, Professor J.Gordon and Ian MacDonald must be acklowledged 
for introducing me to Germinal centres. Dr.G.Johnston and Dr.J.Lord must be thanked 
for their help on the confocal Microscopy, as well as Dr.S.Roberts of Cancer Studies. In
x v i i
77'
I
Pharmacology, I must thank everyone for their help in the calcium measurements, 
especially Mike Finney and Gillian. A big special thanks to Professor R.Michell's group 
for letting me 'borrow' a lot of stuff from their laboratory...Sarah and Andy especially.
All members of the new look group in Birmingham must be thanked for their support 
throughout my time there.
Finally, I want to give a very special thank you to the following people. First,
Anne Henderson, Karen Fordyce, Alison Blake and Moira McCulloch who have been 
friends from Larkhall Academy and even though we don't see each other very often, we 
know we can always call on each other for help whenever we need to. Secondly,
■■V,
Dr.Matt Hodgkins, who has been a great friend as well as a postdoc. Thanks for 
listening. Thirdly, Dr.Celia Briscoe. She is a great friend and a great cook. I wish I was 
as organised as you are. See you in Japan or San Diego...whichever comes first.
The last collègue to be acknowledged deserves a paragraph all to himself. One of 
the original 'sad gang', Michael J.Cross has saved me from myself on many occassions 
and has shared the long hours in the Laboratory. We kept Mamma Mia's Pizza and the 
Golden Bowl Chinese resturant in buisness, not to mention the local Off License...! will 
miss him very much, but I wish him all the success in the world with both his new job 
and the 'babes' in Sweden....keep those phone calls coming! Just remember it's a little 
more expensive from Sweden to Japan.
To meine grosse Schwester, Anja Wanner, I cannot say how much of a support
she has been to me over the last 13 years it's amazing how two people are paired up
together because they are only children and have a love of dogs! My german may not 
have improved over the years, but I’ve gained a sister and a lot of abuse from her English 
teachers, since she has picked up a wonderful Scottish accent. Last but not least a big 
special "How have you put up with me?" must go to my parents, who have been 
supportive both emotionally and financially over the last 7 years of University. They may 
have thought I was daft to give up a Job to go to University, but they never said 
anything. I just want to say how wonderful they are for giving me the opportunity to 
everything I have done in my life to date. Hopefully I can repay you a little in the years to 
come.
...x v iu
.:3I
SU M M A R Y
.'yî-ÿ;;
SUMMARY
Work carried out in this Thesis tried to elucidate the factors involved in the 
regulation and priming of cytosolic phospholipase A% (CPLA2).
The 85 kDa CPLA2 originally identified and purified from U937 cells (Clark et al, 
1991) was shown to be present in Rat-1 Raf ER4 fibroblasts, Swiss 3T3 fibroblasts and 
HL60 cells. This enzyme was shown to be acutely primed by cytochalasin B in 5 day 
DMSO-differentiated HL60 cells and chronically primed by serum in Swiss 3T3 
fibroblasts. These priming agents increased tyrosine phosphorylation, which did not 
result in arachidonate release, but enhanced subsequent agonist-stimulated arachidonate 
release. This increased tyrosine phosphorylation did not enhance the known regulatory 
moieties of cytosolic phospholipase A2 , such as MAP kinase (Lin et a l, 1993), calcium 
(Channon & Leslie, 1990) and GTP-binding proteins (Cockcroft, 1992), therefore 
suggesting that an additional factor was involved in both the acute and chronic priming of 
CPLA2,
However, all of the above had a role to play in the regulation of CPLA2. GTPyS 
did not enhance agonist-stimulated arachidonate release; however, a GTP-binding protein 
was involved in both LPA- and bombesin-stimulated arachidonate release as GDPpS 
inhibited both agonist-medited responses. -stimulated MAP kinase activity
enhanced LPA-stimulated arachidonate release, but did not stimulate arachidonate release 
alone, demonstrating that an additional agonist-stimulated signal was required. LPA, 
bombesin and fMLP all stimulated an immediate increase in intracellular calcium 
concentrations in their appropriate cells. The calcium chelator BAPTA inhibited agonist- 
stimulated arachidonate release to varying degrees in the cells studied, suggesting that 
calcium is essential for maximal agonist-stimulated arachidonate release. Channon & 
Leslie (1990) demonstrated that increased calcium concentrations resulted in a 
translocation of CPLA2 from the cytosol to a membrane fraction. Under all priming 
conditions, western blotting demonstrated that there was a translocation of 
phosphorylated CPLA2 from the cytosol to a membrane fraction, although there was no 
increased calcium concentrations. Therefore, calcium was not responsible for the 
translocation of the enzyme, but was essential for maximum arachidonate release. The
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membrane fraction to which CPLA2 translocated under both priming and agonist 
stimulation was shown to be in the nuclear area and not the plasma membrane as had been 
suggested. In the fibroblastic cell lines and HL60 cells, CPLA2 was expressed under all 
conditions studied. However, there was a differential expression of CPLA2 in B- 
lymphoid cell lines representative of distinct stages in B-lymphocyte development
Therefore, work presented within this Thesis will try to examine the regulation 
and priming of cytosolic phospholipase A2 in both the adherent and suspension cells 
studied. The involvement of the factors responsible will be discussed in relation to the 
nuclear location of the enzyme, compared to the predicted plasma membrane location.
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CHAPTER 1
INTRODUCTION
f
:
1 .1  PHOSPHOLIPID CYCLES
Agonist stimulation of cells has been shown to activate a number of 
phospholipases generating a range of messenger molecules, the properties of which 
are reviewed below.
1 .1 .1  Inositol phospholipids as signalling molecules
Phosphatidylinositol (Ptdlns) is synthesized de novo by a Ptdlns synthase 
activity that catalyzes phosphatidyl transfer from CMP-phosphatidate to inositol. The 
site of this Ptdlns synthase activity has been shown to be predominately the 
endoplasmic reticulum (Imai & Gershengom, 1987), but activity has also been 
demonstrated in the plasma membrane (Cubltt & Gershengom, 1989), which is 
thought to correspond to the distribution of Ptdlns between different cell membranes. 
After various déacylation/ reacylation steps, a Ptdlns complement is produced which is 
dominated by the 1-stearoyl, 2-arachidonyl species (Darnell et a l, 1991; Darnell & 
Saltiel, 1991).
A potential signalling role for inositol-derived lipids was first recognized in the 
1950’s, when Hokin & Hokin (1953) demonstrated that the muscarinic cholinergic 
agonists, acetylcholine and carbamylcholine, could stimulate the incorporation of 
[32p]pi into a total phospholipid fraction of pigeon and duck pancreatic slices. 
Analysis of deacylated lipids showed the agonist-sensitive molecule to be 
"diphosphoinositide" (Dawson, 1954), which was subsequently identified as 
phosphatidylinositol (Hokin & Hokin, 1958). Michell (1975) proposed the
'Phosphatidylinositol response', where the turnover of Ptdlns was inextricably linked 
to intracellular calcium mobilization. Kirk et a/.(1981) and Creba et £z/.(1983) 
demonstrated that it was in fact phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) 
that was specifically degraded upon agonist stimulation. PtdIns-4,5-P2 is synthesized 
by the sequential action of two MgATP-dependent inositol lipid kinases: Ptdlns 4- 
kinase, which acts upon Ptdlns to generate PtdIns-4-P and PtdIns4P 5-kinase, which 
phosphorylates PtdIns-4-P to PtdIns-4,5-P2 (for review see Carpenter & Cantley,
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1990)[Fig. 1.1.1]. These lipids and the enzymes responsible for their synthesis have 
been found to be associated with the endoplasmic reticulum (Helms et aL, 1991), 
nuclear fractions (Payrastre et al., 1992) and the plasma membrane to generate the 
agonist-sensitive pools of PtdIns-4 ,5 -P2 . These different locations may suggest an 
involvement of PtdIns-4 ,5 -P2 in multiple cellular functions.
Two agonist-stimulated enzymes which utilize PtdIns-4 ,5 -P2 as a substrate are 
phosphoinositidases C (PICs), which generate inositol-1 ,4,5-trisphosphate (Ins- 
1,4,ti-Pg) and diacylglycerol (DAG)(Berridge, 1987; Whitman & Cantley, 1988), and 
phosphoinositide 3-kinases (PI3Ks), generating PtdIns-3,4,5-Pg (Hawkins et al., 
1992; Stephens et al., 1993)(see Section 1.1.1.4). Streb er aZ.(1983) demonstrated 
that Ins-1,4,5-Pg triggers the release of calcium from intracellular stores, via specific 
receptors (Ross et al., 1989) and DAG release activates various protein kinase C 
isozymes, as described in Section 1.3.2.1 (Nishizuka, 1986).
Three families of PIC have been identified, p, y and 5, within which there are 
several subtypes. Surprisingly, there are only two regions of homology shared by 
these three families, termed the X and Y regions, which comprise of 150 and 240 
amino acids respectively (Rhee et al., 1991).
1 .2 .1 .1  The PIC-P family
This family contains four members, PIC-pi (150-154 kDa), -P2 (134kDa), - 
P3 and -p4, which are shown to be regulated by heterotrimeric G-proteins. Taylor & 
Exton (1987) initially purified the G-protein responsible from liver, which was found 
to belong to the Gq class of G-proteins (Taylor et al., 1990). The G q family 
comprises at least five G-proteins, G q, G n , G 14, G15 and G16 (Simon et al, 1991). 
G aq purified from a py-affinity gel was found to stimulate PIC-pi but not PIC-p2 
(Park et al., 1992) and G a i6 , when expressed in Cos-7 cells was most effective in 
reconstituting with PIC-p2 (Lee et al., 1992), suggesting there is a specificity to the 
coupling, perhaps producing the first level of distinction between which signalling 
pathways are activated. The newest member of this family, PIC-p4,
Hgure 1.1.1 The phosphatidylinositol cycle
This figure is pictorial representation of the phosphatidylinositol cycle. The 
double-headed arrows ( ^  ^  )represent reversable kinase/ phosphatase
reactions to produce the phosphatidylinositol moieties demonstrated, for 
example PtdIns(3,4)P2 represents phosphatidylinositol phosphorylated upon
positions 3 and 4 of the inositol ring. Highlighted in red is 
phosphatidylinositol 3-kinase, which has been shown to be important in 
various pathways as described in section 1.1.1.4. The substrate of this enzyme 
is phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), which is hydrolysed
by f id lns-spec if ic  Phospholipase C /Phosphatidase C ( P I O  to produce the 
intracellular calcium  m uhihser inositol-1 .4.5 trisphosphate ( Inst 1.4 .5 iPg) and
the protein kinase C (PKC) activator diacylglycerol (DAG).
Figure 1.1.1 Phosphatidylinositol cycle
Ptdlns3P ^  ►Ptdlns(3,4)P2
tdlns 3-kinase
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Phospholipase C
lns(1 ,4,5)P3 + Diacylglycerol (DAG)
PKC activationIntracellular calcium
was purified, cloned and sequenced from bovine retina (Lee et al., 1993; Lee et al., 
1994b) and bovine cerebellum (Min et a l, 1993). The mRNA encoding this enzyme 
is also found in high concentrations within mature rat brain (Tanaka and Kondo, 
1994). Like the other members of the family, PIC-p4 is activated by Gq (Jiang et a l,
1994), but differs in that it shows no preference for any of Gq a  subunits and is not 
activated by py subunits (Lee et al., 1994a). However, this PIC-P isozyme is 
inhibited by ribonucleotides, which are thought to harness the activity of this enzyme, 
which is 4-5 fold higher than that of the other 3 P isozymes in vitro (Lee et a l ,  
1994a).
1 . 1 .1 . 2  The PIC-Y family
This family consists of PlC-yl (145 kDa) and -y2 (146 kDa), which are 
differentially expressed in cells, with the initial purification being from bovine brain 
(Suh et a l, 1988a), HL60 cells, spleen and lung (Ohta et a l, 1988; Emori et a l.
1989; Banno et al., 1990; Homma et a l, 1990). PlCys contain SH2 and SH3 -
domains, which are homologus to the products of various tyrosine kinase-related
oncogenes, such as src, ab l,fes, tck and crk (Mayer et a l, 1988). PlC-yl is a
substrate for receptor protein-tyrosine kinases, such as EGF and PDGF (Margolis et
al., 1989; Meisenhelder et al., 1989; Nishibe et a l, 1989; Wahl et a l, 1989).
However, not all receptor tyrosine kinases, e.g. insulin, phosphorylate PlC-yl
(Downing et a l, 1989; Nishibe et a l, 1990a). PIC-yl is found in the cytosol in
unstimulated cells, however upon EGF and PDGF stimulation there is translocation of
the enzyme to a membrane fraction, which is dependent upon the affinity of the
.phosphorylated tyrosine residues upon the receptor for the SH2 domains of PIC-yl 
(Kim et a l, 1990b; Todderud et a l,  1990). The PICy is then phosphorylated 
(Nishibe et a l, 1990b). PIC-yl is phosphorylated on Tyr 771, 783, 1254 and to a 
lesser extent, Tyr-472, upon EGF and PDGF stimulation (Kim et a l, 1990a; Wahl et 
a l,  1990); of these Tyr-783 and Tyr-1254 are essential for activation (Kim et a l,
1991b). PIC-yl can also be phosphorylated by cyclic AMP-dependent protein kinase
(PKA) on serine-1248 (Oiashaw et a l, 1990), which does not affect the activity of the 
enzyme in vitro (Granja et aL, 1991), but does inhibit subsequent agonist stimulation 
in vivo (Kim et a l, 1989). This suggests that the interaction of PIC-yl with the
activating receptor is affected by PKA-dependent phosphorylation. Inhibition of PIC-
yl activity by phosphorylation on serine-1248 by protein kinase C (PKC) has also 
been demonstrated (Park et a l,  1992), but this is dependent on the system studied 
(Ward & Cantrell, 1990). PIC-y2 has been shown to be regulated in a similar way 
(Sultzman et al., 1991; Totzke et al., 1992), but does not contain a tyrosine residue 
equivalent to Tyr-1254 of PIC-yl.
1 . 1 .1 . 3  The PIC-6 family
This family contains PIC-61 (85 kDa), -62 (85 kDa) and -63 (84 kDa) and 
were initially purified from rat brain (Homma et al., 1988; Suh et al., 1988b), bovine 
brain (Meldrum et al., 1989; Meldrum et al., 1991) and human fibroblasts (Kntz et 
al., 1990) respectively. The regulation of this family of PIC's remains to be clarified.
i
1 . 1 . 1 . 4  Phosphatidylinositol-specific 3-kinase
Two families of agonist-stimulated Ptdlns 3-kinases have been identified. One 
is regulated by tyrosine kinases and consists of a p85 regulatory subunit and a p i 10 
catalytic subunit (Carpenter et al., 1990). This Ptdlns 3-kinase binds to activated 
tyrosine kinase receptors, such as PDGF, via a SH2 domain present within the 
regulatory p85 domain (Escobedo et al., 1991). This association with the activated 
PDGF receptor does not lead to phosphorylation of Ptdlns 3-kinase (Backer et al.,
1992). This suggests that the association with the membrane, via a CaLB domain
subunit phosphorylating the p85 subunit on serine-608 (Carpenter et al., 1993; Dhand 
et al., 1994), leading to a decrease in the Ptdlns 3-kinase activity. However, Lam et
d.
within the p i 10 subunit (End etal., 1993), is essential for activity (Varticovski etal.,
1991). This form of Ptdlns 3-kinase is a dual specificity enzyme, with the p i 10
al. (1994) have shown that this intrinsic serine/threonine kinase activity can also
'phophorylate insulin receptor substrate 1.
I
A G-protein regulated Ptdlns 3-kinase (215kDa) has also been identified 
(Stephens et al., 1994). FMLP- and ATP-stimulated Ptdlns 3-kinase in U937 
myeloid cells involves a pertussis toxin sensitive G-protein, perhaps a member of the 
Gi family (Stephens et al., 1993), and py subunit-mediated activation (Morris et al.,
1995). However, GTP-binding proteins have also been shown to be involved in 
p85/pllO Ptdlns 3-kinase activation, as the majority of the GTP-sensitive Ptdlns 3- 
kinase activity, which had been attributed to the 215kDa Ptdlns 3-kinase, could be 
immunoprecipitated by anti-p85 monoclonal antibodies, even though no similarities 
between the two forms have been found (Thomason et al., 1994). This could be 
explained by the small molecular weight GTP-binding proteins ras and rho. rho has 
been shown to be essential for GTPyS- (Zhang et al., 1993) and LPA-stimulated 
(Kumagai et al., 1993) p85/pl 10 Ptdlns 3-kinase activity. Rodriguez-Viciana et al.
(1994) and Kodaki et al. (1994) identified the direct interaction of GTP-bound ras 
with p85/pllO Ptdlns 3-kinase. This was substantiated by expression of N17 
dominant negative ras leading to a 5-fold decrease in the levels of PtdIns-3 ,4 ,5 -P3 
induced by EGF (Rodriguez-Viciana et al., 1994). Therefore, both heterotrimeric and 
small molecular weight G-proteins maybe involved in the activation of Ptdlns 3-kinase 
activity.
The activation of this enzyme has been shown to be involved in cell growth, 
chemotaxis, intracellular trafficking of the platelet-derived growth factor receptor, 
respiratory burst generation in neutrophils, insulin-stimulated glucose transport in 
adipocytes and the membrane ruffling response of fibroblasts to mitogens (Joly et al,
1994; Kundra et al., 1994; Okada et al., 1994; Roche et al., 1994; Wennstrom et al.,
1994). PtdIns-3 ,4 ,5 -P3 is the product of Ptdlns 3-kinase activity (Stephens et al.,
1993) and has been implicated in the regulation of the GTP-state of the small 
molecular weight G-protein rac (Wennstrom et al., 1994). rac is the common factor in :membrane ruffling (Ridley et al., 1992) and superoxide generation in neutrophils
1 . 1 .2  Phosphatidylcholine cycle
As described above, cell activation triggers a phosphatidylinositol cycle. In
I
(Segal & Abo, 1993), which are stimulated by Ptdlns 3-kinase. Evidence has also 
been presented that suggests that PtdIns-3 ,4 ,5 -P3 can activate Ca^^-insensitive PKC 
isozymes (Nakanishi et al., 1993; Toker et aL, 1994).
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1989, Pelech & Vance proposed a cycle involving the most abundant phospholipid in 
eukaryotic cells, phosphatidylcholine (PtdCho). The PtdCho cycle exhibits several 
features as compared with the Ptdlns cycle:
1. The PtdCho pool is 5 times greater than that of phosphatidylinositols.
2. The resynthesis of phosphatidylcholines from diacylglycerols only needs 
one step instead of 5 for phosphatidylinositol-4,5-bisphosphate synthesis.
3. This resynthesis needs less energy, with only one CTP molecule being 
required to re synthesize one PtdCho from one phosphocholine, whereas one 
CTP and 3 ATP are needed to produce 1 molecule of phosphatidylinositol-4,5- 
bisphosphate.
These differences strongly suggest a specific role for a phosphatidylcholine cycle in 
the signal transduction cascade [Fig. 1.1.2].
1 . 1 . 2 . 1  Synthesis of phosphatidylcholine (PtdCho)
Three enzymatic steps are required for the de novo synthesis of PtdCho in 
what is termed the Kennedy pathway. The enzymes involved are successively choline 
kinase, CTP:phosphocholine cytidylyltransferase and choline phosphotransferase. 
Choline kinase is located within the cytosol and is responsible for phosphorylating 
choline, to produce phosphocholine. Choline phosphotransferase is located within the 
particulate fraction and is responsible for transferring CDP-choline onto diacylglycerol 
to produce phosphatidylcholine (for reviews of these two enzymes see Cornell, 1989 
and Ishidate, 1989). The rate-limiting enzyme within this pathway is 
CTP:phosphocholine cytidylyltransferase (CT), which has been detected in both the
I
Figure 1.1.2 The phosphatidylcholine cycle
This is a schematic diagram of the phospyhatidylcholine cycle. The enzymes 
involved include:
PAP=phosphatidic acid phosphohydrolase 
DAGK=diacylglycerol kinase 
PLC=phospholipase C 
PLD=phospholipase D.
This reaction involves the utilisation of one CTP (cysteine triphosphate) 
molecule, which is converted to CDP (cysteine diphosphate).
> i and Phosphocholine are recycled.
Figure 1.1.2 Phosphatidylcholine cvcle
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cytosol and in the membranes. This enzyme catalyzes, in the presence of CTP, the 
transformation of phosphocholine to CDP-choline which is not reversible in vivo 
(Choy et al., 1977), as the cell concentrations of CDP-choline and pyrophosphate are 
too low (Vance, 1989). The native enzyme exists as a non-covalently linked dimer, 
comprising of two 42kDa subunits (Cornell, 1989), and requires a mixture of fatty 
acids/phospholipids for activity in vivo, with negatively charged phospholipids, such 
as phosphatidylserine or phosphatidylinositols, producing the highest CT activity 
(Feldman et al., 1978; Feldman et al., 1985; Cornell & Vance, 1987). This 
requirement for activity would suggest that the enzyme is only active while associated 
with a membrane, therefore, the enzyme which has been detected within the cytosol is 
probably in the inactive form (Vance & Pelech, 1984). The active form of this enzyme 
is located in the Golgi, endoplasmic reticulum and the nuclear envelope (Vance & 
Vance, 1988; Morand & Kent, 1989; Jamil et al., 1990; Yao et al., 1990; Wang et al.,
1993).
The major event in CT regulation is its membrane translocation (Sleight & 
Kent, 1980). This is mediated by CT phosphorylation and the enzyme only associates
with membranes when phosphorylated (Watkins & Kent, 1991; Hatch et al., 1992).
.The identity of the protein kinase involved has still to be determined. Diacylglycerol 
also increases the association of CT to the membrane targets (Kolesnick & Hemer,
1990), however, the mechanism is still unknown, but it has been suggested that DAG 
may act directly upon CT, or modify the membrane hydrophobicity to allow CT 
interaction (Utal et al., 1991). This also raises the possibility that DAG activates an 
isoform of PKC, which may be the unidentified protein kinase involved.
1 . 1 .2 , 2  Hydrolysis of phosphatidylcholine
PtdCho hydrolysis by PLA2 , PLC or phospholipase D (PLD) is a widespread 
response elicited by most growth factors, cytokines, neurotransmitters and hormones 
(MacNulty etal., 1990; Lin et al., 1991; Cockcroft, 1992)[Fig.l. 1.2.2]. In general, 
the agonists that hydrolyze PtdCho also promote PtdIns-4 ,5 -P2 hydrolysis generating
i
Figure 1.1.2.2 Hydrolysis of phosphatidylcholine by the
phospholipases.
The abbreviations used in this diagram include:
Rl=fatty acid chain attached to the sn-1 position of the diacylglycerol 
backbone
R2=fatty acid chain attached to the sn~2 position of the diacylglycerol 
backbone
PL A i=phospholipase Ai
PLA2=phospholipase A2
PLC=phospholipase C 
PLD=phospholipase D
The arrows indicate the site of action of each of the phospholipases, with the 
diacylglycerol backbone being outlined in black.
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a biphasic increase in DAG, with an initial rapid, transient peak followed by a more 
sustained accumulation (Exton, 1990). The initial DAG peak is due to Ptdlns 
hydrolysis (Pettitt & Wakelam, 1993) and the second to PtdCho hydrolysis (Cook et 
a i, 1991). It has also been demonstrated that although PtdCho is the major source of 
the second phase DAG (Zeisel, 1993), some Ptdlns hydrolysis continues and in some
cells the major source of this phase of DAG is phosphatidylethanolamine 
(PtdEth)(Kester et al., 1989; Kiss & Anderson, 1990; Kiss, 1992).
1 . 1 . 2 . 2 . 1  Agonist-stimulated PtdCho hydrolysis by phospholipase C
IIt was initially thought that PtdCho hydrolysis in response to agonists mainly resulted from activation of phospholipase A2 and C, since the products observed were 
arachidonic acid (AA) and diacylglycerol (DAG). The activation and regulation of 
PLA2 will be discussed in more detail in sections 1.2 and 1.3.
A PtdCho-PLC has been partially purified from heart cytosol (Wolff & Gross,
1985), seminal plasma (Sheikhnejad & Srivastava, 1986), and U937 promyelocytes 
(Clark et al., 1986). These appear to be different isoforms as the enzyme in heart was 
stimulated by calcium, but the one from the seminal fluid was unresponsive to this 
divalent cation (Hinkovska-Galchev & Srivastava, 1992). Both forms are responsive 
to magnesium (Xie & Dubyak, 1991). This enzyme has been suggested to be 
regulated by an unidentified GTP-binding protein (Billah & Anthes, 1990; Exton,
1990; Cockcroft, 1992). Choudhury et al.(1991) demonstrated that colony 
stimulating factor (CSF-l)-stimulated PtdCho-PLC activity in NIH 3T3 fibroblasts
Iwas pertussis toxin sensitive, suggesting the involvement of a member of the Go/Gi 
family. However, this group also demonstrated that a large proportion of the activity 
measured could be immunoprecipitated with anti-phosphotyrosine antibodies. This 
activity was abolished upon phosphatase treatment, strongly implying a role for 
tyrosine phosphorylation in the activation of PtdCho-PLC, however, whether this is 
due to direct or indirect regulation by a tyrosine kinase has still to be elucidated. One 
possibility, is the activation of the MAP kinase cascade by ras, which has been shown
to stimulate PtdCho-PLC activity in NIH 3T3 fibroblats (Lopez-Barahona et al, 1990; 
Cai et al., 1992; Fu et al., 1992). However, all these studies used phosphocholine 
production as a measure of PtdCho-PLC activity, which could in fact have been a 
measure of choline kinase activity upon the product of PtdCho-phosphoiipase D- 
mediated hydrolysis of PtdCho, choline. Choline kinase is also stimulated by ras 
(Macara, 1989),
1 . 1 .2 . 2 . 2  Agonist-stimulated PtdCho hydrolysis by phospholipase D
The recognition that PLD is a major enzyme involved in PtdCho hydrolysis, 
came from the observation that accumulation of phosphatidic acid (PA) sometimes 
proceeds that of DAG and that much of the DAG arises due to the action of 
phosphatidate phosphohydrolase (PAP) on PA (for a review of PAP see Martin et al.,
1994). A major break through in the ability to study PLD specifically, was the 
observation that PA produced by PLD hydrolysis of PtdCho is "trapped” by 
increasing addition of a primary alcohol, such as butanol or ethanol. These primary 
alcohols are stronger nucleophiles than the physiological water molecule, so producing 
phosphatidylalcohol (Bonser et al., 1989). Unlike PA, this molecule is not a substrate 
for PAP, so accumulates in the cell. This unique ability displayed by PLD is termed 
transphosphatidylation, which has been shown to occur in a wide variety of cells (for 
review see Exton, 1994).
The regulation of agonist-stimulated PLD by PKC and calcium has been 
widely studied. PKC (Pai et al., 1991; Pachter et al., 1992; Eldar et al., 1993) 
activation by phorbol esters stimulated PLD activity (Shukla & Halden, 1991), 
however, PKC inhibitors had varying effects on agonist stimulated PLD activity 
(Liscovitch & Amsterdam, 1989; Llahi & Fain, 1992). Down regulation of PKC by 
chronic phorbol ester treatment, has been shown to impair the effect of agonist- 
stimulated PLD (Cook et al., 1991; Plevin et al., 1991; Stewart et al., 1993). Thus 
agonist-stimulated PtdCho-PLD activity could be secondary to PtdIns-4 ,5 -P2 
hydrolysis by PIC. This cannot be the complete picture as many agents including
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#interleukins and EGF, can promote PLD activity in the absence of an input from 
PtdIns-4 ,5 -P2 breakdown (Slivka et al., 1988; Cook & Wakelam, 1991; Ha & Exton,
1993).
Recent evidence suggests that PLD can be activated by an increase in tyrosine 
phosphorylation, but whether it is a direct substrate for a tyrosine kinase or another 
kinase involved in a phosphorylation cascade remains to be elucidated. Briscoe et 
al.{1995) demonstrated that perhydrovanadate, a tyrosine phosphophosphatase 
inhibitor, stimulated PLD activity and genistein, a tyrosine kinase inhibitor, partially
inhibited the activity as measured by the transphosphatidylation reaction. Similar
results have been reported by various groups (Bourgoin & Grinstein, 1992; Lings et 
al., 1992; Kumada et al., 1993), lending support to the involvement of tyrosine 
kinases in the regulation of PLD, however, the kinases have still to be identified. One 
possibility is a non-receptor-associated tyrosine kinase, since \~src increased 
transphosphatidylation activity in Rat-1 fibroblasts (Song et al., 1991; Wyke et al.,
1992).
The regulation of PLD has also been shown to be via GTP-binding proteins, 
however, the evidence to date is confusing. It has been shown that in various cell 
types, GTPyS stimulates PLD and that this effect is mimicked by aluminum fluoride, 
suggesting that a heterotrimeric G-protein is involved (Diaz-Meco et al., 1989; Qian & 
Drewes, 1989; Hurst et al., 1990; Van der Meulen & Haslam, 1990). GDPpS also 
inhibits the agonist-stimulated response (Kanaho etal., 1991; Liscovitch & Eli, 1991) 
and in neutrophils (Agwu et al., 1989; Kanaho et al., 1992) and HL60 cells (Xie et 
al., 1991) the agonist-stimulated response is sensitive to pertussis toxin, suggesting 
that it is a member of the Go/Gi family involved. However, in PCI2 cells (Kanoh et 
al., 1992) and liver plasma membranes (Irving & Exton, 1987), the GTP-binding 
protein involved in PLD activation is pertussis toxin insensitive. The PLD in these 
liver membranes and membranes prepared from other tissues and cells, can be 
activated by GTP analogues in the absence of cytosol (Bocckino et al., 1987). 
However, membranes from neutrophils and HL60 cells could only be activated by the
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sGTP analogues in the presence of cytosol (Anthes et al., 1989; Olson et al., 1991), 
suggesting that a factor within the cytosol was essential for GTP-stimulated PLD 
activity. Brown et al.{l993) and Cockcroft et <3/.(1994) identified this essential factor 
as the small molecular weight GTP-binding protein ARF (ADP ribosylation factor), 
which ADP-ribosylates Gsa iit response to cholera toxin (Moss & Vaughan, 1993).
This 21 kDa protein has been shown to be involved in the regulation of vesicle protein 
trafficking (Rothman & Orei, 1992) and perhaps PLD mediates the action of ARF on 
membrane traffic by its ability to cause changes in the lipid composition of membranes 
(Kahn et al., 1993). Another low molecular weight GTP-binding protein, rho, has 
also been implicated in GTPyS-stimulated PLD activity in neutrophil membranes 
(Bowman et al., 1993). This G-protein is membrane bound, unlike ARF, but its role 
in the activation of PLD has still to be elucidated.
I
1 . 1 . 2 . 2 . 3  Physiological effects of phosphatidylcholine hydrolysis
The increase in DAG produced either by PtdCho-PLC or by the combined 
action of PtdCho-PLD and PAP, is prolonged, providing chronic PKC activation 
(Fallman et al., 1992), which does not cause downregulation. However, initial data 
indicated that PtdCho-derived DAG was unable to activate PKC (Martin et al., 1990;
Leach et al., 1991), whereas Ptdlns-derived DAG in conjunction with elevated 
intracellular calcium was shown to translocate PKC-a, -p, -5 and -e (Kiley et al.,
1991). When studied in more detail it was shown that the biphasic release of DAG is 
mediated by the hydrolysis of different substrates (Pettit et al., 1994). Fatty acid 
composition analysis of the DAG species demonstrated that the initial transient phase 
was from Ptdlns hydrolysis and the second sustained phase from PtdCho hydrolysis 
(Pettitt & Wakelam, 1993). Both phases of DAG are able to stimulate Ca^+- 
independent PKC isoforms, such as PKC-e (Ha & Exton, 1993), but only the initial 
phase of DAG stimulates Ca^+-dependent PKC isoforms, such as PKC-a. The 
activity of PKC can also be regulated by the enzyme DAG kinase, which competes 
with PKC for DAG, which it rapidly phosphorylates to produce phosphatidic acid
14
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(PA) (Besterman et ah, 1986). The rôle of PKC is discussed in section 1.3.2.1.
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The PLD product phosphatidic acid (PA) may act as a signalling molecule itself
or be hydrolised by a phospholipase A^ to lysophosphatidic acid (LPA), as well as be
converted to DAG by PAP. Exogenously applied PA has been reported to stimulate
calcium influx and calcium-mediated processes in various cell types. The effects of
.PA on cells were previously explained by its ability to mobilize extracellular calcium 
by an ionophore effect (Tyson et al., 1976; Hams et al., 1981). However, PA has 
been shown to stimulate phosphoinositide turnover in various cells including
fibroblasts (Murayama & Ui, 1987), A431 cells (Moolenaar et al., 1986) and human 'H
kératinocytes (Ryder et al., 1993), thereby leading to release of intracellular calcium 
reserves. PA has also been shown to inhibit Luteinizing hormone-stimulated 
testosterone production in rat Leydig cells (Lauritzen et al., 1994), lysophospholipase 
transacylase from rat liver (Sugimoto & Yamashita, 1994) and association of rac with 
the rhoQT>l, under non-activating conditions (Chung et al., 1993). It does however, 
stimulate ARFGAP activity (Randazzo & Kahn, 1994), therefore possibly inactivating 
PLD. PA may also have an important role to play in the regulation of the respiratory 
burst, as it has been shown to stimulate arachidonate release in peritoneal macrophages 
(Fernandez et al., 1994) and phosphorylates p74 of the NADPH oxidase complex
(McPhail et al., 1995), perhaps via a PA-activated kinase, which has been partially
.purified from human platelets (Khan et al., 1994).
LPA can act as an extracellular signal and addition of this lipid to many cell 
types often produces rapid and dramatic results. This agonist will be discussed in 
more detail in section 1.6.3. As yet no signalling role has been established for the
;•water soluble products of PtdCho hydrolysis, choline and phosphocholine, but they 
are essential for the synthesis of phosphatidylcholine de novo.
1 .2  PHOSPHOLIPASE A2
Phospholipase A2 catalyzes the hydrolysis of the sn-2 fatty acyl chain of 
phospholipid substrates to yield fatty acids and lysophospholipids. These products 
may themselves act as intracellular second messengers or can be further metabolised as 
the precursors in the production of specific proinflammatory lipid mediators. The 
diversity of mammalian sn-2 acylhydrolases has increased with 2  main enzyme groups 
arising. These are the 14kDa low molecular weight phospholipase A2 's, which have 
been further catogerised into type I, II and III and the 85kDa cytosolic phospholipase 
A 2 , which has been termed type IV. However, even these classifications are
incomplete with the new phospholipase A2 enzymes being discovered, such as the 
42kDa enzyme isolated from human placenta (Buhl et a l, 1995) and a 14kDa, Ca^+- 
dependent phospholipase A2 which contains 16 cysteines, compared to the normal 14 
identified in all low molecular weight phospholipase A2 isoenzymes so far (Chen et 
a l, 1994).
A
1 . 3 . 1  Secretory phospholipase A% (SPLA2 )
Phospholipase A2 activity was first studied in pancreatic juice and cobra 
venom in the early 1950's. The PLA2*s in venom have some digestive functions, but 
are also directly involved in toxicity (Kini and Evans, 1990). Subsequently, PLA2 's 
obtained from various snake and bee venoms and from mammalian pancreas have 
been well characterized, mechanistically elucidated, and structurally defined. These 
extracellular enzymes have been divided into three main groups and several subgroups 
based on their amino acid sequences, as follows: Group I (Cobras and kraits; 
porcine/human pancreas), Group II (rattlesnakes and vipers; human synovial 
fluid/platelets), Group III (bee/lizard). Group I, II and HI have molecular weights of 
13-18 kDa and are perhaps the most elementary of the PLA2 S (Davidson and Dennis,
1990). The amino acid sequences and seven disulphide bonds are conserved among 
the Group I and II species, whilst the Group III bee venom enzyme has distinct and 
rearranged sequence homologies, however x-ray crystallography has revealed identical
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catalytic residues (Thunnissen et ah, 1990). These secretory enzymes do not form a 
classical acyl enzyme intermediate characteristic of serine proteases, but utilize the 
catalytic site His 48, assisted by an Asp, to polarize a bound H2O which then attacks 
the carbonyl group. This transition state is stabilized by the binding of a Ca^+ ion in 
the conserved Ca^^-binding loop, which explains the requirement for millimolar 
calcium for activity (Verheij et al., 1980). While the majority of the Group I, II and 
in  enzymes that have been studied are extracellular non-human enzymes, a growing 
number of Group I and II enzymes have been found in human tissues. The best 
characterized is the Group II PLA2 originally isolated from human synovial fluid 
(Wong and Dennis, 1990). However, Group II enzymes have also been found in 
non-secreted locations, for example in rat liver mitochondria (Van den Bosch et al., 
1989).
The human Group I and II phospholipase A2 enzymes have a number of 
diverse roles. Group I is mainly secreted from the pancreas as an inactive zymogen, 
which is converted into the active form by proteases, therefore it has a suggested role 
as a digestive enzyme (de Haas et al., 1968). This enzyme has also been detected in 
rat stomach (Yasuda et al., 1990) and human serum (Nishijima et al., 1983). These 
enzymes have also been suggested to have a role in vascular function, as Group I 
binding sites have been found on vasculature (Hanasaki and Arita, 1992), with the 
same binding sites being found on Swiss 3T3 fibroblasts. Binding of Group IPLA2 
to these 200kDa binding sites induced DNA synthesis, increased proliferation and 
glucose transport. (Arita et al., 1991). Group II phospholipase A2 enzymes may serve 
as a link joining the proximal and distal limbs of the inflammatory response (Larsen 
and Henson, 1983; Murakami et al., 1990). This has been suggested to be due to a 
high level of Group II PLA2 in peritoneal exudate fluid (Franson et al., 1988) and 
ascitic fluid after intraperitoneal injection of casein or zymosan (Gans et a l, 1989). In 
addition Group II PLA2 degrades the membrane phospholipids of gram-negative 
bacteria (Kaplan-Harris et a l, 1980), thus a host defence function has been assigned 
to this enzyme. However, the observation of enhanced Group II PLA2 secretion
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during activation of certain cell systems and the demonstration of its contribution to 
prostaglandin production using antisense RNA (Barbour and Dennis, 1993) argue that 
this enzyme also plays a role in signal transduction and eicosanoid production.
s;
1 .2 .2  Cytosolic phospholipase A% (CPLA2)
Several hormones, neurotransmitters, growth factors and cytokines have been 
found to stimulate phospholipase A2 activity via occupation of extracellular receptors, 
resulting in the hydrolysis of phospholipids and the consequent release of free fatty 
acids. These include basic fibroblast growth factor (Sa & Fox, 1994); thrombin 
(Kramer et al, 1993a); macrophage colony stimulating factor (Nakamura et al, 1992); 
platelet-derived growth factor (Domin &Rozengurt, 1993); bradykinin (Kaya et a l,
1989); carabacol (Konrad et a l,  1992); transforming growth factor-a (Liu et a l,
1993); interleukin-la (Lin e ta l,  1992); bombesin (Takuwa e ta l, 1991; Currie e ta l,
1992); f-methyl-leucine-phenylalanine (Suga et a l, 1990) and lysophosphatidic acid 
(van Corven et a l,  1989), some of which may mediate their effects by increasing 
intracellular calcium concentrations.
A phospholipase A2 , which has different structural and biochemical properties 
to secretory phospholipase A2 , but performs the same catalytic function, was purified 
from the human monocytic leukemic U937 cell (Clark, et a l, 1990; Sharp et a l,
1991); rat kidney (Gronich et al, 1990) and platelets (Kim et a l, 1991a; Takayama, et 
a l, 1991). As this phospholipase A2 activity was recovered predominately in the 
cytosolic fraction of cells and tissues it was termed cytosolic phospholipase A2 
(CPLA2). The primary structure of CPLA2 has been elucidated by cDNA cloning and 
the deduced CPLA2 protein sequence has several interesting structural features. These 
include a 6 8 -amino acid stretch at the N-terminus termed CaLB, which is a sequence 
motif associated with calcium and phospholipid binding. This motif has been 
identified in various proteins and has been shown to confer a teraiary configuration 
between a single calcium atom, phospholipid and the enzyme of interest. This is 
followed by a 109-amino acid segment that exhibits 33% homology with
:
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phospholipase B from P. notatwn (Masuda et al., 1991), which contains the active 
site. In the middle of the sequence there is a 34-amino acid segment that is deficient in 
hydrophobic amino acids and may represent a flexible 'hinge' region. Towards the C- 
terminus, there is a proline rich domain, which is preceeded by serine 505, the MAP 
kinase phosphorylation site. Throughout the sequence there are numerous diverse 
consensus phosphorylation sites for both serine/threonine and tyrosine protein kinases 
(Kemp & Pearson, 1990). The inferred sequence of murine CPIA2 is greater than 
95% homologous to the human CPLA2 (Clark et al., 1991), indicating great structural 
similarity between CPLA2 from different species. From the purifications highlighted,
CPLA2 was shown to be a polypeptide of approximately lOOkDa, however from 
subsequent cDNA cloning the predicted molecular mass was found to be 85.2kDa 
(Sharp et al., 1991). This inconsistency between predicted and electrophoretic 
molecular weight could be due to post-translational modifications or to the proline-rich 
(>12% of total residues) domain towards the C-terminus. The structure and function 
of such proline-rich regions in proteins is reviewed by Williamson (1994).
The 85 kDa CPLA2 has been shown to have a 5- to 10-fold preference for .y/i- 
2 -arachidonyI-containing phospholipid substrates, but there is debate to whether or not 
there is a preference for a choline head group (Diez, et al., 1992; Currie et a l,  1992).
The enzyme does not discriminate between 1-acyl or 1-alkyl linked phospholipids 
(Kramer et al., 1988), which it does not hydrolyse in intact phospholipids (Kramer et
V
al., 1986), but readily acts upon lyso-phosphatidylcholine micelles, with no 
preference for the available fatty acid at the 5«-l position (Leslie, 1991). This 
lysophospholipase activity will be discussed below, but it has recently been shown 
that both the phospholipase A2 and the lysophospholipase activities of CPLA2 are 
catalyzed by the same active site residue, serine 228 (Sharp et ai, 1994).
CPLA2 is a calcium-responsive enzyme, which can be activated by 
submicromolar concentrations of calcium (300nM-2p.M) as would be achieved during 
cell stimulation (Leslie et al., 1988), however, in vitro other divalent metal ions can 
substitute for calcium in the catalytic mechanism of CPLA2 (Kramer et al., 1986;
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Gronich et al., 1988)* Divalent cations are essential as CPLA2 is inactive in the 
presence of excess chelating agents. The primary structure of CPLA2 highlighted a 6 8 - 
amino acid stretch in the N-terminal portion termed the 'CaLB domain' that shows 
38% sequence homology with the C2 region of protein kinase C. This sequence has 
been implicated in the Ca^'^-dependent binding of PKC to lipids and is absent in Ca^+- 
independent forms of PKC (Masuda et al., 1991). This CaLB domain has also been 
identified in the GTPase activating protein (GAP), phospholipase Cyi and the synaptic 
vesicle protein p65 (Clark et al., 1991), but it has been demonstrated that the C2 
domain in PKC merely confers the specificity for Ca^+ and that Ca^+ is bound mainly 
to the Cl domain (Luo & Weinstein, 1993). The possible role of calcium in the 
regulation of cPLA% will be discussed below.
Another probable regulator of cPLA% activity is phosphorylation as the protein 
sequence contains consensus phosphorylation sites for protein kinase A (PKA), PKC, 
casein kinase ÏI (Kemp and Pearson, 1990) and MAP kinase (Nemenoff et al., 1993).
1 .3  REGULATION OF CYTOSOLIC PHOSPHOLIPASE A%
The regulation of cytosolic phospholipase A2 is complicated by the presence of 
multiple phospholipase A2 forms within cells. For instance, three distinct sn-2 
acylhydrolase activities have been characterised in cultured mast cells (Murakami et ]
al., 1992b) and gerbil brain (Rodorf et al., 1991), whilst an additional form of 
phospholipase A2 has been purified and characterized from heart (Gross, 1992) and 
been shown to exist as 2 isoforms (Hazen et al., 1993). Both isoforms have a 
molecular weight of 40kDa and preferentially hydrolyze arachidonate at the sn-2 
position, however, these myocardial cytosolic phospholipase A2 isoforms are calcium- 
independent.
jiii'
sPLA2 may be secondary to receptor-mediated activation of PLC leading to the
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1 . 3 . 1  Calcium
Mobilization or availability of intracellular calcium appears to be an essential 
step for activation of both the type II 14-kDa PLA2 and the 85kDa PLA2 . Many 
studies have demonstrated that treatment of cells with a calcium ionophore induces 
maximal arachidonate release from intracellular phospholipids. Thus, the activation of
formation of Ins-1,4,5-P] and thus an increase in intracellular free calcium 
concentrations (Meade et aL, 1986). However, Ins-1 ,4 ,5 -P3 production and
arachidonate release can be dissociated (Burch & Axelrod, 1987; Slivka & Insel, 
1988) since arachidonate can be released in the absence of PtdIns-4 ,5 -P2 hydrolysis 
(Kanterman et al, 1990; Gil et aL, 1991; Virdee et al, 1994). CPLA2 activity has also 
been shown to be dependent upon extracellular calcium in C62B glioma (Brooks et 
a i, 1989), endothelial (Whately et a l, 1989) and MDCK-Dl cells (Insel et a l, 1991).
As the regulation of PLA2 activity by increased calcium shows some cell type
specificity, separate roles for the ion are suggested. CPLA2 binds to membranes in a
calcium dependent manner through the N-terminal domain. Therefore, increased
intracellular calcium concentrations from either Ins-1,4,5-P3-sensitive pools or from
.increased flux from the extracellular medium could induce the association of CPLA2 
with cellular membranes. Channon & Leslie (1990) demonstrated that CPLA2 activity 
was translocated from the cytosol to a membrane fraction in the presence of 
micromolar concentrations of calcium and many groups observed that during 
purification of CPLA2 from cells broken in the presence of the calcium chelator EGTA, 
the majority of PLA2 activity was in the cytosol, whereas when broken in the presence 
of calcium concentrations approaching those measured in activated cells, activity was 
mainly found in the membrane fraction (Krause et a l, 1991; Rehfeldt et a l, 1991). 
This translocation of CPLA2 was also observed in thrombin-stimulated human platelets 
(Kramer et a l, 1993b), suggesting that the Ca^+-mediated translocation occurs in 
vivo. Wijkander & Sundler (1992a) demonstrated using 45Ca^+, that there was a 
single binding site for calcium in a ternary complex with the 85 kDa phospholipase A2
I
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and the phospholipid. However, hydrolytic activity could be obtained in the absence 
of calcium using high conentrations of NaCl or other salt, implying that calcium is 
required for interfacial association with lipid but not for catalysis.
1 . 3 . 2  Phosphorylation
As described earlier, the sequence of cloned CPLA2 demonstrated various 
possible phosphorylation sites. As calcium has been shown not to be involved in 
catalysis, it is perhaps phosphorylation which activates phospholipase A2 .
1 . 3 . 2 . 1  Protein kinase C (PKC)
. :In many cell types the activation of PKC is not sufficient to induce liberation of 
cfr-unsaturated fatty acids, however, several observations support the notion that PKC 
may be important in the regulation of phospholipase A2 . For example, the cytosolic 
phospholipase A2 activity recovered from phorbol ester-stimulated mesangial cells was 
increased several fold, suggesting a stable modification of the enzyme (Gronich e ta l,
1988) and in CHO cells overexpressing CPLA2 phorbol ester stimulated the 
phosphorylation of CPLA2 on serine residues (Lin et a i, 1992). This phorbol ester- 
stimulated phosphorylation of CPLA2 has been shown by various groups (Wijkander 
& Sundler, 1992b; Kramer et a l, 1993a; Qui et al, 1993) and correlates to an increase 
in the in vitro Vmax of CPLA2 but with no effect on calcium requirements or substrate 
specificity. This was supported by the observed decrease in PLA2 -mediated 
arachidonate release in response to phorbol ester when expression of PKCa was 
inhibited by an antisense cDNA (Godson et a l, 1993). However, down-regulation of 
PKC by chronic phorbol ester treatment, did not effect the EGF-stimulated PLA2 in 
mesangial cells (Bonventre et al., 1990) or ATP-stimulated arachidonate release in 
FRTL-5 rat thyroid cells (Smallridge & Gist, 1994).
I
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1 . 3 . 2 . 2  Tyrosine phosphorylation
It has been suggested that intrinsic tyrosine kinase activity is required for 
apparent PKC-independent activation of phospholipase A2 . CHO cells transfected 
with a truncated, tyrosine kinase defective, EGF receptor produced no EGF-stimulated 
phospholipase A2 activity, compared to control cells transfected with the complete 
EGF receptor (Clark & Dunlop, 1991). However, the phospholipase A2 present in 
the cells containing the truncated receptor was activatable, as calcium ionophore- 
stimulated arachidonate release was detected (Goldberg eî al., 1990). Kast et 
ût/.(1993) demonstrated that CPLA2 was specifically immunoprecipitated with 
antiphosphotyrosine antibodies after TGFot stimulation, which exerts its biological 
activity via the EGF receptor (Hunter, 1989), but not phorbol ester-treated or control 
cells. These results suggest that CPLA2 or a tightly associated protein, which is 
coupled to the tyrosine kinase receptors described, maybe phosphorylated upon 
tyrosine residues . CPLA2 has been shown to be phosphorylated upon tyrosine 
residues, but there was no increase in phosphorylation upon agonist stimulation 
(Currie et al., 1994). It appears that the involvement of tyrosine kinases in the 
regulation of CPLA2 is not by direct agonist-stimulated tyrosine phosphorylation of 
CPLA2 , but the tyrosine phosphorylation of some regulatory protein. The tyrosine 
phosphorylation of a regulatory protein may then lead to the phosphorylation of 
CPLA2 upon serine/threonine residues,
1 . 3 .2 . 3  MAP Kinase
Growth factor signalling is mediated by growth factor receptors containing an 
integral tyrosine kinase. In response to growth factors the receptor tyrosine kinases 
are activated to initiate intracellular signalling events. This tyrosine phosphorylation 
can be rapidly translated to changes in the phosphorylation of cytoplasmic and nuclear 
proteins on serine and threonine residues, leading to alteration in the properties of the
i ■ *
target proteins. In general, two broad approaches have been adopted in the study of 
these phosphorylation events in growth factor signal transduction. One was to work
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'down' from the receptor in a stepwise manner to identify relevant components in the 
signalling pathway. The second approach was to start with a cellular event known to 
be affected by the growth factors and to work 'up' toward the receptor. These 
approaches have led to the identification of a signal transduction pathway initiated by 
growth factor receptors [Fig.L3.2.3].
The MAP kinase cascade was elucidated primarily by the upstream approach.
One of the first identified target proteins for enhanced serine/threonine
.phosphorylation upon growth factor stimulation, was ribosomal protein S6 , which 
produced a convenient marker for the elucidation of upstream events. Two enzymes 
that can phosphorylate ribosomal protein S6  on growth factor stimulation were 
identified, p7 Qs6k (Cobb & Rosen, 1983; Novak-Hofer & Thomas, 1984; Kozma et 
aL, 1990) and p9 0 s^k (Erikson & Mailer, 1985; Alcorta et al., 1989). These S6 
kinases are themselves activated by serine/threonine phosphorylation and it was later 
shown that partially purified microtubule-associated protein-2 (MAP-2) protein kinase 
obtained from insulin-stimulated 3T3-L1 cells (Ray & Sturgill, 1987) could 
phosphorylate and reactivate phosphatase-treated S6 kinase (RSK) obtained from 
Xenopus laevis oocytes (Sturgill et al., 1988). This observation was subsequently 
confirmed in experiments using insulin-activated MAP-2 kinase and non-stimulated
RSK from rat liver (Gregory et al., 1989) or epidermal growth factor (EGF)- 
stimulated MAP-2 kinase and non-stimulated RSK from Swiss 3T3 fibroblasts (Ahn 
& Krebs, 1990), implicating MAP-2 kinase as an S 6  kinase kinase. The original 
name, MAP-2 kinase, was later changed to MAP kinase, and when it was cloned, the 
gene was designated as extracellular regulated kinase (ERK)(Boulton et aL, 1990).
MAPK and ERK are often used interchangeably, but it has been suggested that ERK-1 
(p4 4^ 4 PA:) and ERK-2 (p 4 2 ^^^ ), are the name for one particular group of isoforms 
within the MAPK family.
MAP kinase can be inactivated by either the protein tyrosine phosphatase,
CD45, or by the protein serine/threonine phosphatase, PP2A, indicating that both 
tyrosine and serine/threonine phosphorylations are required for its activity (Anderson,
24
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Figure 13.23 The MAP kinase signalling cascade 
This diagram demonstrates the possible components of this signalling cascade 
such as: RAS 21 kDa small molecular weight G-protein
Raf-1 74kDa MAP kinase kinase kinase which
phosphorylates serine/threonine residues 
Protein kinase C 
MOS Germ cell-specific serine/threonine protein
kinase
B-Raf Serine/threonine kinase expressed primarily in
brain and in the nervous system which is 54% 
homologous to c-Raf-1 
MEKK MEK kinase
MEK Mitogen-activated, ERK-activating kinase
MAPKK MAPK kinase
MAPK Mitogen-activated protein kinase / microtubule-
associated protein kinase 
ERK Extracellular regulated kinase
PM A Riorbol myristyl acetate
It must be noted that the following terms can be interchanged:
1. MAPKK and MEK
2. MAPK and ERK
The arrows highlight the targets of the component of interest
Figure 1.3.2.3 MAP kinase signalling cascade
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et aL, 1990). In quiescent or in unstimulated cells, the MAPK isoforms exist in a 
dephosphorylated form, and are only activated when phosphorylated on both Thr 183 
and Tyr 185, for mammalian 41kDa MAPK(ERK2)(Payne e ta l,  1991), and Thr 188 
and Tyr 190, for Xenopus 42kDa MAPK (Posada & Cooper, 1992). The 
phosphorylation of the two residues seems to be a sequential reaction in which 
tyrosine phosphorylation proceeds threonine phosphorylation (Haystead et a i, 1992).
These TEY sites are located in subdomain VIII just upstream of the conserved Ala- 
Pro-Glu (APE) motif found in all serine/threonine kinases (Hanks et aL, 1988). 
Phosphorylation of both regulatory residues or each one individually causes shifts in 
the mobility of the ERK on sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE), which is often used as a marker for their activities.
However, this is not always accurate as singly phosphorylated ERK lacks kinase 
activity. As well as the requirement for catalytic activity, phosphorylation of both 
regulatory residues also appears to be the main requirement for translocation of ERK 
to the nucleus (Chen et aL, 1992; Lenormand et al., 1993). These proline-directed 
protein kinases can phosphorylate a large number of proteins, which have serine or
,threonine residues next to proline residues (Gonzalez et al., 1991). These ERK 
substrates are located in both the cytoplasm and the nucleus, including cytosolic 
phospholipase A^ (Lin et al,, 1993), nuclear transcription factors, such as Elk-\ (Rao 
& Reddy, 1993), upstream proteins of the MAPK cascade, such as raf-I, and 
cytoskeletal elements such as Tau. The phosphorylation of these cytoskeletal elements 
appears to regulate cytoskeletal rearrangements and cellular morphology (Minshull et 
al., 1994). Therefore, it is possible that ERK activation controls events leading to the 
Gq/Gi transition of the cell cycle (Boulton et al., 1990). Tamemoto et al.{\992) 
reported a biphasic activation of two MAPKs during the cell cycle in CHO cells. In 
these cells ERK-1 and -2 showed enhanced activities in the Gi through S and G2/M 
phases and were activated biphasically in the G% phase and around the M phase.
MAPK is capable of autophosphorylation (Seger et a l, 1991), but is activated 
by MAPK kinases (MAPKK) (Posada Sc Cooper, 1992; Seger et al„ 1992).
f
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Purification of these kinases confirmed that MAPKK (also referred to as MEK) is a 
single kinase that catalyzes serine/threonine as well as tyrosine phosphorylation, 
making it a member of a small family of dual specificity kinases (Matsuda et al., 1992; 
Seger et a l, 1992). Cloning of MAPKK revealed five isoforms of the enzyme 
(Yashar et al., 1993). These are regulated by phosphorylation on serine/threonine 
residues, with phosphorylation of serine 218 and 2 2 2  being essential for activity 
(Alessi et a i, 1994; Seger et al., 1994) and phosphorylation of serine 212, threonine 
286, 292 and 386 have a role to play in the inactivation of MAPKK (Rossomando et 
al., 1994; Zheng & Guan, 1994). Sontag et al. (1993) also demonstrated that 
activation of MEK occurs through the inhibition of serine/threonine phosphatases, 
such as phosphatase PP2A.
Kyriakis et al.(1992) demonstrated that raf-1, a known serine/threonine 
kinase, is capable of phosphorylating and activating MAPKK after growth factor 
stimulation, raf-1 is the product of c-raf-1, the cellular homologue of v-raf, the 
transforming gene of the murine sarcoma virus 3611 (Rapp et al., 1988) and is a 70- 
75 kDa serine/threonine kinase, which contains a kinase domain in the COOH-terminal 
half of the molecule and a regulatory domain occupying the remainder. The 
mechanism of raf-1 has been studied extensively and has been shown to be 
downstream of ras (Moodie et al., 1993), which does not activate raf-1, but recruits 
the enzyme to the plasma membrane, where it is activated (Stoke et al., 1994; Leevers 
et al., 1994). The activation of raf-1 coincides with hyperphosphorylation of the 
enzyme possibly by protein kinase C (PKC), which has been shown to phosphorylate 
raf-1 directly (Morrison et a l, 1993) or ceramide-activated protein kinase (Yao et a l,
1995). Tyrosine kinases may also be involved, as it has been shown that p56^^  ^can 
phosphorylate and activate raf-1 and tyrosine phosphorylation is essential for 
activation (Fabian e ta l, 1993).
IkB is an additional substrate for raf-1 which may transmit signals by releasing 
cytoplasmic, active NFkB, which can than be translocated to the nucleus (Li & 
Sedivy, 1993). In addition to raf-1, other MAPKKKs (MAP3K) have been
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identified, including MEK kinase (Lange-Carter et a l, 1993), o-mos (Posada et a i,
1993), rû5-dependent ERK kinase stimulator from Xenopus oocytes (Itoh et al.,
1993), a high molecular weight complex from unfertilisedXg/iopwj eggs (Matsuda et 
al., 1993) and an insulin-stimulated MAP3K from adipocytes (Haystead et al., 1994). 
However, it has been suggested that each of these MAP3Ks activate a different group 
in the MAPKK family (Yau et al., 1994).
I
Physiologically the MAP kinase cascade has been implicated in proliferation 
and differentiation. Miltenberger et al. (1993) used antisense c-raf-l to show 
interference with the NÏH-3T3 cell proliferation, whereas constitutively-activated raf-1
■ .1had an accelerated effect. Pages et al. (1993) demonstrated that a dominant negative 
form of ERK-1 caused a reduction in the number of NIH 3T3 fibroblasts and their 
ability to proliferate. However, there is also evidence that cell proliferation is 
independent of the MAP kinase cascade (Wang et al., 1992; Casillas et al., 1993).
The MAP kinase cascade have also been implicated in processes such as monocytic 
differentiation (Han et al., 1993), neurite outgrowth of PC 12 cells (Qui & Green,
1992), T-cell maturation (Alberola-Ea et a l, 1995) and mast cell development (Tsai et 
al., 1993).
1 . 3 . 3  GTP-binding proteins
Studies with different cells provided evidence to support a role for GTP- 
binding proteins in the regulation of cytosoic phospholipase A2 . Both the classical 
heterotrimeric and the small molecular weight, ra^-like, G-proteins have been 
implicated (for review see Burch, 1989; Axelrod, 1990; Cockcroft, 1992).
1 . 3 . 3 . 1  Heterotrimeric G-proteins
Heterotrimeric G-proteins comprise 3 polypeptides ; an a-subunit that binds 
and hydrolyzes GTP, a p- and a y-subunit. The py subunits only dissociate under 
denaturing conditions and when the a  subunit is in the GDP-bound state it associates 
with py. When GTP is bound to the active site, the a  subunit dissociates from both
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the py subunit and the activated receptor and activates its effector. The intrinsic 
GTPase activity of the a  subunit inactivates it by hydrolyzing the bound GTP to GDP, 
stimulating the reassociation with Py subunits and the inactive receptor, ready for 
subsequent agonist stimulation. Therefore, the rate of GTP-hydrolysis controls the 
duration of both a  and py subunit activation, as re-association inactivates both 
subunits (for review see Neer, 1995).
Over 20 different G-protein a  subunits have been identified and divided into 4 
major classes, according to the similarity of their amino acid sequences, with 
individual cells usually containing at least 4 types of a  subunits (for review see Neer,
1994). There are five known mammalian p subunits, which are 53-90% identical (for 
review see Simon et aL, 1991; Watson et a l,  1994), whereas the six known y 
subunits vary (for review see Cali et al., 1992) and can interact with most but not all 
of the p subunits. For example, the Pi subunit can form a dimer with only y% and yg 
subunits and p2 can only interact with yz (Schmidt et al., 1992).
The heterotrimeric complex has been shown in some cases to be located to 
membranes via lipid attachments (for review see Yamane & Funf, 1993). Go and G{ 
a  subunits are irreversibly myristolated at the N-terminal glycine, which facilitates the 
association with py. Gg a  subunit is palmitoylated at cys-3, which can be removed 
upon P-adrenergic receptor occupation, leading to adenylyl cyclase inhibition (for 
review see Casey, 1994). All the y subunits are prenylated, which is essential for 
membrane attachment of the Py subunit and may influence the specificity of the 
py/receptor interaction (Kisselev et al., 1994). This coupling of heterotrimeric G- 
proteins to an activated receptor is also regulated by a group of serine-threonine 
protein kinases, termed G-protein coupled receptor kinases (GRKs)(for review see 
Premont et al., 1995), which may act conversely to py subunits by desensitizing the 
receptor.
The pathways activated by these heterotrimeric G-proteins have been 
extensively studied, with the various a  and py subunits having a myriad of effects. In 
the regulation of phospholipase A2 , both a  and py subunits have been implicated.
%
Using antiserum to the pertussis toxin-sensitive Gi and Go a  subunits, histamine-,
thrombin- and noradrenalin-stimulated arachidonate release was inhibited in rabbit
platelets (Kajiyama et a l, 1990; Murayama et ah, 1990). A dominant-negative G|2  cc
subunit inhibited thrombin and purinergic receptor activation of CPLA2 , suggesting
that it is this specific member of the Gi family which is involved (Gupta et a l, 1990).
.However, the very closely related member of this family. Gig a  subunit, has been 
shown to stimulate phospholipase A2 , leading to the activation of K+ channels in 
epithelia (Cantiello et al., 1990) and mediate the m2  muscarinic acetylcholine receptor- 
mediated arachidonate release (Hunt et aL, 1994). Agonist-stimulated arachidonate
release has also been shown to be pertussis toxin-insensitive. This pertussis toxin- 
insensitive PLA2 activity could be stimulated by calcium mobilization via receptor- 
stimulated, Gq-mediated PIC activation (Conklin et a l, 1992). Recently the first 
strong evidence for a direct involvement of Gi2  in receptor stimulated arachidonic acid 
release was shown by Winitz et al.{199A). This group demonstrated that a genetic 
mutant of the Gj2 ot subunit (aj2G203T) expressed in CHO cells, inhibited thrombin- 
and ATP-stimulated arachidonate release, but had no effect upon agonist-stimulated 
calcium mobilization. This mutant was engineered by mutating the conserved residue 
Gly203 to Thr203 of the Gi2 a  subunit. Gly203 corresponds to Gly 225 in the Gg a  
subunit which inhibited receptor-stimulated adenylyl cyclase when mutated to a Thr 
(Osawa & Johnson, 1991). It must be noted that this has yet to be repeated using 
other cell types and/or agonists,
py subunits have been shown to be positive regulators of adenylyl cyclase, 
P IC -pl-3, phospholipase A2 , PtdIns-3 kinase and the P adrenergic receptor kinase 
(reviewed in Clapham & Neer, 1993). The interaction of py subunits with their 
effectors has been suggested to be via plextrin homology (PH) domains (Inglese etal.,
1995) and as 71 proteins including phospholipases, kinases and cytoskeletal proteins, 
have been identified to contain PH domains (Auffray et a l, 1980), py subunits could 
play a vast role in the regulation of intracellular activities . One pathway which has 
been demonstrated to be activated by py subunits is MAP kinase, which is dependent
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Mupon ras activation (Crespo et aL, 1994). The other major signalling kinase which 
may be activated by py subunits, is protein kinase C (PKC). Ron et al.(199A) isolated 
an intracellular receptor/docking protein for PKC, which enhanced PKC-stimulated 
Histone 1 phosphorylation when bound. As this receptor is a homolog of the p 
subunit of heterotrimeric G-proteins, it raises the possibility that the py subunits may 
act upon PKC directly.
&1 .3 .3 ,2  Small molecular weight G-proteins
Mammalian cells contain at least 50 related small molecular weight GTP- 
binding proteins, including ras, rab, ARP, rho and rac, which regulate processes as
i.
diverse as cell replication and differentiation, cytoskeletal organization, secretion and
endocytosis (for review see Glomset & Farnsworth, 1994; Hall, 1994). Their role in
GTP-dependent signalling pathways can be distinguished from heterotrimeric G-
proteins, as aluminium fluoride does not stimulate activity (Kahn, 1991). The best
characterized of these are the ras proteins, which are involved in receptor-mediated
signal transduction, such as EGF-stimulated arachidonate release in Rat-1 fibroblasts
.(Warner et al., 1993) and direct activation of phosphatidyIinositol-3 kinase (Stokoe et 
al., 1994). The regulation of raj-mediated signalling is reviewed in Burgering & Bos 
(1995), but involves GTPase-activating proteins (GAP's) and guanine nucleotide- 
exchange factors (GEF's) (for review see Boguski & McCormick, 1993). Due to 
their low level of intrinsic GTPase activity, ras proteins are dependent on GAP's for 
deactivation. rajGAP proteins undergo a calcium-dependent translocation to cellular 
membranes mediated via a CaLB domain and are deactivated by phosphorylation upon 
tyrosine residues (Serth et al., 1992). rasGEF exchanges bound GDP for free GTP, 
thus activating ras. In EGF-stimulated ras activity, this GEF has been identified as 
SOS  1, which is found in the inactive form within the cytosol, .yoj-1 is translocated to 
the membrane by binding to grb 2, via SH3 domains, which then binds to activated 
EGF-receptors via SH2 domains (Li et al., 1993). However, the subsequent 
activation of ras depends upon the prénylation state of the protein (Porfini et al.,
■=% 1
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1994). The insulin receptor and non-receptor tyrosine kinases may also directly or 
indirectly phosphorylate she, which has been shown to bind to the grb 2-sos 1 
complex via SH2 domains, and so recruit it to the membrane and thus activate ras (Lai 
et ah, 1993; Skolnik et al., 1993). The activity of this complex is inactivated by MAP 
kinase phosphorylation of sos 1 (Cherniack et al., 1994) producing a negative 
feedback loop, as MAP kinase is activated via ras-dependent raf-1 activation. This 
ra^-dependent activation of MAP kinase has been demonstrated for both LPA (Howe 
& Marshall, 1993) and fMLP (Worthen et al., 1994) and was initially thought to be 
mediated via a direct interaction of ras with raf. However, recently it has been 
demonstrated that ras activation is not required for raf activity, only for plasma 
membrane targeting of raf-l. This membrane associated raf is constitutively active 
(Stokoe et al., 1994; Leevers et al., 1994) when phosphorylated upon tyrosine 
residues (Marais et al., 1995) and interacts with the cytoskeleton in a complex with 
various proteins including two chaperones hsp90 and p50 (Wartmann & Davis,
1994). The ra^-mediated membrane localization of ra/has been shown to be inhibited 
by increased levels of cAMP. This led to the suggestion that raf is phosphorylated by 
cAMP-dependent protein kinase (PKA), disrupting the docking complex, as ras 
activity is unaffected (Cook & McCormick, 1993; Hordijk et al., 1994). One of the 
major substrates of MAP kinase is CPLA2 , which may have a role in prolonging ras- 
stimulated MAP kinase activity, as fatty acids have been shown to sustain a high level 
of GTP-bound ras (Alblas et al., 1993; Bandyopadhyay et al., 1995) perhaps by 
inhibiting the GTPase activating protein (Tsai et al., 1989).
The vectorial movement of proteins between compartments of the exocytotic 
and endocytotic pathways of eukaryotic cells is mediated by carrier vesicles, that bud 
from a donor organelle and are targetted to and fuse with, the appropriate acceptor 
organelle. ARF, rab, and the rho family have been implicated in vesicular transport 
and are likely to control the assembly and disassembly of protein complexes, 
maintaining the structural and functional integrity of subcellular compartments (for 
review see Nuoffer & Balch, 1994).
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ADP"ribosylation factor (ARF) was initially of interest due to the fact it 
stimulated ADP-ribosylation of the a  subunit of Gs by cholera toxin (Kahn & Gilman,
1984). This small molecular weight GTP-binding protein was also found to regulate 
the reversible binding of cytosolic coat proteins to Golgi membranes (for review see 
Donaldson & Klauser, 1994) and nuclear/endosome fusion (Boman et al., 1992;
Taylor et al., 1992). However, recently work has focused on its role in regulating 
PLD either directly or indirectly (Brown etal., 1993; Zhang et a i, 1995),
rab was shown to be mainly involved in the process by which transport 
vesicles dock and/or fuse with their target membranes (for review see Pfeffer, 1994;
Schell et al., 1995). These are also regulated by both GAP and GEF proteins, but
have an additional regulatory protein termed guanine nucleotide-dissociation inhibitor 
(GDI), which inhibits GDP/GTP exchange, preventing the GDP bound form from 
binding to membranes, where rab is normally found in complex with the GDI (BoUag 
& McCormick, 1991).
Another GDI has been identified which is specific for the rho family (Ohga et 
al., 1989; Segal & Abo, 1993). This family of GTP-binding proteins have been 
shown to be involved in the organisation of the cytoskeleton and consists of nine 
proteins, including rho A, B and C as well as rac 1 and 2, which have 50-55% 
homology with each other and around 30% homology with ras (Ridley & Hall, 
1993). In serum-starved Swiss 3T3 fibroblasts, there is almost a complete dissolution 
of the actin cytoskeleton and disassembly of focal adhesions, which leaves only a faint 
cortical ring of polymerized actin (Ridley & Hall, 1992). Upon addition of serum or 
growth factors such as LPA, the formation of stress fibres, focal adhesions and 
membrane ruffling are observed. By microinjection studies, it was shown that both 
stress fibre and focal adhesion formation was r/zo-dependent and membrane ruffling 
was rac-dependent (Ridley & Hall, 1992; Ridley et al., 1992). The signal 
transduction pathways leading to stress fibre formation and membrane ruffling are of 
great interest (for review see Ridley, 1994). For stress fibre and focal adhesion 
formation, tyrosine kinases have been implicated (Ridley & Hall, 1994) as well as
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kinases involved in the synthesis of phosphatidylinositol species, for example Ptdlns- 
4 kinase (Chong et al., 1994) and PtdIns-3 kinase (Zhang et al., 1993). These were 
all thought to be mediated via rho, as ADP-ribosylation of rho by the botulinum C3 
exoenzyme, inhibited LPA-induced protein tyrosine phosphorylation and PtdIns-3 
kinase activation in cultured Swiss 3T3 fibroblasts (Kumagai et al., 1993), correlating 
with the inhibition of LPA-stimulated stress fibre formation reported by Ridley & Hall 
(1992). The products and substrates of both PtdIns-3 and PtdIns-4 kinase have also 
been implicated in the uncapping of F-actin in permeabilized platelets, leading to actin 
assembly. However, this effect is mediated by rac and not rho (Hartwig et a l, 1995). 
This could also be mediated via the activation of a tyrosine kinase, as a
serine/threonine protein kinase has been demonstrated to be activated by rac, termed 
p65, which has sequence homology to the putative protein product of S. cerevisiae
STE20 gene. The product of this gene is required to transmit the pheremone signal
from G-protein py-subunits to downstream components, including the tyrosine kinase
p l2 0 ^LK (Manser et al., 1994). rac has mainly been studied in relation to its role in
the NADPH oxidase complex in phagocytic cells (for review see Segal & Abo, 1993).
The activation of this complex is dependent upon the presence of rac, but is not
.required to be translocated with the complex to the membrane, for activity. It is thus 
thought to play a role in the assembly/configuration of the active complex within the 
cytosol (Le Cabec et al., 1994; Phillips et al., 1995). Both rac and rho have been 
shown to activate MAP kinase cascades (Vojtek & Cooper, 1995), one substrate of 
which is cPLA2 . The metabolites of CPLA2 activity have been implicated in EGF- 
stimulated actin remodelling in A431 cells, with leukotrienes being involved in cortical 
actin polymerization and prostaglandins being involved in the degradation of 
cytoplasmic actin filaments (Peppelenbosch et al., 1993). This has been suggested to 
be due to the regulation of CPLA2 by rac, as a constitutively active rac mutant, racVVl, 
generated leukotrienes in a growth-factor-independent manner (Peppelenbosch et al.,
1995). Therefore, this could be the pertussis-toxin insensitive route of agonist- 
stimulated arachidonic acid release.
A '-;
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1 .3 .4  Priming
Polymorphonuclear neutrophilic leucocytes or neutrophils play a critical role in 
the defence against infecting micro-organisms. Endocytosed bacteria are killed by the 
triggering of a non-mitochondrial oxidase and the subsequent production of a number 
of reactive oxygen species (Babior, 1984). In human neutrophils, the activated 
NADPH-oxidase is a multi-component electron transport chain composed of a
membrane flavocytochrome bggg, containing haem, flavin and NADPH-binding sites 
(Rotrosen et al., 1992) and 3 cytosolic components p47, p67 and rac (Abo et al.,
1991). This (Didsbury et al., 1989) was purified in a complex with rhoGDI
(GDP-dissociation inhibition factor)(Fukumoto et al., 1990). The activation of the 
oxidase has been shown to be mediated by phosphorylation and arachidonic acid 
(Dana et al., 1994). Translocation of rac to the membrane maybe involved, however, 
GTPyS-stimulated NADPH-oxidase activity has been observed without this movement 
of rac (Phillips et al., 1995). The membrane composition may play a role in the 
regulation of NADPH-oxidase, since both phosphatidic acid (Qualliotine-Mann etal..
1993) and DAG (Park & Babior, 1993) activate NADPH-oxidase, suggesting roles 
for PLD, PKC or membrane fluidity changes.
The Respiratory burst is a two-step process involving an initial priming phase
followed by a subsequent triggering event. There are a number of physiologically
important primers, including IL-1, IL-6 , interferon-y (IFN-y), granulocyte-
macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor-a (TNF-
a)(Berkow et al., 1987; Worthen et al., 1988; Borish et al., 1989; Humphreys et al.,
1989; Yuo eta l., 1990; Sample & Czuprynski, 1991; Yuo eta l., 1991) and the
.neurotransmitter undecapeptide substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe- 
Gly-Leu-Met-NH2)(Perianin et at., 1989; Wozniak et al., 1989; Lloyds & Hallett, 
1993). 'Priming' of neutrophils leads to an exaggerated oxidase response to agonists 
such as the peptide fMLP, the complement fragment C5a, interleukin- 8 (DL-8) and 
platelet activating factor (PAF) (Phillips & Hamilton, 1989; Phillips & Hamilton, 
1990). The mechanisms by which priming occurs are as yet unclear.
A number of studies have implicated a rise in intracellular calcium in the 
mechanism of priming (Kuhns et al., 1988; Forehand et al., 1989; Koenderman et al, 
1989), which could induce translocation of PKC to the cell membrane (Phillips et al.,
1989). Later, this same group reported an increase in the expression of an 
uncharacterized isozyme of PKC, in response to various priming agents (Phillips et 
al., 1992). Priming has also been shown to occur in a calcium-independent manner 
(Berkow et a/.,1987; Naccache et al., 1988; Kamad et al., 1989; Lloyds & Hallett, 
1993). The most recent studies into the mechanism of priming have suggested a role 
for tyrosine phosphorylation. Substance P, TNFa and GM-CSF stimulate tyrosine 
phosphorylation in neutrophils (McColl et al., 1991; Grinstein & Furuya, 1992; 
Lloyds et al., 1993), which can be mimicked by the tyrosine phosphophosphatase 
inhibitor, orthovanadate (Swamp et al., 1982). This artificial elevation of tyrosine 
phosphorylation has been shown to prime both neutrophils and differentiated HL60 
cells (Lloyds et al., 1993; Lloyds & Hallett, 1994; Lloyds and Hallett, 1995). This 
group suggest that a 74kDa tyrosine phosphorylated protein is involved in this 
tyrosine phosphorylation-mediated priming response. However, this has still to be 
identified. The main enzyme known to be activated by a tyrosine kinase cascade is 
MAP kinase (Thompson et al., 1993), TNFa may prime by activating the 
sphingomyelin pathway to stimulate ceramide-activated protein kinase, which activates 
raf-l by phosphorylating Thr 269 (Yao et al., 1995). One of the major substrates of 
MAP kinase is CPLA2 (Clark et al., 1991), which has been shown to be translocated 
to a membrane compartment by the priming agent GM-CSF in human neutrophils 
(Durstin et al., 1994). This priming agent increases MAP kinase activity and produces 
a small CPLA2 response on its own, however, it potentiates the arachidonate release to 
a subsequent fMLP stimulation. This could be due to the priming agent causing 
translocation of CPLA2 to a membrane compartment, with the subsequent fMLP- 
stimulated calcium release activating the enzyme. This maximum activation of the 
enzyme is not seen in response to GM-CSF, perhaps since this agonist does not 
stimulate a rise in intracellular calcium concentrations. Therefore, tyrosine
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.phosphorylation caused by the priming agents may be involved in a relocation of the 
enzyme of interest into a more enzymatically favourable en virement and/or 
confirmation.
Another factor which has been shown to enhance many physiological 
responses in neutrophils is cytochalasin B (CytB)(Honeycutt & Niedel, 1986). The 
action of CytB is poorly understood, but is most likely to manipulate the cytoskeletal 
network (for review see Cooper, 1987). This compound is a member of a family of 
cell permeable, fungal metabolites, which inhibit cell ruffling and stimulate adherent 
cells to round up (Schliwa, 1982; Yahara et al., 1982). These effects are thought to be 
due to cytochalasins binding to the 'barbed' end of actin filaments and "capping" 
them. Actin-binding proteins (for review see Weeds, 1982), such as profilins 
(Reichstein & Korn, 1979), cap the 'barbed' end of the actin filaments causing 
monomer dissociation from the 'pointed' end, to establish a new monomer:polymer 
equilibrium (Kirschner, 1980). At physiological KCl and with MgCl2 in excess of 
ImM, actin exists predominately in the polymerised form, with a very small (<lpM) 
concentration of free monomer. The 'capping* effect results in inhibition of actin 
filament growth, producing shortened filaments and a weakened cytoskeleton (TUney 
& Inoue, 1982).
1 .3 .5  Substrate regulation of cPLÂ2 activity
The detailed characterization of the kinetic properties of CPLA2 is complicated 
by the fact that binding of CPLA2 to the lipid-water interface must occur prior to 
catalysis. To study the affinity of the enzyme for its substrate and the factors in the 
membrane which may affect it, various in vitro assays have been utilised. CPLA2 is 
expressed as an activated phosphoprotein in SF9 cells (de Carvalho et al., 1993).
Using this it was found that mixed liposomes consisting of the synthetic negatively 
charged phospholipid dimyristoyl-glycero-phosphomethanol (PM) with 3-5 mol% of 
natural phospholipids, bound CPLA2 irreversibly, but did not produce linear, time- 
dependent phospholipid hydrolysis (Diez et al., 1992). These non-linear kinetics can
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be explained by the reaction products of CPLA2 preventing the dissociation of the 
enzyme from the water/substrate interphase, therefore restricting its access to new 
substrate. In an in vivo system, these products would be metabolized, possibly via 
the enzyme's intrinsic lysophospholipase activity, as discussed in the following 
section.
However, lipid moieties do play a role in CPLA2 regulation as it was shown 
that incorporation of long-chain unsaturated diacylglycerols into substrate 
phospholipid liposomes, markedly enhance CPLA2 activity (Dawson et a l, 1983; 
Dawson et al., 1984). These DAGs promote alterations in the structure of 
phospholipid membranes (Das & Rand, 1986), rendering them more susceptible to 
phospholipase degradation. Anionic phospholipids were also shown to enhance 
cPLA2"hydrolysis of PtdCho liposomes, with phosphatidylinositol-4 ,5 -P2 producing 
the most pronounced effect (Leslie & Channon, 1990). This may act in a similar 
manner to the synthetic substrate PM, i.e. mediating the tight association of CPLA2 
with the substrate and thus lowering the concentration of calcium required for 
maximum activation.
All of this evidence demonstrates that the composition of the membrane and the 
lipid products generated upon cell activation via PIC and/or PLD hydrolysis may 
regulate CPLA2 activity.
1 .4  ROLE OF PHOSPHOLIPASE A2 PRODUCTS
Phospholipids are hydrolyzed to produce free fatty acids and 
lysophospholipids, both of which have been suggested to have a role in cellular 
responses.
1 .4 .1  Lysophospholipids
Lysophospholipids have been shown to play an important role in the 
pathogenesis of a broad spectrum of diseases and have been associated with 
myocardial infarctions, infections, neoplasia and asthma (Weltzien, 1979; Bar-sagi &
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Feramisco, 1986; Mock & Man, 1990; Hall & Laubach, 1991; Langton & Cesaveo,
1992). The least active of the lysophospholipids is lysophosphatidylethanolamine 
(LysoPE), which appears to be utilized in the ethanolamine cycle to resynthesize 
phosphatidylethanolamine (PtdEth), which is found in high concentrations in platelets, 
but in very low amounts elsewhere. Lysophosphatidylserine (LysoPS) is involved in 
the synthesis of PtdCho by enhancing the CDP-choline pathway (Bruni et al., 1992). 
One of the most studied lysophospholipids is lysophosphatidic acid (LPA), which has 
a myriad of effects as described in section 1.6.3. Finally, lysophosphatidylcholine 
(LysoPC) has been shown to be a stereospecific chemoattractant for mouse 
lymphoblastic cells (Hoffman et al., 1982), human monocytes (Quinn et al., 1988) 
and has been postulated to be generated at sites of inflammation, tissue injury and 
repair. Golan et al.{\9%6) demonstrated that the parasite Schistosoma mansoni utilises 
LysoPC to lyse adherent human red blood cells and to fuse to human neutrophils. The 
mechanism by which this extracellular LysoPC mediates many of its effects is yet 
unclear, but Besterman & Domanico (1992) have postulated the possible mechanisms 
and kinetics.
Given the varied functions of lysophospholipids, the concentrations of these 
lipids must be regulated. It has been shown that there is a vast number of 
lysophospholipases, whose activity is increased in the protection of cells from the 
cytotoxic effects of lysophospholipids (Weller et al., 1984), in attenuation of signal 
transduction processes (Asaoka et al., 1992) and in host-mediated destruction of 
parasites (Golan et a l, 1986). These lysophospholipases have been isolated from a 
number of different tissues and cell types, including brain (Gross & Sobel, 1991), 
porcine gastric mucosa (Sunaga et a l, 1995) and neutrophils (Laubach & Hall, 1991). 
Of major interest are the proteins which have been identified to contain both 
lysophospholipase and phospholipase A2 activities, such as cytosolic phospholipase 
A2 . In view of the proposed role of this enzyme in the regulation of non-esterified 
arachidonate by its phospholipase A2 activity (discussed in section 1.4.2), the 
lysophospholipase activity, which was 10-fold higher than that of PLA2 in vitro, may
serve to remove the other product of this activity, the lysophospholipid (Leslie, 1991; 
Pind & Kuksis, 1991). She et a/.(1994) demonstrated that cPLA2 was able to 
hydrolyse all lysoPC species, i.e. with oleoyl, palmitoyl, myristyl or stearoyl in the 
sn-1  position, 1-oleoyl-lysoPS and 1-oleoyl-lysoPA. However, any
1
lysophospholipase activity was abolished when the sn-2 positon was acetylated.
1 .4 .2  Free fatty acids produced by cPLÀ2
1 .4 .2 .1  From lysophospholipase activity
This activity hydrolyses the fatty acid at the sn-l position, which is normally 
saturated, of the lysophospholipid produced after the phospholipase A2 hydrolysis. 
As described above this activity hydrolyses all the lysoPC substrates, releasing 
myristate, stearate, oleate and palmitate. More oleate is produced from the hydrolysis 
of lysoPS and lysoPA. These saturated fatty acids play a role in the homeostasis of 
the cell, but are probably utilized to a greater extent in the reacylation of cellular 
phospholipids via an acyl-CoA synthetase activity with a broad acyl specificity (Chem 
& Kinsella, 1983), which has been identified in liver and adipose tissue (Normann et 
al., 1981). : : l
1 .4 .2 .2  From phospholipase A2 activity
Cytosolic phospholipase A2 activity hydrolyzes the cw-unsaturated fatty acid at
the sn-2 position. This particular enzyme has a preference for arachidonic acid
(C20:4(n-6)), which can account for as much as 25% of the total phospholipid fatty
acid content (Buttke et al., 1985) and is principally synthesized in the liver from
dietary linoleic acid (Habenicht et al., 1990), Arachidonate is transported to various
cell types by serum albumin or lipoproteins and the serum levels are low in
.comparison to other fatty acids. The transported arachidonic acid is incorporated into
.membrane phospholipids, which requires conversion of the fatty acid into
arachidonyl-coenzyme A (AA-CoA) by arachidonyl-CoA synthetase, and its
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-subsequent estérification by arachidonyl-lysophospholipid transferase. Electron 
microscopy autoradiography has been used to study the distribution of arachidonate in 
HSDM iCi murine fibrosarcoma cells (Neufeld et al., 1985). At steady states of 
labelling, i.e. after 24 hours, the plasma membrane had obtained a specific activity 
similar to that of the endoplasmic reticulum, which contained more than half of the 
cell-associated arachidonate at all times. Thus, the ER is a major site for both 
incorporation and storage of arachidonate. Mitochondria were labelled less intensely 
than other membranes, while both the nuclear membrane and other cytoplasmic
'
structures were highly labelled.
Arachidonyl-CoA synthetase has been demonstrated in mouse peritoneal 
macrophages (Fernandez et al., 1992), brain (Jakschitz et al., 1983) and platelets 
(Wilson et al., 1982), which specifically activates arachidonate (20:4(n-6)), 8,11,14- 
eicosatrienoate (20:3(n-9)) and 5,8,11-eicosatrienoate (20:3(n-9)) (Banerjee &
Rosenthal, 1985). These fatty acids can inhibit this enzyme when in excess, which 
would suggest that this enzyme is the rate limiting step of arachidonate incorporation.
However, at physiological arachidonate concentrations, this enzyme is able to keep the 
level of free arachidonate low, thus minimizing basal synthesis of eicosanoids 
(Neufeld et al., 1983). These eicosanoids are metabolites of arachidonic acid which is 
released from intracellular phospholipids upon agonist stimulation. It has been 
suggested that arachidonate acts as an intracellular signal, independent of eicosanoid 
production, as it has been shown to activate calcium channels in ventricular myocytes 
(Huang et al., 1992), release calcium from intracellular stores (Currie et al., 1992) and 
inhibit the expression of stearoyl-CoA desaturase 2 (SCD2) gene (Tebbey & Buttke,
1993).
The eicosanoids are produced from the metabolism of arachidonic acid via the 
cyclooxygenase, lipoxygenase and epoxygenase enzymes. Cyclooxygenase or 
prostaglandin G/H synthase, which catalyzes the conversion of arachidonate into two 
reactive intermediates, prostaglandin G and H, which are precursors of the 
prostaglandins (PG's), prostacyclin (PGI2) and thromboxane (TXA2). Two cDNA's
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encoding cyclooxygenase have been isolated from cDNA libraries of sheep seminal
fluid. One has a 2.8kDa mRNA, which may have splice variants (Diaz et al., 1991)
and appears not to have a role in the inflammatory process. The second cDNA is a 
4.1kDa mRNA, the level of which rapidly increases in human monocytes stimulated 
with pro-inflammatory agents, such as interleukin 1(5 and decreases in response to 
anti-inflammatory agents such as dexamethasone (O'Banion e ta l,  1991; O'Banion et 
a l,  1992). The protein expressed by this 4.1 kDa mRNA is identical to TISIO, the 
product of a primary response gene, which supports the role of arachidonate 
metabolism in the regulation of cell division (Kujubu et al., 1991; Kujubu & 
Herschman, 1992). The role of cyclooxygenase products as mediators of cell division 
was supported by the demonstration that EGF-stimulated prostaglandin E2 (PGE2) 
and F2 ot (PGP2a) generation in BALB/c3T3 fibroblasts, EGF-dependent DNA 
synthesis and c-myc expression, could be inhibited by specific cyclooxygenase 
inhibitors (Handler et a l, 1990). However, the products of the cyclooxygenase 
pathway may also act transcellularly via specific membrane receptors. A high-affinity 
receptor for TXA2 has been identified (Hirata et a l, 1991) along with a PGE2 
receptor, which inhibits adenylyl cyclase (Sugimoto et al, 1992).
The second pathway of arachidonic acid metabolism is the lipoxygenase 
pathway, which produces hydroperoxyeicosatetraenoic acids (HPETE), which 
undergo a complex metabolism to the corresponding hydroxyacids (HETE) or 
leukotrienes. Leukotriene B4 (LTB4) has been shown to be an important modulator of 
immune cell function and is one of the most powerful chemokinetic and chemotactic 
agents known (Rola-Pleszczynski, 1989). High- and low-affinity receptors have been 
identified, which appear to mediate signal transduction pathways via a GTP-binding 
protein (Mong et a l, 1986). The leukotrienes and other lipoxygenase products have 
been shown to activate K+ channels in a variety of cell types (Margalit & Livne, 1991) 
and modulate hormone and neurotransmitter secretion (Freeman et a l, 1991; Bordeau 
et a l, 1992; Landt et a l, 1992). It has also been suggested that other polyunsaturated 
fatty acids, such as linoleic, may be metabolized via this enzyme pathway and play a
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role in mitogenesis (Glasgow & Eling, 1990). Of interest, is that members of both the 
cyclooxygenase (Rollins & Smith, 1980) and the lipoxygenase (Woods et al., 1995) 
pathways have been detected at the nuclear membrane and the endoplasmic reticulum.
A further pathway is the epoxygenase enzymes, which include the cytochrome 
p450 enzyme. This pathway catalyzes the conversion of arachidonate into 
epoxyeicosatrienoic acids (ETT), which are hydrolyzed to corresponding diols by 
epoxide hydrolase (Needleman et al., 1986). The products of this pathway are potent 
inhibitors of the Na+/K+ ATPase activity (McGiff, 1991), which supplies the driving 
force for transcellular transport of electrolytes and organic solutes, playing a central 
role in the reabsoptive capacity of the kidney.
1 .4 .3  Regulation of PKC by phospholipase À2 activation
McPhail et al. (1984) initially demonstarted that PKC could be activated by cis- 
unsaturated fatty acids. Further investigations showed that cf.y-unsaturated fatty acids, 
which are normally located in the sn-2 position of the diacylglycerol backbone, such 
as oleic, lioleic, linolenic, arachidonic and docosahexanoic acids, greatly enhanced the 
diacylglycerol (DAG)- and phorbol ester-dependent activation of PKC (Seifert etal., 
1988; Shinomura etal., 1991; Chen & Murakami, 1992). This enhancement of these 
responses by ci.y-unsaturated fatty acids is similar to that seen in the differentiation of 
HL60 cells to macrophages (Asaoka et al., 1993) and the glutamate release from 
isolated nerve terminals (Herrero et al., 1992). However, cw-unsaturated fatty acids 
cannot activate PKC alone, but only in the presence of DAG or phorbol ester, 
suggesting that these fatty acids prime PKC, by either changing the conformation of 
the enzyme or manipulating the lipid enviroment to one that produces a higher activity. 
The other product of phospholipase A2 activity, lysophospholipid, has a very similar 
role in the regulation of PKC. Lysophosphatidylcholine (LysoPC) the product of PC 
hydrolysis by PLA2 has some biological activities such as enhancement of sustained 
Na+ current (Undrovinas et al., 1992), chemotaxis (Quinn et al., 1988), smooth 
muscle relaxation (Saito et al., 1988) and induction of EGF-like growth factor in
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monocytes (Nakano et al., 1994), but cannot activate PKC alone. Only when added 
to intact cells together with a membrane-permeant DAG or phorbol ester, LysoPC 
significantly potentiates subsequent cellular responses, such as T-lymphocyte 
activation (Berry & Nishizuka, 1990) and HL60 cell differentiation (Asaoka et al.,
1992).
!1.5 INHIBITION OF PHOSPHOLIPASE Ag ACTIVITY AND
CONSEQUENCES TO THE CELL
Type II or non-pancreatic secreted phospholipase A2 is secreted from platelets, 
mast cells and other cell types, exerting its actions in the degradation of foreign 
bacteria (Elsbach & Weiss, 1993), the release of histamine from mast cells (Murakami 
et al., 1992a) and arachidonate release from macrophages and endothelial cell lines
(Murakami et al., 1993; Barbour & Dennis, 1993). Pancreatic secretory 
phospholipase A2 or Type I appears to have a proinflammatory role mediated via a 
specific receptor, leading to a rise in prostaglandins (Arita & Hanasaki, 1993). The 
calcium-independent phospholipase A2 may be involved in the degradation of 
membranes that accompanies myocardial infarction (Gross, 1992) and in the liberation 
of free arachidonate in hormone-stimulated aortic smooth muscle cells (Lehman et al., 
1993). Finally, cytosolic phospholipase A2 functions in a receptor-mediated 
intracellular signal transduction pathway, leading to the rapid release of arachidonate 
from membrane phospholipids and the biosynthesis of eicosanoids (Kramer et al., 
1993a). Therefore, possible phospholipase A2 inhibitors would have a great 
therapeutic value.
The analysis of PLA2 inhibition is more difficult than for most enzymes, as the 
enzymatic hydrolysis of naturally occurring, long-chain phospholipids necessarily 
occurs at the lipid/water interface (for review see Gelb et al., 1994). Inhibition of the 
secretory PLA2 's by various compounds has been extensively studied. Various 
compounds have been isolated from marine organisms, which inhibit both Type I and 
II phospholipase A2 activities (Potts et al., 1992). These naturally occuring products
4 4
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do not resemble the substrate of the enzyme, unlike phospholipid analogues which 
have a phosphonate or phosphate in the place of the ester at the sn-2 position of the 
phospholipid. The analogues are tight-binding inhibitors of SPLA2, but have no effect 
on cytosolic phospholipase A2 (Jain et aL, 1991; Baybunt et aL, 1993). However, an 
analogue of arachidonic acid in which the COOH group is replaced with a 
trifluoromethyl ketone (COCF3), is a tight binding, reversible inhibitor of CPLA2 .
This compound (AACOCF3) is more than 1000-fold less potent as an inhibitor of 
sPLA2's, probably due to the non-specificity exerted by these enzymes for the fatty 
acid at the sn-2 position (Street et al., 1993). Utilization of this inhibitor demonstrated 
that CPLA2 plays an important role in the generation of thrombin-stimulated 
arachidonate release (Bartoli et al., 1994), which results in the inhibition of 12-HETE 
biosynthesis in human platelets (Riendeau et a l, 1994). NMR studies suggested that 
AACOCF3 forms a hemiketal adduct with an active site nucleophile [enzyme-X-
C(OH)(CF3)-AA](Trimble e ta l,  1993).
:
In considering the factors that determine the magnitude of enzyme-inhibitor 
dissociation constants, one must examine not only the interactions of the inhibitor and 
the enzyme, but also the interactions that the inhibitor forms with its enviroment, when 
not bound to the enzyme. Some drugs, such as Chlorpromazine, interact with 
phospholipids and exert their actions by blocking the interaction of proteins with their 
lipid substrates or activators. Chlorpromazine has been demonstrated to inhibit 
transcription initiation in Ehrlich ascites tumour cells, by blocking the interaction of 
PLA2 with anionic phospholipids (Hirai et a l, 1991). The PLA2 affected here has 
still to be determined as crude lysates were used, which has also been the problem 
with a further group of PLA2 inhibitors. These inhibitors include a-Tocopherol, 
which has antioxidant properties in biological membranes, where it prevents the 
peroxidation of membrane lipids (Burton et a l, 1986). Potentially, the effects of 
tocopherols on eicosanoid synthesis may be limited by their poor solubility in aqueous 
solutions. When the phytol chain was shortened, the hydrophobicity of these
I
.1
molecules was increased, corresponding to an increase in the inhibition of
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prostaglandin production. This effect is not due to an inhibition of the cyclooxygenase 
pathway, but by a direct or indirect inhibiton of phospholipase A2 (Pentland et ah,
1992). Indirect inhibition of PLA2 has also been shown to occur in human 
neutrophils, pretreated with BIRM270 (Farina et ah, 1994) and in bombesin- 
stimulated Swiss 3T3 fibroblasts treated with Demethoxyviridine (DMV) and 
wortmannin (Cross et a l, 1995).
DMV and wortmannin belong to the viridine family of steroidal antibiotics (for 
review see Hanson, 1995) and were shown to inhibit bombesin-stimulated 
arachidonate release in Swiss 3T3 fibroblasts in vivo, but had only a small (30%) 
effect upon baculovirus expressed or immunoprecipitated CPLA2 activity.
Wortmannin has been shown to inhibit various agonist-stimulated responses, 
including insulin- and serum-stimulated glycogen synthase kinase-3 (GSK-3) and c- 
m/activity, resulting in MAP kinase inhibition. However, this data was interpreted to 
be due to the specific inhibition of phosphatidylinositol-3 kinase (PI-3 kinase), by this 
compound and not to a direct inhibition of the enzyme being studied. Ptdlns 3-kinase 
is not activated by bombesin in Swiss 3T3 fibroblasts and it has been shown that c~ 
rqf, an upstream activator of MAP kinase, cannot be activated by phosphatidylinositol- 
3,4,5-Pg, the product of PI-3 kinase activity (Cross et al., 1994). Therefore, much of 
the data published based on the specific inhibition of PI-3 kinase by wortmannin, must 
be re-examined.
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1 .6  AGONISTS STUDIED
1 .6 .1  Bom besin
Bombesin is a tetrapeptide isolated from frog skin and has many biological 
roles. The mammalian equivalents of this peptide are gastrin release peptide (GRP) 
and neuromedin B (NMB), which have been shown to play a role in I
neurotransmission (Minamino et al., 1985), exocrine secretion (Knigge et a i, 1984),
to act as growth factors for human foetal (Spindel et al., 1987) and small cell lung 
carcinoma (Cuttitta et al., 1985), as well as be a potent mitogen for Swiss 3T3 
fibroblasts in vitro (Takuwa et al., 1991).
Bombesin binds to a single class of high affinity receptors (Brown et al.,
1988; Sinnett-Smith etal., 1988; Battey et al., 1991) and is a member of the G-protein 
linked, seven transmembrane spanning receptor superfamily. Three subtypes of this 
receptor have been identified, however, there appears to be a preference for one 
specific subtype in any specific cell type (Schrenck et a l, 1989; Shapira et a l, 1991), 
with Swiss 3T3 fibroblasts expressing a GRP receptor subtype as determined by 
using a specific GRP receptor antagonist (Shapira etal., 1991).
The bombesin receptor in Swiss 3T3 fibroblasts is linked to a pertussis toxin 
insensitive G-protein, which may be a member of the Gq/Gn family (Fischer &
Schonbrunn, 1988). This group also demonstrated that occupation of this receptor 
activated PIC, which could lead to a rise in intracellular calcium concentrations via 
inositol-1,4,5-P3 sensitive pools. The transient rise in inositol-1,4,5 -P3 in response 
to bombesin has been well characterised (Takuwa et al., 1987; Cook et al., 1990;
Plevin et al., 1990). Cook et al.(l990) demonstrated that bombesin stimulated a
•I.
biphasic diacylglycerol (DAG) response, with the initial phase corresponding to 
inositol-1,4,5 -P3 generation produced from PIC-stimulated PtdIns-4 ,5 -P2 hydrolysis 
and the second phase has been proposed to be from either PLC- (Muir & Murray,
1987) or PLD-raediated (Cook & Wakelam, 1989) hydrolysis of phosphatidylcholine.
This DAG activates protein kinase C (PKC) as described in section 1.3.2.1, with
evidence that this PKC activity maybe involved in the expression of the cellular 
oncogenes c-fos and c-myc (Bravo et al., 1987).
Bombesin may have a role in cAMP accumulation in Swiss 3T3 fibroblasts, 
but this has still to be clarified (Fischer & Schonbrunn, 1988; Millar & Rozengurt,
1988; Takuwa et al., 1991). Another regulatory pathway stimulated by bombesin is 
tyrosine phosphorylation (Cirrillo et al., 1986), which has been shown to have a 
major role in bombesin-stimulated PLD activation (Briscoe et al., 1995) and in the 
regulation of cytosolic phospholipase A2 as discussed in section 1.3.2.2.
1 .6 .2  Formyl-methyl-leudne-phenylalanine (fMLP)
The neutrophil plays a critical role in nonspecific host defence by responding 
to chemoattractants, such as formyl-Methyl-Leucine-Phenylalanine (fMLP) (a peptide 
derived from a bacterial chemoattractant (Collins, 1987)) and C5a (a peptide derived 
from the C5 complement factor)), leading to accumulation of neutrophils at an 
inflammatory site (Sandborg & Smolen, 1988).
The mechanism by which neutrophils respond to fMLP, is mediated via a 
specific seven transmembrane-spanning, G-protein-linked receptor (Thomas et al.,
1990). This receptor has been shown to exist in both a low- and high-affinity state 
(Fay et ah, 1991; Posner et al., 1994; Prossnitz et al., 1995a), with only the high 
affinity, liganded state interacting with a pertussis toxin-sensitive G-protein (Schreiber 
et al., 1993a), via the second intracellular loop and the carboxyl-terminal domain 
(Prossnitz et a l, 1993; Schreiber et al., 1993b). This carboxyl-terminal domain is a 
substrate for G-protein coupled receptor kinase 2, which may play a role in 
desensitization of the fMLP-receptor (Prossnitz et al, 1995b).
The G-protein involved in the fMLP response was found to be G|2  (Bokoch & 
Gilman, 1984) and has been shown to mediate adenylyl cyclase inhibition (Gilman,
1987). The a-subunit of Gi2 can activate potassium ion channels (Yatani et al., 1988) 
and py-subunits have been shown to regulate specific isoforms of PICP (Camps et a l,
1992). The other phospholipases, i.e. PLA2 and PLD, have also been shown to be
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regulated by GTP-binding proteins and both are activated by fMLP (Cockcroft, 1992), 
however, whether it is Gj2 involved has still to be elucidated (Cockcroft & Stutchfield,
1989).
Recently it has been demonstrated that fMLP stimulated tyrosine 
phosphorylation (Grinstein & Furuya, 1992; Thompson et a l,  1993; Torres et al.,
1993), which led to increased MAP kinase activity. This produced a flurry of interest 
in the pathway leading from the fMLP receptor occupation and MAP kinase activation. 
Grinstein et a/.(1994) highlighted the involvement of MEK-1 and Worthen et 
fl/.(1994) demonstrated the activation of ras and raf-l by fMLP. This raf-l activation 
is not via PKC, as a potent PKC inhibitor had no effect on fMLP-stimulated ra/-l 
activity (Toullec et al., 1991). Therefore, the activation of MEK-1 in response to 
tyrosine kinase-linked receptors (Lange-Carter et a i, 1993), appears to be involved in 
fMLP-stimulated MAP kinase activation. Gi2-mediated activation of ras and rc^A has 
been demonstrated in Rat-la cells transfected with the m2 muscarinic receptor (Winitz 
et a i, 1993), Rat-1 cells transfected with the a2-adrenergic receptor (Alblas et al.,
1993) and fibroblasts stimulated with lysophosphatidic acid (Howe & Marshall,
1993). However, evidence for a direct involvement of a tyrosine kinase in ras or raf 
activation by seven transmembrane-spanning receptors in neutrophils is currently 
lacking.
1 .6 .3  Lysophosphatidic acid
The best known examples of phospholipid-derived signalling molecules 
include diacylglycerol (DAG), inositol-1,4,5-trisphosphate (Ins-1 ,4 ,5 -P3) and 
prostaglandins, which are all rapidly generated when cells are stimulated by certain 
growth factors and hormones. The simplest naturally occuring phospholipids, 
phosphatidic acid (PA) and lysophosphatidic acid (LPA), are of particular interest in 
that they are not only critical intermediates in de novo lipid biosynthesis (for review 
see Bishop & Bell, 1988) and are rapidly produced in activated cells but can also 
stimulate cell proliferation when added to appropriate target cells in culture.
'f
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In agonist-stimulated cells, it has been shown that the level of PA rapidly rises 
within the plasma membrane. PA can be generated via phosphorylation of newly 
formed diacylglycerol (DAG) by DAG kinase (Kanoh et al., 1990) or more directly, 
through the action of cellular phospholipase D (PLD) acting on phosphatidylcholine 
(PC) and perhaps also phosphatidylethanolamine (PE) (Bocckino et al., 1987; Exton,
1990). The generation of LPA during cell activation has been less thoroughly 
examined, however, it has been shown that LPA accumulates rapidly in thrombin- 
stimulated platelets (Lapetina et al., 1981; Watson et al., 1985; Gerrard & Robinson, 
1989). The production of LPA may be secondary to PA formation through the 
activation of a PA-specific phospholipase A2 , which has been identified in platelets 
(Billah etal., 1981).
In addition to being rapidly produced in stimulated cells, PA and LPA can 
exert their own biological effects upon target cells. Tokumura et a/. (197 8 ) 
demonstrated effects on blood pressure of intravenously administered soybean 
lecithin, of which LPA was shown to be the active compound. Subsequent studies 
demonstrated that LPA was in fact a contractile agonist on smooth muscle (Tokumara 
et al., 1980). Both lipid moieties can stimulate thymidine incorporation in Rat-1 
fibroblasts (Van Corven et al., 1992) and LPA is as potent as EGF or 10% foetal calf 
serum. This effect on cell proliferation appears to be highly specific and dependent 
upon the acyl chain length of the LPA species. It has been shown that the long-chain 
LPA species, such as C isii, are more active than the short chain analogues (Van 
Corven et al., 1992). This would be consistent with a model in which the degree of 
partitioning into the lipid bilayer is a major determinant of mitogenic potency of these 
phospholipids. However, the partitioning of LPA into the lipid bilayer cannot fully 
explain the specific intracellular signalling pathways stimulated by this phospholipid.
Nanomolar concentrations of LPA have been shown to induce transient 
increases in intracellular calcium concentrations in many cell types, including Rat-1 
fibroblasts (van Corven et a l, 1989), A431 carcinoma cells (Moolenaar etal., 1986), 
platelets (Watson et a l, 1985), PC 12 cells (Dyer et al., 1992) Xenopus laevis
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oocytes (Durieux et a i, 1992; Femhout et al„ 1992; Ferguson & Hanley, 1992; Tigyi
and Miledi, 1992). LPA has also been shown to induce an increase in overall tyrosine
phosphorylation (Hordijk et al., 1994; Seufferlein & Rozengurt, 1994) and more
specifically, increases the phosphorylation of focal adhesion kinase (pl25^^^)
(Saville et a i, 1994). This latter finding may be involved in the observation, that LPA
induced rapid formation of actin stress fibres and assembly of focal adhesions in
Swiss 3T3 fibroblasts, which was shown to be inhibited by the microinjection of the
low molecular weight G-protein, rho (Ridley & Hall, 1992; Barry & Critchley, 1994).
Further evidence indicating a positive role for G-proteins in LPA signalling, is that
LPA inhibited forskolin-stimulated cAMP accumulation, DNA synthesis (van Corven
et al., 1989) and p2 F^s activation was sensitive to pertussis toxin (van Corven et al.,
1993). Plevin et al.{\99\) demonstrated that GTPyS potentiated LPA-stimulated
phosphatidylinositol-4,5-bisphosphate (PtdIns-4 ,5 -P2 ) hydrolysis and GDPPS
abolished the response. This evidence led to the possibility that LPA-stimulated
.intracellular signalling pathways were mediated via a G-protein-linked, specific cell
surface receptor. However, the existence of a membrane receptor for the compound
has been difficult to prove, as the lipophilic nature of LPA causes unacceptably high
background in binding assays. Therefore, a radiolabelled, photoactivateable
crosslinking LPA analogue, [^^P] diazirine-LPA, which is less lipopholic, was
utilized and found to label a plasma membrane protein with an apparent molecular
.mass of 38kDa (van der Bend et al., 1992). However, the identification of this 
protein has yet to be published. Even though this putative receptor has yet to be 
identified, the evidence supporting the existence of a receptor-mediated LPA response 
outweighs the support for the detergent-like properties of LPA stimulating the 
activities. For example, LPA does not permeabilize cells as measured by Ca^+
.leakage, even at millimolar concentrations (Jalink et a l, 1990) and several cell types, 
such as fresh human neutrophils (Jalink et al., 1990) and K562 cells (a human 
erythroleukaemia line) (Durieux etal., 1993), are unresponsive to LPA, which would 
not be expected of a nonspecific detergent.
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1 .9  AIMS
The aim of this study was to determine the physiological regulation of 
stimulated cytosolic phospholipase A2 and to examine the role of priming in cell 
responsiveness.
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CHAPTER 2
MATERIALS AND METHODS
MATERIALS AND METHODS
2 .1  CELL LINES AND MATERIAL
2 .1 .1  Cell lines
Swiss mouse 3T3 fibroblasts
Kindly donated by Dr.K.D.Brown, A.F.R.C., Institute of Animal Physiology, 
Babraham, Cambridge, CB2 4AT, U.K.
Human promyelocytic leukemic HL60 ceils
Obtained from Dr George Bimie, Beatson Institute for Cancer Research, Bearsden, 
Glasgow, G61 IBD.
Rat-1 and Raf ER4 Rat-1 fibroblasts
Kindly donated by Dr.S.Cook, Onyx Pharmaceuticals, Richmond, CA., USA.
Amersham International pic, Buckinghamshire, England
[5,6,8,9,11,12,14,15-3H]arachidonic acid (214.3Ci/mmol)
[l-l^C]arachidonic acid (55mCi/mmol)
L-3-Phosphatidylcholine, 1 -stearoy 1-2- [1-1 ^ C] arachidonyl (55.6mCi/mmol) 
[9,10-%] oleic acid (2-lOCi/mmol)
[2-3H] myo-inositol (10-20Ci/mmol)
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2.1 .2 .M aterials
The following is a list of sources of the materials used during the course of this 
project.
Affiniti Research Products Ltd., Nottingham, England.
Monoclonal anti-MAP kinase antibody.
I
Rainbow Markers
Enhanced chemiluminescence (ECL) reagent kit 
Sheep anti-mouse HRP-linked antibody
BDH Chemical company, Poole, England
HEPES
Boehringer Mannheim (UK) Ltd., Lewes, England
Bovine serum albumin (fraction V)
ATP
GDPpS
GTPyS
Wortmannin
Canberra Packard, Pangbourne, England
Ultima Flo A.F. scintillation fluid
Costar, Cambridge, MA., USA
Nitrocellulose
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Biorad Laboratories Ltd., Biorad House, Maylands Avenue, Hemel 
Hempstead, Hertfordshire, HP2 7TD
Analytical Grade Anion Exchange Resin, AG 1-X8,200-400 mesh
il
Calbiochem (Novabiochem(U.K.) Ltd.), Nottingham, England
BAPTA/AM 
Microcystin LR 
Pertussis Toxin
"j-
Difco Laboratories, Detroit, Michigan, USA
Streptolysin O
Fisons scientific apparatus, Loughborough, England
Magnesium chloride, sodium chloride, glycine, Tris, sodium dodecyl sulphate, D- 
glucose, potassium chloride
Gibco Life Technologies, Paisley, Scotland
Glutamax, heat-inactivated foetal calf serum, newborn calf serum, sodium bicarbonate 
(7.5%), Dulbecco's Modified Eagle's Medium with Glutamax (DMEM), RPM I1640 
with Glutamax, RPMI 1640 (phenol red free) with Glutamax.
J.& W. Scientific, 91 Blueravine Road, Folsom, CA95630, USA.
DB-23 Gas chromatography column
Pierce and Warriner, Chester, England
Micro BCA protein assay reagent kit
Roche (UK) Ltd., Welwyn Garden City, England
The provision of the drug RO-31-8220, a PKC inhibitor, by Drs. G.Lawton and 
T.Hallam is greatfully acknowledged.
SAPU, Law Hospital, Law, Scotland
Goat Serum 
Sheep Serum
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Whatman Ltd., Maidstone, England
PE SIL G polyester backed Silica G TLC plates 
P81 paper 
Filter paper
All other chemicals were obtained from the Sigma Chemical Co., Poole, England.
: '
Rabbit anti-cPLA2 antibody and partially purified CPLA2 was kindly donated by 
Dr.C.Jackson, Fisons Pharmaceuticals, Loughborough, England.
Mouse anti-MAP kinase antibody (ERK 16) was kindly donated by Dr.J.Tavare,
Department of Biochemistry, University of Bristol, Bristol.
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2 .2  BUFFER COMPOSITION 
Phosphate buffered saline (PBS)
146tnM sodium chloride, 5.4mM potassium chloride, 9.6mM di-sodium hydrogen 
orthophosphate, 1.5mM potassium di-hydrogen orthophosphate.
PBS was adjusted to between pH7.2-7.4 with IM sodium hydroxide and IM 
hydrochloric acid.
Hank's buffered saline
1.26mM calcium chloride, 5mM potassium chloride, 0.5mM magnesium chloride,
0.85mM magnesium sulphate, 137mM sodium chloride, 4mM sodium hydrogen 
carbonate, 0.27mM sodium di-hydrogen phosphate.
/When freshly prepared, the pH was adjusted to between 7.2-7.4.
Low calcium (ISOnM) Hank's buffered saline (Hanks)
1.26mM calcium chloride, 0.5mM magnesium chloride, 0.9mM magnesium sulphate, 
5.37mM potassium chloride, 137mM sodium chloride, 4.2mM sodium hydrogen 
carbonate, 0.35mM sodium di-hydrogen phosphate, 2.5mM EGTA 
When freshly prepared, the pH was between 7.2-7.4
Low calcium Hank's buffered saline with glucose and BSA (IcHBG)
Hanks was prepared as above and lOmM D-glucose, 20mM Hepes and 0.1% (w/v) 
BSA (fraction V) added and the pH was adjusted to 7.4.
DMEM with glucose and BSA (DBG)
Powdered Dulbecco's modified eagle's medium was reconstituted in distilled water as 
per manufacturers instructions and lOmM D-glucose (final concentration), 0.1% (w/v) 
BSA (fraction V), 20mM Hepes, 0.375% (w/v) sodium bicarbonate added. The pH 
was adjusted to 7.4 at 37°C.
RPMI 1640 with glucose and BSA (RBG)
RPMI 1640 with or without phenol red with lOmM D-glucose (final concentration), 
0.1% (w/v) BSA (fraction V), 20mM Hepes, 0,375% (w/v) sodium bicarbonate 
added. The pH was adjusted to 7.4 at 37°C.
Permeabilisation buffer
20mM Hepes, 120mM potassium chloride, 6 mM magnesium chloride, 2mM 
potassium di-hydrogen orthophosphate, 0.1 mM EGTA, 61|iM calcium chloride 
(0.5mM calcium), 2.5mM ATP and 1 mg/ml BSA.
The pH was adjusted to 7.4 with IM potassium hydroxide.
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2 .3  CULTURE AND PRESERVATION OF CELL LINES.
2 . 3 . 1  Routine culture
Cells were incubated at 37°C, in a humified atmosphere of air/C0 2  (19:1). 
Cells were discarded at passage 14 or if they exhibited aberrant or transformed
morphology.
'■W
Adherent cell lines
Swiss 3T3 mouse and Rat-1 fibroblasts were maintained in Dulbecco's 
modified eagle’s medium with Glutamax containing 10% (v/v) newborn calf semm.
-
ARat-1 Raf ER4 fibroblasts were maintained in this medium supplemented with 
400|ig/ml Geneticin.
Suspension cell lines
Human promyelocytic leukemic HL60 cells were maintained in RPMI 1640 
medium with Glutamax, containing 15% (v/v) heat-inactivated foetal calf serum, at a 
density of 2 x10  ^cells per ml medium.
2 . 3 . 2  Cell passage
Adherent cell lines
:Sterile trvpsin for cell passage
0.1% (w/v) Trypsin, 0.85mM EDTA, lOmM glucose was prepared in PBS (pH7.4).
Aliquots were filtered and stored at -20°C.
When no greater than 70% confluent, the cells were passaged at a ratio of 1 to
5.
I
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Suspension ceils 
HL60 cells were passaged every 3 days when the density was normally 1x10^ 
cells per ml (determined using a haemocytometer). A specific volume of cell 
suspension was removed and added to fresh medium to give a final cell density of 
2 x10  ^cells per ml.
2 . 3 . 3  Cryogenic preservation of cell lines
Adherent cells
.i
Cells were removed from the flask surface by trypsinisation. Swiss 3T3 and 
Rat-1 fibroblasts were then resuspended in medium containing 20% (v/v) newborn 
calf serum and 8 % (v/v) DMSO in DMEM with Glutamax. 1ml aliquots containing 
approximately 10  ^cells were frozen in cryogenic freezing vials at -20^C for 2  hours 
and then left overnight at -80%, before being submerged in liquid nitrogen. Rat-1 
Raf ER4 cells were treated exactly as Swiss 3T3 fibroblasts, but they were
resuspended in foetal calf serum containing 10% DMSO (v/v), after trypsinisation.
They were aliquoted and frozen as described.
Suspension cells
■The cell density of the HL60 cells was determined and then the cell suspension 
was centrifuged at lOOxg for 3mins. The cell pellet was then resuspended in medium 
containing 20% (v/v) foetal calf serum and 8 % (v/v) DMSO in RPMI 1640 with 
Glutamax, to give a density of 10^ cells per ml. The cells were then aliquoted into 
cryogenic freezing vials and frozen down exactly as described for the adherent cells.
Cells brought up from storage in liquid nitrogen were thawed rapidly at 37^0 
and the contents of one vial was added to 10ml of the appropriate complété medium in 
a 25ml centrifuge tube. The cells were then pelleted by centrifugation at 100 xg for 3
I
minutes. The supernatant was discarded and the cells resuspended in fresh complete 
medium. This washing process was repeated 3 times and the adherent cells were
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resuspended in 5ml of the appropriate complete medium and transferred to a 25cm^ 
tissue culture flask and incubated overnight.
In the case of the suspension cells, the final pellet was resuspended in 10ml of 
fi'esh medium and transferred to a 80cm^ tissue culture flask and incubated. After 24 
hours, the adherent cells were either passaged into 80cm^ flasks, or fed with fresh 
medium.
2 .4  MEASUREMENT OF ARACHIDONIC ACID GENERATION
2 . 4 . 1  Preparation of samples for radioactive measurements
Adherent Cells
Swiss 3T3 fibroblasts were seeded at a density of 2x10^ cells per mi into 24 
well plates in DMEM containing 10% (v/v) NBCS. When the cells were between 80- 
90% confluent, the media was removed and replaced with DMEM containing either 
2% (v/v) or 10% (v/v) NBCS and 0.5|iCi [5,6,8,9,11,12.14,15-3H] arachidonic acid 
per well. Rat-1 and Raf ER4 Rat-1 fibroblasts were seeded at IxlO^ cells per ml in 
DMEM containing 10% (v/v) NBCS and 400p.g/ml Geneticin in the case of the Rat-1 
Raf ER4 fibroblasts. When between 80-90% confluent, the media was aspirated and 
replaced with DMEM containing 0.5fiCi [5,6,8,9,11,12,14,15-^H] arachidonic acid 
per well.
After the labelling period of 24-36 hours, cells were washed 3 times with %
0.5ml DBG containing 0.1% BSA (w/v) (FractionV), 20mM Hepes (pH7.4) and 
lOmM glucose at 37% for a total of 45mins. 200p.l of agonist, which was diluted in 
DBG containing 0.1% (w/v) BSA, was used for the stimulations as described. For
I
control time points, buffer alone was added.
To terminate the reaction, when measuring intracellular arachidonate release,
the media was aspirated and 500|al ice-cold methanolracetic acid (100:1.5) was added.
.There was no initial aspiration when the total arachidonate level was being studied.
The wells were then scraped using a wax-filled pipette tip and the suspension added to
'■'I
60
61
a 2ml glass vial on ice. The wells were washed with a further 200)111 methanohacetic 
acid (100:1.5), which was transferred to the glass vial. Lipids were extracted by the
:-ivaddition of 350fxl chloroform and 4|Ltg arachidonic acid. Vials were vortexed and 
either left at room temperature for 30min or overnight at -20°C.
Following extraction, the phases were split by adding 350|il of chloroform and 
630|il, in the case of intracellular arachidonate samples, or 430fil, in the case of total 
arachidonate measurements, of water to each vial and vortexed. The samples were 
then centrifuged at 1000 xg for 5min. The upper aqueous phase and the interface of 
cell debris was removed and the lower, organic phase was dried down under vacuum 
in a vacuum centrifuge. The samples were then returned to ice, ready for thin layer 
chromatography.
Suspension Cells 
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 with glutamax 
medium containing 15%(v/v) heat-inactivated foetal calf serum (HIFCS) and 1.3% 
(v/v) DMSO. They were allowed to differentiate for 3 days before 0.25fxCi per ml 
[5,6,8,9,11,12,14,15-%] arachidonic acid was added for 17 hours.
To remove labelling medium, cells were pelleted by centrifugation at 100 xg 
for 3 minutes. The cell pellet was resuspended in RPMI 1640 containing 0.1% BSA 
(w/v) (fraction V) and incubated for 2 hours. The cells were pelleted again and 
resuspended to a density of 1x10^ cells per ml in RPMI 1640 containing 0.1% BSA 
(w/v), 20mM Hepes (pH7.4) and lOmM Glucose. lOOp.1 of the cell suspension was 
added to 2ml glass vials at 37°C. Agonists were made up in RPMI 1640 containing 
0.1% BSA (w/v), 20mM Hepes (pH7.4) and lOmM Glucose. The same buffer was 
added for the control time points. 50}il of agonist or buffer was added and the 
suspension agitated and incubated for the desired time. Reactions were terminated by 
adding 700|il methanohacetic acid (100:1.5) and incubation on ice. Lipids were 
extracted by the addition of 350|il chloroform and 4|ig arachidonic acid. Vials were 
vortexed and left either at room temperature for 30min. or overnight at -20%.
- :
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After extraction, phases were split by the addition of 350p.l chloroform and a 
volume of water, which when added to the volume of the reaction volume, gave 630[il 
total. The vials were then centrifuged at 1000 xg for 5 mins and the upper and inter­
phase removed. The lower phase was dried down in a vacuum centrifuge in 
preparation for thin-layer chromatography.
2 .4 . 2  Thin Layer Chromatography
Samples were resuspended in 30[il chloroform methanol (2:1) and spotted 
onto Silica Gel, PE SIL G polyester backed plates which had been heat activated at 
120% for 30 min. A further 15p.l was then used to wash out the vials and this was 
spotted onto the silica plate. The plates were developed in a pre-equilibrated thin-layer 
chromatography tank containing hexane:diethylether:acetic acid(glacial) (70:30:2 v/v). 
When the solvent front was at the top of the plates, they were removed and allowed to 
air dry, before being placed in an iodine tank to visualise the arachidonic acid.
The iodine-stained arachidonate spot was identified and each spot was marked 
in such a way that an equal area was outlined. The plates were then placed face down 
over a steam bath, in order to get rid of any final traces of iodine and to soften the 
silica. The silica spots were excised from the plate and placed in a scintillation vial. 
1ml of methanol was added to the silica and left for 15minutes, before 10ml 
scintillation fluid was added. The scintillation vials were then capped, vortexed and 
placed in the dark overnight, before the radioactivity content was determined using 
liquid scintillation spectrophotometry.
2 .5  WESTERN BLOT ANALYSIS
2 . 5 . 1  cPLA2 l o c a t i o n  AND PHOSPHORYLATION STATE
2 . 5 . 1 . 1  Preparation of samples 
Adherent cells
Swiss 3T3 fibroblasts were grown in 80cm^ flasks in DMEM containing 10%
(v/v) newborn calf serum until 80-90% confluent. After this time the medium was 
changed to contain either 10% (v/v) or 2% (v/v) NBCS and left for 24 hours, to 
synchronise both populations into the Gq/G i phase of the cell cycle. This occured by 
either contact inhibition for the cells in high serum or by serum starvation as in the 
case of those in DMEM containing 2% (v/v) NBCS.
Rat-1 fibroblasts were grown in SOcm  ^flasks in DMEM containing 10% (v/v)
NBCS until 80-90% confluent. The medium was then changed to serum-free DMEM 
for 24 hours.
Raf ER4 Rat-1 fibroblasts were grown in 80cm^ flasks in DMEM containing 
10% (v/v) NBCS and 400|Lig/ml geneticin until 80-90% confluent. The medium was I
then changed to serum-free DMEM for 24 hours.
For experiments, the cells were washed 3 times with DBG containing 0.1%
(w/v) BSA at 37%  in a total of 45minutes, before treatment with the test reagent. 
Reactions were terminated by media aspiration and 2 rapid washes with ice-cold PBS, 
before adding 5ml PBS and placing on ice. The cells were scraped into the PBS and 
the cell suspension transferred to a 25ml centrifuge tube. The flask was then washed 
with a further 5ml PBS which was added to the cell suspension.
Suspension cells 
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium 
containing Glutamax, 15% (v/v) heat-inactivated foetal calf serum and 1.3% (v/v)
;;DMSO and differentiated for 4 days. The cells were pelleted by centrifugation at 100
63
xg for 3 minutes and resuspended in 20ml RPMI 1640 containing 0.1% (w/v) BSA, 
lOmM glucose and lOmM Hepes (pH7.4). This washing procedure was repeated, 
before the cell pellet was resuspended to a density of 1x 10  ^ cells per mi. 1ml cell 
suspension was incubated at 37%  in a 15ml centrifuge tube. Test reagents were 
added as indicated, with gentle agitation after each addition. Reactions were 
terminated by addition of 10ml ice-cold PBS and transfer to ice.
2 . 5 . 1 , 2  Lysis procedure
The cells were pelleted by centrifuging at lOOOxg for lOminutes. The 
supernatant was discarded and the pellet resuspended in 0.5ml of ice-cold Lysis buffer 
1 (20mM Hepes(pH7.4), 2.5mM EGTA, 20mM PMSF, 2mM orthovanadate, 
40p,g/ml leupeptin and 40|ig/ml aprotinin) and placed on ice for 1 hour. The cell 
suspension was homogenised in a 1ml glass-on-glass homogeniser. The homogenate 
was then transferred to an eppendorf tube and spun at 50xg for 5 minutes to pellet the 
nuclei and any unbroken cells. The supernatant was then transferred to 1ml 
ultracentrifuge tubes and centrifuged at 150000xg for SOminutes.
The supernatant was carefully removed and transferred to an eppendorf, to 
which 0.5ml ice-cold lysis buffer 2 (lysis buffer 1 plus lOOmM NaF, lOmM MgCl2 , 
2mM EDTA, 2mM NaCl, 80mM NaPPi and 2% (w/v) Triton X-100) was added and 
the samples vortexed, before being stored on ice. The membrane pellet was 
resuspended in 0.5ml lysis buffer 3 (lysis buffer 1 with 50mM NaF, 5mM MgCl2 , 
ImM EDTA, ImM NaCl, 40mM NaPPi and 1% (w/v) TritonX-100) transferred to an 
eppendorf tube and vortexed. Both the cytosolic and membrane fractions were then 
sonicated in a sonicating water bath for 5 minutes to ensure solubilisation. Insoluble 
material was pelleted by centrifugation at 4°C at 14000 xg for 15mins and the 
supernatants were transferred to fresh eppendorf tubes. Lysates were stored at -8CNC. 
The protein concentrations of the lysates were determined using the micro BCA 
protein assay kit.
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2 . 5 . 1 . 3  TCA precipitation of samples for western blot analysis.
■The protein content of each lysate was adjusted to that required in 0.95ml 
distilled water. lOpl of 2% (w/v) deoxycholate was added and the samples vortexed.
The proteins were then precipitated by the addition of 0.25ml of 24% (w/v) 
trichloroacetic acid (TCA) and incubation at 4^C for 15 minutes. The proteins were
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Ïthen pelleted by centrifuging at 14000 xg for 20 minutes at 4oC. The supernatant was 
removed and 20 pi of 2M Tris/HCl (pH 8.3) and Lamelli (30% (w/v) urea, 5% (w/v) 
SDS, 6 % (w/v) DTT, 20mM Tris/HCl (pH8.3) and 0.2% (w/v) bromophenol blue) 
was added to each pellet. The samples were vortexed and allowed to solubilise for at 
least one hour at room temperature. The samples were pulsed in a microcentrifuge in 
preparation for SDS-PAGE.
I-'®
2 . 5 . 1 . 4  SDS-PAGE for cPLAi
Phosphorylated and non-phosphorylated CPLA2 were separated on 22x16cm, 
1.5mm thick, vertical polyacrylamide gels using 12.5% "low bis" polyacrylamide 
resolving gels as kindly explained by Dr.Lin-Ling Lin (Genetics Institute, Boston, 
MA, USA). These gels have the following constituents :
30% (w/v) Acrylamide 18.66ml
1% (w/v) Bisacrylamide 4.50ml (0.1% final)
L5M Tris/HCl (pH 8.3) 11.00ml
10% (w/v) SDS 0.45ml
Water 9.23ml
10% (w/v) ammonium persulphate (APS) 220pl
TEMED 25pl
Prior to the addition of the 10% (w/v) APS and the TEMED the pH was 
always checked to be pH 8.3, as this is critical for the separation of phosphorylated
:and non-phosphorylated forms of cPLA2 - Immediately after preparation, the
:
resolving gel was poured into the gel apparatus and overlaid with 0.1% (w/v) SDS,
When polymerised, the overlay was removed and 3% polyacrylamide stacking gels 
(pH 6 .8) were poured and the comb positioned.
2 . 5 . 1 . 5  SDS-PAGE gel electrophoresis
Polymerised gels were assembled into the gel apparatus as described by the 
manufacturers and the wells filled with running buffer (25mM Tris, 190mM Glycine,
0.1% (w/v) SDS). Samples were loaded into the wells using a Hamilton syringe and 
run at 35 mAmps, 60 volts per gel for 36 hours until the 30kDa marker had run off the 
resolving gel. 2 0 jig of CPLA2 partially purified protein was also loaded.
2 . 5 . 1 . 6  Immuno-blotting of CPLA2
After electrophoresis the higher molecular weight proteins (200-68kDa) were 
transferred to nitrocellulose by wet blotting in a buffer containing 25mM Tris, 190mM 
Glycine, 0.1% (w/v) SDS and 20% (v/v) methanol, according to manufacturers 
instructions. Gels were routinely stained with Coomassie-blue stain (500ml distilled 
water, 400ml methanol, 100ml acetic acid and 0.1% (w/v) coomassie blue) and 
destained (500ml distilled water, 400ml methanol and 1100ml acetic acid) subsequent 
to blotting, to check for efficiency of transfer.
The nitrocellulose was rinsed briefly in NaTT (150mM NaCl, 20mM Tris/HCl 
pH 7.2. 0.1% (v/v) Tween 20), then blocked for 4 hours at 4°C in NaTT containing 
5% (w/v) non-fat milk (NFM) and 5% (v/v) goat serum. The blot was then incubated 
overnight at 4°C or for 2 hours at room temperature in NaTT containing 1 % (w/v)
NFM, 1% (v/v) goat serum and a 1:10,000 dilution of rabbit anti-cPLA2 antibody.
After incubation with first antibody, the blot was washed in NaTT containing 1%
(w/v) NFM for 2 hours, changing the wash buffer frequently. The nitrocellulose was 
then incubated at 4°C for 1.5 hours in NaTT supplemented with 1% (w/v) NFM and a 
1:2000 dilution of goat anti-rabbit IgG linked to horseradish peroxidase and pre­
absorbed with human serum proteins (IgG-HRP). The blot was then repeatedly 
washed over 2 hours with NaTT. The horseradish peroxidase labelled proteins were
Î
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detected using enhanced chemical luminescence (ECL). Luminescence was detected 
by autoradiography film for times ranging from 10 seconds to 10 minutes.
2 . 5 . 2  MAP KINASE DETECTION AND PHOSPHORYLATION
STATE
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2 . 5 . 2 . 1 Preparation of cell lysates 
Adherent cells
Swiss 3T3 and Rat-1 Raf ER4 fibroblasts were grown in 6 -well tissue culture 
plates and quiesced as described in section 2.4.1, After agonist stimulation, the 
reactions were terminated by washing twice with ice-cold PBS. To 5 wells of each 
plate, 0.5ml Laemilli buffer was added. The remaining well of each tissue culture 
plate was used for the determination of protein content, by incubating with 1ml PBS 
containing 0.1% (v/v) NP 40 at 37%  for 1 hour. The samples were then transferred 
to eppendorf tubes and sonicated in a water bath for 5 minutes. Any insoluble material 
was removed by centrifuging at 14000xg for 15 minutes. Protein content was 
determined using the micro BCA protein assay kit.
Suspension cells
HL60 cells were grown at a density of 5x10^ cells per ml in RPMI medium 
containing 15% (v/v) HIFCS and 1.3% (v/v) DMSO for 5 days. Cells were pelleted 
and resuspended in RPMI containing 0.1% (w/v) BSA and lOmM glucose, to a 
density of 1x10^ cells per ml. 1ml of cell suspension was added to 15ml centrifuge 
tubes and stimulated. The reaction was terminated by the addition of 10ml ice-cold 
PBS and transfer to ice. Cells were pelleted by centrifugation and the supernatant 
discarded. To each pellet, 0.5ml Lamelli buffer was added and the samples 
solubilised at 37°C for 1 hour. One pellet was used for protein determination as 
described above. Insoluble material was pelleted by centrifugation.
1
.
2 . 5 . 2 . 2  SDS-PAGE for MAP Kinase
SDS-PAGE analysis of cell lysates was performed in vertical 1.5mm thick, 
polyacrylamide gels, with the size and constituents of the gels being identical to those
total protein was added to each well and the gels run for 36 hours at 35mA, 60 volts 
per gel or until the 30kDa marker had run off the resolving gel.
68
' - '■ 'S M i?
.for cPLA2 described in Section 2.5.1.5. A volume of sample corresponding to 50|ig
2 , 5 . 2 , 3  Immuno-blotting of SDS-PAGE gels for MAP kinase
After electrophoresis the lower molecular weight (68-30kDa) proteins were 
transferred to nitrocellulose by wet blotting in buffer containing 25mM Tris, 190raM 
Glycine, 0.1% (w/v) SDS and 20% (v/v) methanol, according to manufacturers 
instructions. Gels were routinely stained with Coomassie-blue stain subsequent to 
blotting, to check the efficiency of transfer.
The nitrocellulose was rinsed briefly in NaTT (150mM NaCl, 20mM Tris/HCl 
pH 7.2. 0.1% (v/v) Tween 20), before blocking at 4^C for 4 hours in NaTT 
containing 3% (w/v) BSA. Nitrocellulose was then incubated overnight at 4°C or for 
2 hours at room temperature, with a 1:500,000 dilution of a monoclonal anti-ERK 1/2 
antibody in NaTT containing 1% BSA (w/v). Membranes were then washed 
extensively for a total of 2 hours in NaTT, prior to a 2 hour incubation at 4°C with a 
1:10,000 dilution of a sheep anti-mouse IgG linked to horseradish peroxidase in 
NaTT. The membranes were then washed for 2 hours in NaTT, with the wash buffer 
being changed frequently. The horseradish peroxidase linked proteins were then 
detected using ECL. Luminescence was detected by autoradiography for times 
ranging from 10 seconds to 10 minutes.
,dii'
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2 . 5 . 3  DETECTION OF TYROSINE PHOSPHORYLATED
PROTEINS
2 . 5 . 3 . 1  SDS-PAGE gel preparation for Tyrosine phosphorylation
The preparation of samples for tyrosine phosphorylation detection was 
identical to that described in Section 2.5.2.1. SDS-PAGE analysis of samples carried 
out on vertical, 14x16cm, 1.5mm thick, 10% (w/v) polyacrylamide gels, which 
comprised of:
30% (w/v) acrylamide : 0.8% (w/v) bisacrylamide 8.0ml 
1.5M Tris/HCl : 0.4% (w/v) SDS (pH 8 .8 ) 6.0ml
50% (v/v) Glycerol 1.6ml
Water 8.2ml
1 0 %  (w/v) APS 9 0 j L t l
TEMED 8pl
Prior to the addition of the 10% (w/v) APS and the TEMED the pH was 
readjusted to 8 .8 . Immediately after preparation, the resolving gel was poured into the 
assembled gel apparatus and overlaid with 0.1% (w/v) SDS. Following 
polymerisation, the overlay was removed and a 3% (w/v) polyacrylamide stacking gel 
(pH 6 .8 ) was poured and the comb positioned.
. / !Polymerised gels were assembled and the wells filled with running buffer 
(25mM Tris, 190mM glycine, 0.1% (w/v) SDS). A volume of sample corresponding 
to 50|xg total protein was loaded and the gels run overnight at 12mA, 30volts per gel 
until the dye front reached the end of the resolving gel.
2 .5 .3 .2  Imm unoblotting of SDS-PAGE gels for Phosphotyrosine
After electrophoresis, the proteins were transferred to nitrocellulose by wet- 
blotting with efficiency of transfer being Checked, as previously described.
The nitrocellulose was rinsed briefly in NaTT, then blocked for 4 hours in 
NaTT containing 3% (w/v) BSA. The blot was then incubated overnight at 4®C in 
NaTT containing 3% (w/v) BSA and a 1:5000 dilution of PY54 antibody. After 
incubation with the first antibody, the blot was washed in NaTT for 2 hours, changing 
the wash regularly. The nitrocellulose was incubated at 4°C for 1 hour in NaTT 
containing 3% (w/v) BSA and a 1: 10,000 dilution of sheep anti-mouse IgG linked to 
horseradish peroxidase and pre-absorbed with human serum proteins. The blot was 
then washed repeatedly over the next 2 hours with NaTT.
ECL was used to detect horse radish peroxidase linked proteins, with 
luminescence being detected by autoradiography for times ranging from lOseconds to 
10 minutes.
2 .6  MAP KINASE IN  VITRO  ACTIVITY MEASUREMENTS
2 .6 .1  Preparation of samples
Adherent cells
Swiss 3T3 and Rat 1 Raf ER4 fibroblasts were seeded into 60x15mm3 petri 
dishes at 2x 10  ^cells per ml, cultured and quiesced as described in Section 2.5.1.1.
On the day of the experiment, the petri dishes were washed 3 times for a total 
of 30 minutes at 37®C with DBG. Stimulations were carried out as described and 
reactions terminated by washing twice with ice-cold PBS and transfer to ice. The PBS 
was replaced with 0.5ml Lysis buffer (ImM potassium dihydrogen phosphate, ImM 
EDTA, lOmM MgCl2 , 50mM p-glycerophosphate, 5mM EGTA, ImM sodium 
orthovanadate, 40|ig/ml aprotinin, 40jag/ml leupeptin, O.lmM PMSF and 0.5% (w/v) 
Triton X-100) and incubated on ice for 1 hour. The dishes were scraped and the 
suspension transferred to eppendorf tubes, which were vortexed and centrifuged at
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14000 xg for 15 minutes to pellet insoluble material. The supernatant was transferred 
to a fresh eppendorf and the protein content of each sample determined using the BCA 
protein assay kit. A volume corresponding to 50|ig of total protein was then removed 
to assay MAP kinase activity.
Suspension cells
HL60 cells were seeded at 5x10$ cells per ml, maintained and differentiated as 
described in Section 2.5.1.2. The cell density was determined using a 
haemocytometer and the cells washed twice in RBG. The final washed pellet was 
resuspended in the RBG at a density of 2x10? cells per ml and lOOpl of this 
suspension was incubated at 37°C in eppendorfs. Agonists were diluted in RBG and 
stimulations carried out as described. Reactions were terminated by washing twice in 
1ml ice-cold PBS, with the final washed pellet resuspended in 0.5ml lysis buffer and 
incubated on ice for 1 hour. The samples were vortexed and centrifuged at 14000xg 
for ISminutes to pellet insoluble material. The supernatant was transferred to fresh 
eppendorfs and the protein content determined using the BCA protein assay kit. A 
volume corresponding to 50)ig total protein was transferred to a clean eppendorf, 
ready for MAP kinase activity measurements.
2 . 6 .2  MAP kinase activity measurements
The samples containing 50p,g protein were made up to 500pl with lysis buffer, 
to which 5|i.l of rabbit anti-ERK 1/2 was added and allowed to mix for 2 hours at 4®C. 
The immunocomplexes were captured by addition of protein-G to the samples and 
mixing for 1 hour at 4^C. Protein G complexes were pelleted by centrifuging at 
14000 xg for Iminute. The pellet was then washed twice in buffer A (ImM Tris/HCl 
[pH7.2], 0.5% (w/v) sodium deoxycholate, lOOmM NaCl, ImM EDTA, ImM 
sodium orthovanadate and 1% (w/v) Triton X-100), twice in buffer B (ImM Tris/HCl 
[pH7.2], IM NaCl, ImM sodium orthovanadate and 0.1% (w/v) Triton X-100) and 
once in buffer C (5mM Tris/HCl [pH7.2] and 150mM NaCl).
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To the final pellet, 20|il assay buffer (50mM MOPS (pH7.4), 3.75mM EGTA, 
25mM MgCl2 , 0.25mM sodium orthovanadate, 2|iM IP20 and 5p,M microcystin LR) 
was added along with 0.5mg myelin basic protein in a final total volume of 45jil. The 
total reaction mixture was then mixed gently and pelleted by pulsing in a bench top 
microfuge. All additions were carried out at 4°C.
Reactions were initiated by the addition of 5|0.10.5mM ATP containing 5p.Ci 
[y-32p] ATP, mixing and incubating at 30°C for lOminutes. Reactions were 
terminated by the addition of 50|il ice-cold 2M HCl and tubes were transfered to ice.
The reaction mixture was pelleted by centrifugation at 14000xg for 1 minute at 4°C. 
The samples were then carefully resuspended and 50|il of each suspension spotted 
onto P81 paper, which was carefully washed with a total of 1 litre of 150mM 
orthophosphoric acid, with the wash being changed frequently. Finally, the papers 
were washed briefly in 100% ethanol and allowed to air dry. The samples had been 
spotted onto defined areas, which were removed and added to scintillation vials along 
with 1ml of methanol. After 30minutes at room temperature, 10ml of scintillation 
fluid was added, the vials vortexed and placed in the dark overnight, before the 
radioactivity was determined by liquid scintillation spectrophotometry.
2 ,7  CYTOSOLIC PHOSPHOLIPASE A-> IN VITRO ACTIVITY 
MEASUREMENTS.
2 . 7 . 1  Preparation of substrate
A stock of liposome was prepared as follows:
167.5jig stearoyl-arachidonyl phosphatidylcholine, 2|xCi stearoyl-f^^C] 
arachidonyl phosphatidylcholine, 8 |ig phosphatidylinositol-4,5-bisphosphate (PIP2) 
and 29p.g l-stearoyl-2-arachidonyl glycerol (DAG) were mixed and dried under a 
stream of nitrogen. 15ml 50mM Tris/HCl (pH 7.4) was then added and the solution 
vortexed for 30 seconds, prior to freezing in dry ice for 15 minutes.
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Prior to use, the substrate was thawed whilst sonicating in a sonicating water 
bath at room temperature and quickly vortexed.
2 .7 .2  Assay procedure
The liposomes were diluted to a final volume of 0.5ml in 100|iM KCl, 10|iM 
CaCl2 and 50mM Tris/HCl (pH7.4) to give a liposome containing 7pM l-stearoyl-2- 
arachidonyl phosphatidyl choline (containing [^^C] in the two position), 2.3|iM 1- 
stearoyl-2-arachidonyl glycerol and 0.3p.M phosphatidylinositol-4,5-bisphosphate. 
The liposome mixture was added to round bottom glass tubes and placed on ice. The 
liposomes were then pre-incubated for 5 minutes at 37°C in the presence of inhibitor 
or vehicle.
The reaction was initiated by the addition of either partially purified cytosolic 
phospholipase A2 from platelet cytosol, total cell lysate from Swiss 3T3 fibroblasts or 
immunoprecipitated CPLA2 from Swiss 3T3 fibroblasts. Immunoprécipitation was 
carried out as described in section 2 .6 .2 , using a 1:10  dilution of rabbit anti-cPLA2 
antibody. After washing, the final pellet was resuspended in 50(il 50mM Tris/HCl 
(pH7.2) and added to the prepared liposomes. This immunoprécipitation isolated both 
phosphorylated and non-phosphorylated CPLA2 as shown in figure 2.7.2. Upon 
addition of enzyme, the samples were vortexed and returned to 37°C for a further 5 
minutes. The reaction was terminated by the addition of 700|il ice-cold 
methanol:acetic acid (100:1.5) and transfer to ice.
350|il of chloroform was added and the samples vortexed. They were then left 
at room temperature for 30 minutes to allow extraction of the lipids into the organic 
solvent. The phases were split by the addition of 350|il of chloroform, 130|il of 
water, vortexing and centrifuging at lOOOxg for 5 minutes. 600|il of the lower 
organic phase was then transferred to a 2 ml glass vial and dried in a vacuum 
centrifuge. Free [^"^CJarachidonate was isolated by thin-layer chromatography and 
quantified by liquid scintillation spectrometry as previously described in Section
2.4.2.
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Figure 2.7.2 Immunoprécipitation of cytosolic phospholipase A2
Rat-1 Raf ER4 fibroblasts were grown in SOcm  ^flasks in DMEM containing 10% (v/v) 
NBCS and 400mg/ml geneticin until 80-90% confluent. The medium was then changed 
to serum-free DMEM for 24 hours. Quiesced cells were washed twice with DBG and 
incubated with either DBG or ImM p-estradiol for 1 hour at 37°C. Termination of 
reaction and preparation of lysates as described in sections 2.5.1.1 and 2.5.1.2. 200pg 
total protein was used for immunoprécipitation as described in section 2 .6 .2 . 
Immunoprecipitated (IP) CPLA2 was utilised as described in section 2.7.2 with 50p.g of 
total protein being used for cell lysate (CL) experiments. Result is representative of 2 
individual experiments.
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2 .8  MEASUREMENT OF CALCIUM RELEASE
2 . 8 . 1  Adherent cells
Swiss 3T3 and Rat-1 Raf ER4 fibroblasts were seeded onto a coverslip in a 
3 5 x 10 mm2 petri dish, at a density of IxlO^ cells per ml, cultured and quiesced as 
described in Section 2.5.1.1. Prior to stimulation, the Rat-1 Raf ER4 cells were 
treated with or without lp.M p-estradiol in HBG at 37°C for 1 hour.
All cells were transferred to HBG prior to loading with Indo-l-AM, which 
was added at 37°C for 20 minutes, at a final concentration of IjiM. After this time, 
the coverslips were transferred to a fluorescent microscope stage, linked to a laser 
which monitored the fluorescence at 351nm and 363nm, corresponding to Ca2+- 
bound and -unbound Indo-1. The cells were submerged in HBG until the cells to be 
monitored were selected. The HBG was then removed and the agonist perfused on 
for a total of 5 minutes. The change in the ratio of Ca2+-bound and -unbound Indo-1 
in the cells selected was monitored and recorded.
2 . 8 . 2  Suspension Cells
HL60 cells were seeded at 5 x 10  ^ cells per ml, cultured and differentiated as 
described in Section 2.5.1.2. The cells were washed twice in RBG and the cell 
density determined using a haemocytometer. The washed pellet was resuspended to a 
density of 10  ^cells per ml in RBG and incubated with 2pM Fura-2-AM at 37°C for 
45 minutes. The cells were washed twice in RBG and resuspended at a density of 
5 x 1 Qb cells per ml. Agonists to be tested were reconstituted to the required 
concentration in RBG.
1ml of cell suspension was preincubated with RBG or RBG containing 5|iM 
cytochalasin B or 0.5mM pervanadate at 37®C in a fluorimeter which monitored the 
excitation wavelengths 340nm and 380nm, corresponding to Ca2+-bound and - 
unbound Fura-2 respectively. The emission wavelength was 510nm. Agonists were
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added through a porthole, therefore reducing any effects of stray light upon the 
fluorescence.
Incubations proceded for between 5-20minutes, with the ratio of the Ca2+- 
bound and -unbound fluorescence being recorded. To quantitate the amount of Ca2+ 
released, the total calcium concentration in the cells was measured by lysing with 
Triton X-100. A background level was determined by chelating the total calcium with 
excess EGTA. Using these values, the actual amount of Ca2+ released could be 
determined using the software supplied by the manufacturer.
2 .9  CONFOCAL MICROSCOPY
2 .9 .1  Preparation of samples
Adherent cells
Swiss 3T3 and Rat-1 Raf ER4 fibroblasts were seeded onto 'microspot' 
adherent microscope slides at 2x10^ cells per ml in lOOxlSmm^ petri dishes, cultured 
and quiesced as described in Section 2.5.1.1. The quiesced cells were washed twice 
with DBG at 37^0 prior to the incubations described. Reactions were terminated by 
washing twice with ice-cold PBS and transfer to ice. The cells were then 
immunostained.
Suspension cells
HL60 cells were seeded at 5 x1 0  ^cells per ml in RPMI 1640 containing 15%
(v/v) HIPCS and 1.3% (v/v) DMSO in the case of the differentiated cells. The cells
were then grown for 5 days and the cell density determined by using a
haemocytometer. Cells were washed twice in RBG, with the washed pellets being
resuspended in RBG at a density of 10^ cells per ml. lOOpl aliquots of cell
.suspension were transferred to eppendorf tubes and incubated at 37^C. Agonists were 
dissolved in RBG and the incubations carried out as described. Reactions were
-
terminated by washing twice in ice-cold PBS. The final cell pellet was resuspended in
i1ml ice-cold PBS and 20|il of cell suspension spotted onto clean 'microspot' 
microscope slides. The cells were then immunostained as described below.
2 . 9 . 2  Imm unostaining of cells
Cells adhered to 'microspot' slides were fixed in 4% (v/v) paraformaldehyde 
for 8 minutes, washed in PBS and then furthered fixed in ice-cold acetone for 10 
minutes. The acetone was allowed to evaporate and the slides placed into a prepared 
damp box, where all antibody additions would be carried out. The slides were 
blocked with 10% (v/v) foetal calf serum containing 0.1% (w/v) sodium azide in PBS, 
at room temperature for 30 minutes. The slides were washed briefly after blocking 
and a 1:50 dilution of either rabbit anti-cPLA2 antisera or pre-immune sera in blocking 
solution, was added to individual microscope wells and incubated for 90 minutes at 
37°C in a pre-prepared damp box. The slides were washed 3xlOminutes in PBS at 
room temperature. After washing, the slides were returned to the damp-box and a 
1:50 dilution of anti-rabbit FITC-linked antibody diluted in blocking solution, was 
added to the wells treated with anti-cPLA2 , preimmune serum and a control well, in 
order to detect any non-specific staining by the second antibody. The damp box was 
then incubated at 37°C for 60 minutes. After this time, the slides were briefly washed 
in ice-cold PBS and transferred to fresh PBS for 30 minutes. The PBS in the bath 
was continually agitated. The cell nuclei were then stained by placing the cells in a 
bath of PBS containing 10|ig/ml propidium iodide for 2 minutes at room temperature. 
Following propidium iodide staining the slides were washed briefly in PBS and any 
non-immuno stained areas gently dried off. To each treated well, a drop of 2.5% 
(w/v) Diazabicyclo[2.2.2] octane (DABCO) in glycerol was added and a glass 
coverslip overlaid, with great care being taken to remove any excess from the slide. 
The effectiveness of staining was checked under a fluorescent microscope, prior to 
confocal microscopy.
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2 . 9 . 3  Measurement of fluorescence intensity.
Fluorescence was measured using an argon/ion confocal laser scanning 
microscope. The wavelengths utilised for the dual fluorescence were 488nm for 
Fluorescein and 568nm for propidium iodide, with additional enhancement filters 
attached. Images were colour-banded to give an instant visual analysis for the 
intensity of staining and quantitative data was obtained for intra- and extra-nuclear 
staining by extracting the specific staining observed in the nucleus, which was well 
defined when propidium iodine was used. Using the computer-operated control of the 
focus level, a series of optical *xy sections' in the z (vertical) axis were obtained as 
well as mean pixel intensity measurements. All images were stored on flexible disk 
catridges and hard-copy records were obtained using an on-line Matrix colour graphic 
camera.
2 . 10  CHEMICAL MEASUREMENT OF BASAL AND STIMULATED
ARACHIDONIC ACID LEVELS
2 . 1 0 . 1  Preparation of samples
Five 80cm2 flasks of Swiss 3T3 fibroblasts were cultured in DMEM 
containing 10% (v/v) NBCS, with or without 0.1|ig/ml arachidonate or O.lpg/ml 
deuterated arachidonate. When 80-90% confluent, fresh DMEM containing 10% (v/v) 
NBCS was added and the cells allowed to quiesce by contact inhibition.
The flasks were washed 2x15 minutes in DBG at 37°C. Agonists were made 
up in DBG and the incubations described carried out at 37°C. Reactions were 
terminated by aspiration and the addition of ice-cold methanol:acetic acid (100:1.5) 
before being transferred to ice. Flasks were scraped and the suspension transferred to 
a glass screw-top test-tube with a further 3ml methanol: acetic acid (100:1.5), which 
had been used to wash the scraped flask. The lipids were then extracted and the free 
fatty acids isolated as descibed in Sections 2.4.1 and 2.4.2.
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The fatty acids were eluted from the silica by washing with 10ml redistilled 
diethyl ether, which was collected into clean glass screw-topped test-tubes. The 
diethyl ether was then evaporated under a stream of nitrogen, leaving the concentrated 
free fatty acids ready for derivatisation.
2 . 1 0 . 2  Derivitisation of free fatty acids.
To the extracted free fatty acids, 2ml of dry methanol containing 2.5% (v/v) 
sulphuric acid was added and the capped test-tubes incubated at 7CPC for 2 hours. 
The solution was allowed to cool to room temperature and the reaction terminated by 
the addition of 5ml 5% (w/v) NaCl. The methylated free fatty acids were extracted by 
washing the NaCl solution with 3x3ml redistilled hexane, with the top phase of 
hexane being transferred to clean test-tubes each time. The hexane was evaporated 
under nitrogen. A series of hexane washes were performed with the volume being 
reduced on each occasion, until the derivatised free fatty acids were resuspended in 
25jil redistilled hexane and transferred to a insert vial. The insert vial was placed in a 
2ml glass vial which was sealed with a metal cap containing a rubber speculum.
2 . 1 0 . 3  Gas chromatography
The prepared samples were placed on the autosampler of a Hewlett Packard 
5890 Series II gas chromatographer which was linked to a Hewlett Packard 5972 
Mass selective detector. l |il of the sample was auto injected onto a DB-23 column
(30m X 0.25mm, with a filter thickness of 0,25 microns), where the carrier gas was
high purity Helium. The GC Mass Spectometer was set at the following parameters; 
Injection head pressure 12 psi
Flash vapouriser 220°C
Purge time 1 minute
Initial flow rate 1.5ml/min
Detection inlet 270°C
Temperature gradients 55°C (2min) > 140^C (70°C/min) > 210°C (l°C/min)
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All detectable products were recorded and manipulated using MS Chem Station 
software (G1034C), supplied by the manufacturer.
2 . 11  PERMEABILISATION OF CELLS USING
STREPTOLYSIN-0
Permeabilisation of cells and all subsequent washes and treatments were 
performed in permeabilisation buffer as described for whole cell experiments 
described in Section 2.2.
2 .1 1 .1  Determination of cell permeabilisation using entry of 
Ethidium Bromide
Swiss 3T3 fibroblasts were seeded at IxKri cells per ml into 6  well plates in 
DMEM containing 10% (v/v) NBCS. When 80-90% confluent, fresh culture medium 
was added and the cells allowed to quiesce by contact inhibition. On the day of the 
experiment, the cells were washed 3 times for a total of 30 minutes with HBG at 
37°C. Permeabilisation buffer containing 0.0-1.0 unit/ml Streptolysin-O and l|ig/ml 
ethidium bromide was added to individual wells and incubated at 37^0 for 5 minutes. 
The cells were then washed twice with ice-cold PBS and viewed under the fluorescent 
microscope. Figure 2.11 shows that 0.6 unit per ml Streptolysin-0 permeabilised 
90% of the cells, without disrupting their morphology.
2 .1 1 . 2  Protocol for permeabilisation
Swiss 3T3 fibroblasts were grown on 24 well plates, quiesced and labelled as 
described for intact cells in Section 2.4.1. After labelling, the cells were washed 2x10 
minutes with DBG and then permeabilised by incubation with 150|al 0.6 units/ml 
Streptolysin-O in permeabilisation buffer for 5 minutes at 37°C. This was followed 
by washing the cells twice with 200|il permeabilisation buffer over 10-15 seconds, 
prior to stimulation with 150p.l agonist at the concentrations and times described.
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Figure 2.11 Permeabilisation of Swiss 3T3 fibroblasts by 0.6
units/ml streptolysin O
Cells were treated ass described in section 2.11.1. Results presented are representative of 
2 individual experiments and demonstrate (a) Morphology of permeabilised cells and (b) 
Nuclear staining by ethidium bromide.
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Reactions were terminated by the addition of 0,5ml ice-cold methanol:acetic acid 
(100:1.5) and the fatty acids isolated and quantified as described in Sections 2.4.1 and
2.4.2.
2 . 12  MEASUREMENT OF STIMULATED INTRACELLULAR
INOSITOL PHOSPHATE GENERATION
2 . 1 2 . 1  Preparation of samples
Rat-1 Raf ER4 fibroblasts were seeded at 1x10^ cells per ml in 24-well plates 
in DMEM containing 10% (v/v) NBCS and 400pg/ml Geneticin. When 80-90% 
confluent, the medium was changed to serum-free, inositol-free DMEM containing 
SjiCi/ml [2-3H] myo-inositol for 48 hours. The cells were then washed 2xl5minutes 
with DBG before incubation with DBG containing lOmM LiCl for 10 minutes at 
31^C. Incubations were commenced by replacing the medium with 200p.l of the test 
reagent in DBG containing lOmM LiCl for the times indicated. Reactions were 
terminated by aspiration and the addition of 400jil ice-cold 5% (v/v) perchloric acid.
The wells were scraped and the debris transfeired to an eppendorf tube and 
each well washed with 2 0 0 }il water which was added to the corresponding eppendorf 
tube. The cell extracts were neutralised by the addition of KOH/Hepes (1.5M/60mM) 
containing universal indicator. All manipulations were carried out at 4°C. The 
neutralised extracts were centrifuged at 14,000 xg for 10 minutes at 4®C to remove the 
precipitated potassium perchlorate and the supematent transferred to a fresh eppendorf 
tube before being stored at 4°C overnight.
2 . 1 2 . 2  Determination of individual inositol phosphate species
Pre-prepared Dowex AG 1-X8 anion exchange resin columns were washed 
through with 5ml distilled water. 5ml sodium tetraborate (NaTB)/EDTA 
(5mM/0.5mM)(pH6.7) was added to the column reservoir, to which the neutralised 
sample was added prior to addition to the column. The column was washed through
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2 . 13  MISCELLANEOUS PROCEDURES
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with a further 5ml NaTB/EDTA followed by 10ml distilled water. Finally, 10ml 
NaTB/ammonium formate (AF) (5mM/60mM), followed by 10ml distilled water were 
washed through the columns. The washes that have been described, have cleared any 
free inositol and glycerophosphoinositol from the columns, leaving only the inositol 
phosphates bound. 10ml of the following reagents were added to the column in the 
order listed, eluting the inositol phosphate species specified and collected for 
scintillation spectrophotometry :
0.2M ammonium formate/0. IM formic acid Inositol Monophosphates
0.4M ammonium formate/0.IM formic acid Inositol Bisphosphates
0.8M ammonium formate/0. IM formic acid Inositol Trisphosphates
1.2M ammonium formate/0. IM formic acid Inositol Tetrakisphosphates
2.0M ammonium formate/0. IM formic acid Inositol Penta/HexaJdsphosphate
For 0.2-0.8M ammonium formate, 5ml of elutant was transferred to a fresh 
scintillation vial and 15ml scintillation fluid added. For 1.2M and 2.0M ammonium 
formate elutants, 10ml scintillation fluid was added directly. All samples were 
vortexed and radioactivity quantitated using liquid scintillation spectrophotometry.
2 . 1 3 . 1  Activation of sodium orthovanadate
The pH of a lOmM solution of sodium orthovanadate was adjusted to pH 10 
using IM NaOH and IM HCl. The yellow solution was boiled until clear, then cooled 
to room temperature and the pH readjusted to pH 10. This procedure was repeated 
until the solution remained clear and the pH stable. Aliquots were then stored at -2(PC 
until required.
2 . 1 3 . 2  Preparation of Perhydrovanadate
lOmM activated sodium orthovanadate and lOmM hydrogen peroxide were 
mixed and incubated at 25°C for 15 minutes. Residual hydrogen peroxide was
%removed by the addition of Catalase (200fig final concentration), giving a final 
concentration of 5mM perhydrovanadate. Control cells were treated with a solution 
where DBG or RBG was substituted for sodium orthovanadate.
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2 . 1 3 . 3  Analysis and presentation of results
Unless otherwise stated all experiments were performed at least 3 times and 
each data point represents the mean ± standard deviation (s.d.) of triplicate 
determinations. Statistical significance was estimated by an unpaired Students't' test 
on an Apple Macintosh Stat-works program and the significance was generally taken 
as values of p<0.05.
EC50 and IC50 values were calculated from dose-response curves fitted to 
logistic equation (non-linear regression analysis). However, for presentation puposes 
dose-response curves were presented as simple line graphs from the Apple Macintosh 
Cricket Graph programme.
C H A PTER  3
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3 .1  INTRODUCTION
Various components of serum have been documented to have effects upon the 
growth and differentiation of cells (Perkins et a i, 1994). Such effects have been 
mainly determined at the DNA level (Hill & Triesman, 1995) with a number of serum 
response elements having been identified (Triesman, 1992). However, serum is a 
complex mixture containing, for example, growth factors, immunoglobulins, lipid 
moieties such as lysophosphatidic acid (LPA) and albumin, all of which have been 
shown to have a marked effect upon the cell.
The sensitivity of the cell to these factors determines the conditions used to 
both maintain them in culture and to quiesce them for experimental procedures. The 
procedure of quiescing is where the cells are synchronised into the Gq/Gi phase of the 
cell cycle and therefore, not dividing or differentiating. The cells are thus prepared for 
a stimulus such as a growth factor. Quiesced cells can be achieved by manipulating 
the serum content of the growth medium in two ways. Firstly, there is serum 
deprivation, where the serum concentration is lowered to such a concentration that 
there are not enough growth factors available to stimulate division, but enough to
■ ■maintain the cells' viability. Secondly, there is contact inhibition, which is only 
applicable to cells of an adherent nature which stop growing when they physically 
contact neighbouring cells. This procedure is normally carried out in complete cell 
culture medium, which is replenished at regular intervals until a dense monolayer of 
cells is visualised. Both methods are widely used in signal transduction studies, but 
the possible differences in the response of the cells to subsequent agonist stimulation 
has not been investigated.
The data in this chapter suggest that cPLA^ in Swiss 3T3 fibroblasts quiesced 
by contact inhibition in normal serum concentrations is more responsive to stimulation 
by the peptide agonist bombesin than cells quiesced by serum withdrawal. This could 
be described as a 'priming' event. Priming by such agents as granulocytic 
macrophage colony stimulating factor (GMCSF) (Yuo et aL, 1991) and the 
cytochalasins (Honeycutt & Niedel, 1980), such as cytochalasin B, has been widely
studied in haemopoietic cells. These latter priming agents do not in themselves 
stimulate a signalling pathway, but do enhance the response of the signalling enzyme 
in question upon agonist stimulation. The mechanism of action of these priming 
agents has not been fully elucidated, but several possibilities have been suggested, 
such as increased tyrosine kinase activity (Lloyds et al,, 1993), increased MAP kinase 
activity (Thompson et aL, 1993) and intracellular calcium release (Forehand et al „ 
1989). Specifically, in the case of the cytochalasins, it has been shown that there is a 
capping of G-actin, which results in the truncation or disassembly of the F-actin 
cytoskeletal structure (for review see Weeds, 1982).
The premyelocytic human leukemic HL60 cell is a well defined model in which 
to examine the possible effects of priming upon cytosolic phospholipase A2 activity 
using cytochalasin B as the priming agent. These cells have been shown to have a 
requirement for priming for various signalling components, such as the stimulation of 
phospholipase D by the the non-hydrolysable forms of guanosine triphosphate 
(GTPyS) (Cockcroft, 1992). The HL60 cells have been treated with dimethyl 
sulphoxide (DMSO), to differentiate these cells to a neutrophil-like cell, in order to 
study the effect of priming upon an agonist-stimulated response. When differentiated 
in this way, there is an induction in the expression of the chemotactic peptide 
formylMethylLeucinePhenylalanine (fMLP) receptor (Collins, 1987), over a period of 
3-5 days DMSO treatment. fMLP has been shown to stimulate PLD and CPLA2 
activity in both GMCSF- and cytochalasin B-primed DMSO-differentiated HL60 cells 
(for review see Cockcroft, 1992).
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3 . 2  RESULTS
3 .2 .1  Product of CPLA2 activity.
Arachidonic acid (20:4) is considered to be the preferred acyl group on
phospholipids hydrolysed by CPLA2 . However, other cfr-unsaturated fatty acids such
as oleic acid (18:1) have been found to be released upon agonist stimulation.
Therefore, using both [4,5,8,9,11,12,14,15-3H] arachidonate and [9,10-3H] oleate
labelled Rat-1 fibroblasts, the kinetics of the partial mitogen endothelin 1-stimulated
release of these fatty acids was studied. Figure 3.1(a) shows that endothelin 1-
stimulated oleate release was biphasic, with an initial 3-fold over basal transient phase
which was maximal at 5 seconds and returned to basal by 2 minutes. The second
sustained phase was maximal, also 3-fold, at 10  minutes, remaining elevated at 2 0
.minutes. The EC50 for this response at 5 seconds was 3nM (± 2.5nM) and maximal 
at lOnM as shown in Figure 3.1(b). The arachidonate release in response to
■endothelin 1 was also biphasic, but shows differences in kinetics as shown in Figure 
3.2(a). The initial transient phase is maximal at 15 seconds, 4-5 fold over basal, but 
does not return to basal. The second sustained phase was still elevated at 20 minutes,
3-fold above basal. The EC50 value at 15 seconds was also 3nM (±1.5nM) and 
maximal at 30nM as shown in Figure 3.2(b).
The bombesin-stimulated Swiss 3T3 fibroblast has been an extensively studied 
model for phospholipase A2 activation (Currie et al., 1992) and being a fibroblast cell 
it is a good comparison to the Rat-1 fibroblast. Using the chemical technique of Gas- 
chromatography, Figure 3.3(a) demonstrates that various fatty acids are released in 
bombesin-stimulted Swiss 3T3 fibroblasts. However, due to modifications to the 
small amount of fatty acids that occur during the various steps in the preparation of the 
samples, it is difficult to determine the exact nature of the majority of these fatty acid 
species. Therefore, since arachidonate has historically been the major fatty acid of 
interest, but is of such low abundance, the cells were cultured in the presence of 
lp,g/ml arachidonic acid. The inclusion of arachidonate in the culture medium of
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Swiss 3T3 fibroblasts was to produce maximum incorporation of arachidonate into the 
sn~2 position of the phospholipid glycerol backbone, therefore providing a larger pool 
of substrate for bombesin-stimulated phospholipase A2 activity. Detailed quantitative 
analysis was carried out on the fatty acids released upon bombesin-stimulation and 
Figure 3.3(b) demonstrates that arachidonate was indeed released. The basal level of 
free intracellular arachidonate from five 75cm^ flasks, approximately 4x10^ cells, of 
contact inhibited confluent Swiss 3T3 fibroblasts was approximately 30pg, which rose 
to 90pg, as determined by standard curve analysis, upon bombesin-stimulation.
3 . 2 . 2  Kinetics of arachidonate release in bombesin-stimulated
Swiss 3T3 fibroblasts quiesced by both contact inhibition 
and serum deprivation.
Using [4,5,8,9,11,12,14,15-3H] arachidonate labelled contact inhibited Swiss 
3T3 fibroblasts, the effect of bombesin stimulation was measured. As shown in 
Figure 3.4(b), the arachidonate release was biphasic, with an initial 2-fold, transient 
phase which was maximal at 30 seconds and returned to basal around 10 minutes. 
The second sustained phase was 60% above basal, but remaining elevated at 30 
minutes. When the cells were quiesced by serum deprivation, where the cells were 
cultured in 2% (v/v) newborn calf serum for 24 hours, the response to bombesin was 
also biphasic as shown in Figure 3.4(a). However, there were clear differences in the 
magnitude and kinetics of both the initial transient and second sustained phases of the 
response. The initial transient phase was maximal at 30 seconds, 2.3-fold above 
basal, returning to basal by 10 minutes. The second sustained phase was still 
increasing at 30 minutes, 3-fold above basal and returned to basal by 60 minutes 
(result not shown).
The initial phase of arachidonate release differed in magnitude between the 
quiescing method used (Figure 3.4(a) and (b)). Figure 3.5(a) shows that in 2% (v/v) 
NBCS the response is indeed maximal at 30 seconds, however, in cells cultured by 
contact inhibition in 10% (v/v)NBCS, as shown in Figure 3.5(b), the response is
maximal at 10 seconds, returning towards basal by 30 seconds. This appears to show 
that some component of serum is at a high enough concentration to prime CPLA2 
activity in 10% (v/v) NBCS, but does not stimulate arachidonate release in isolation, 
since the basal levels are identical under both serum conditions.
3 .2 .2 .1  Possible serum components which may chronically prime 
cPLÂ 2 in Swiss 3T3 fibroblasts.
Serum fractionation was not attempted, however two possible components 
insulin and lysophosphatidic acid (LPA) were examined.
Inclusion of insulin (lOng/ml) for 24 hours with 2% (v/v) NBCS resulted in a 
rapid bombesin-stimulated arachidonate release, identical to that observed in cells 
cultured in 10% (v/v) NBCS (Figure 3.6(a)). The inclusion of insulin prolonged the 
response, which remained elevated at 60 seconds, at which time the response in non- 
treated cells had returned to basal. Insulin did not affect the kinetics of bombesin- 
stimulated arachidonate release in 10% quiesced cells (results not shown).
When Swiss 3T3 fibroblasts were quiesced in 2% (v/v) NBCS containing 1'
lOp-M LPA for 24 hours, the basal level of arachidonate increased, as shown in Figure 
3.6(b). Non-LPA treated cells gave a 2-fold response to a 1 minute stimulation with 
lOOnM bombesin, however, in LPA-treated cells this response was 4-5 fold above 
basal. For cells quiesced in 10% (v/v) NBCS, inclusion of lOpM LPA in the 
quiescing medium did not increase the basal level of free intracellular arachidonate. In 
the absence of lOjiiM LPA, there was no significant bombesin-stimulated arachidonate 
release at the time point chosen, however, bombesin stimulation produced a 4-fold 
response in cells quiesced in the presence of LPA. When studied in more detail, the 
enhanced bombe sin-stimulated arachidonate release observed in cells quiesced in the
presence of LPA is dependent upon the quiescing method adopted. Figure 3.7 i
demonstrates that cells quiesced in 2% NBCS produce an enhanced bombesin 
response at very low concentrations of LPA (where the basal level is taken as the 
bombesin-stimulated arachidonate release in the absence of LPA), where as cells |
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quiesced in 10% NBCS do not. When the concentration of LPA in the quiescing 
medium increased, the magnitude of respose in both 2 % (v/v) and 10% (v/v) 
converged at a threshold concentration of IjlM LPA.
3 . 2 . 2 . 2  Effect of priming at the receptor-G-protein level
Swiss 3T3 fibroblasts quiesced under both conditions were stimulated with 
various concentrations of bombesin for times which corresponded to the maximum 
release of arachidonate in the initial transient phase. Figure 3.8(a) and (b) demonstrate 
that the apparent affinity of the receptor for bombesin was unaffected by priming, with 
both conditions giving an EC50 value of 3nM ± 2.5nM.
To examine the role of GTP-binding proteins, streptolysin O-permeabilised 
cells and the non-hydrolysable analogues of GTP and GDP, GTPyS and GDPpS 
respectively, were utilised. Arachidonate release was observed in response to 
bombesin which was potentiated by GTPyS in cells cultured in 2% (v/v) NBCS, but 
was not in the cells cultured at the high serum concentration (Figure 3.9(a) and (b)). 
This bombesin concentration was just maximal (lOnM), however, when a 
supramaximal concentration of lOOnM bombesin was used, there appeared to be a 
small inhibition of bombesin-stimulated arachidonate release by GTPyS, which was 
more pronounced in 10% (v/v) NBCS cultured Swiss 3T3 fibroblasts (Figure 
3.10(a)). This inhibition can be mimicked to a further extent by using GDPpS, which 
fully inhibits bombesin-stimulated arachidonate release under both conditions, an 
example of which is shown in Figure 3.10(b) for 10% (v/v) NBCS cultured cells.
In an attempt to examine the type of GTP-binding protein involved in this 
response, cells were incubated with pertussis toxin for 18 hours. Figure 3.11(a) 
demonstrates that bombesin-stimulated arachidonate is pertussis toxin insensitive. 
However, Figure 3.11(b) demonstrates that the heterotrimeric GTP-binding protein 
activator, Aluminium Fluoride, produced no arachidonate release until after 5 minutes, 
in both intact and Streptolysin O permeabilised cells.
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3 . 2 . 3  HL60 cells as a model to study acute priming of CPLA2
Premyelocytic human leukemic HL60 cells were differentiated to a neutrophil- 
like cell using 1.3% (v/v) dimethyl sulphoxide (DMSO) over a period of 5 days. Over 
this time, the arachidonate release in response to the chemotactic peptide fMLP, the 'I'phorbol ester PMA and the tyrosine phosphophosphatase inhibitor perhydrovanadate 
was studied, with the cells being primed by cytochalasin B prior to agonist g
stimulation. Figure 3.12(a) demonstrates that a tyrosine kinase regulated 
phospholipase A2 was highly active after only 2 days of differentiation. The phorbol 
ester did not produce a response until after 5 days differentiation and the fMLP
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•Sreceptor was apparently only at high enough levels to produce a significant response 
after 3 day DMSO treatment.
When 5 day DMSO-difPerentiated HL60 cells were screened with various 
agonists in the absence of cytochalasin B, no arachidonate release was detectable at the 
time point chosen (Figure 3.12(b)). Preincubation for 5 minutes with 5|J.M 
cytochalasin B, produced a significant increase in fMLP-stimulated arachidonate I
release. This response was both time- and dose-dependent as shown in Figure 
3.13(a) and (b). fMLP-stimulated arachidonate release in cytochalasin B primed 5 day 
DMSO-differentiated HL60 cells is a rapid monophasic response, maximum at 1 f
minute and remaining elevated at 10 minutes. At 5 minutes, the EC50 value was 
approximately 30nM (± 5nM) and maximal at lOOnM, the concentration used for all 
kinetic studies.
Figure 3.1(a) Endothelin 1-stimulated intracellular [^H] oleate
release in Rat-1 fibroblasts
Cells labelled for 24 hours in DMEM containing 10% (v/v) newborn calf serum and 
5jiCi/ml [9,10-3H] oleic acid. Cells stimulated with lOOnM endothelin 1 (#) orHBG 
(O ) for the times indicated upto (i) 5 minutes and (ii) 20 minutes. Result 
representative of 3 individual experiments. Presented as % basal ± s.d., with basal 
levels of 2000 ± 65 dpm.
Figure 3.1(b) Dose-dependency of ET-1-stimulated intracellular
[^H] oleate release at 5 seconds.
Cells labelled as above and stimulated for 5 seconds with increasing concentrations of 
ET-1 shown (#). Results presented as % basal ± s.d., obtained by stimualting with 
HBG for 5 seconds, which gave a value of 2000 ± 230 dpm. Experiment 
representative of 3 similar experiments.
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Figure 3.2(a) Endothelin 1-stimuIated intracellular pH]
arachidonate release in Rat-1 fibroblasts.
Rat-1 fibroblasts labelled with l|iCi/ml [4,5,8,9,11,12,14,15-%] arachidonic acid for 
24 hours in DMEM containing 10% (v/v) newborn calf serum. Cells stimulated with 
lOOnM ET-1 (#) or HBG (O) for the times indicated upto (i) 5 minutes and (ii) 20 
minutes. Result shown is representative of 3 separate experiments and values given as 
% basal ± s.d., where the basal level is 1000 ±150 dpm.
Figure 3.2(b) Dose-dependency of ET-l-stimuIated intracellular
pH] arachidonate release at 15 seconds in Rat-1 
fibroblasts.
Cells labelled as above and stimulated with the concentrations of ET-1 shown for 15 
seconds (#). Values depicted as % basal ± s.d., with the basal level being 400 ± 35 
dpm when the cells stimulated with HBG for 15 seconds.
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Figure 3.3(a) Bombesin-stimulated free fatty acid release in Swiss
3T3 fibroblasts as determined by gas 
chromatography.
Cells were cultured in DMEM containing 10% (v/v) newborn calf serum until a 
confluent monolayer was obtained. Cells were stimulated with either lOOnM 
bombesin or HBG for 1 minute at 37°C and the methylated free fatty acids prepared 
and separated by Gas chromatography using an attached mass spectophotometer 
facility. Possible increases as marked upon the figure.
Figure 3.3(b) Bombesin-stimulated arachidonate release in Swiss
3T3 fibroblasts as determined by gas 
chromatography.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) newborn calf 
serum and 0.1 jag/ml arachidonic acid until a confluent monolayer was observed. Cells 
were then stimulated with either lOOnM bombesin or HBG for 1 minute at 37°C and 
the methylated free fatty acids prepared and separated using gas chromatography 
utilising an attached mass spectophotometer. Arachidonate is marked on the figure.
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Figure 3.4(a) Bombesin-stimulated intracellular pH ] arachidonate
release in Swiss 3T3 fibroblasts quiesced using 
DMEM containing 1%  (v/v) NBCS.
Cells cultured in DMEM containing 10% (v/v) NBCS until 80-90% confluent. 
Medium then changed to DMEM containing 2% (v/v) NBCS and l^C i/m l 
[4,5,8,9,11,12,14,15-%] arachidonic acid for 24 hours. Stimulations were carried 
out for the times indicated with either lOOnM bombesin (#) or DBG (O). Result is 
representative of 3 separate experiments with values being presented as % basal ± 
s.d,, where the basal level is 550 ± 60 dpm.
Figure 3.4(b) Bombesin-stimulated intracellular pH] arachidonate
release in Swiss 3T3 fibroblasts quiesced in DMEM 
containing 10% (v/v) NBCS.
Swiss 3T3 fibroblasts cultured in DMEM containing 10% (v/v) NBCS until 80-90% 
confluent when medium was changed to DMEM containing 10% (v/v) NBCS and 
l|iCi/ml [4,5,8,9,11,12,14,15-%] arachidonic acid for 24 hours. Cells stimulated 
for the times indicated with either lOOnM bombesin (# )  or DBG (O). Result is 
representative of 3 individual experiments and presented as % basal ± s.d., with a 
basal level of 500 ± 40 dpm.
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Figure 3.5(a) Short time course of bombesin-stimulated
intracellular [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced in DMEM containing 2% (v/v) 
NBCS.
Swiss 3T3 fibroblasts cultured as described in Figure 3.4(b) and stimulated for the 
times shown with either lOOnM bombesin (# )  or DBG (O). Result shown is 
representative of 5 individual experiments and the values presented are % basal ± s.d., 
where the basal level is 475 ± 35 dpm.
Figure 3.5(b) Short time course of bombesin-stimulated
intracellular [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced in DMEM containing 10% (v/v) 
NBCS.
Swiss 3T3 fibroblasts cultured as described in Figure 3.4(a) and stimulated for the 
times indicated with either lOOnM bombesin ( • )  or DBG (O ). Result is 
representative of 5 individual experiments and the values presented as % basal ± s.d., 
where the basal level is equivalent to DBG stimulated arachidonate which was 
measured at a level of 435 ± 40 dpm for the times shown.
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Figure 3.6(a) Effect of Insulin upon bombesin-stimulated
intracellular [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced in DMEM containing 2% or 
10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when the medium was changed to DMEM containing l|iC i/m l 
[4,5,8,9>11,12,14,15-3H] arachidonic acid and either 2% (v/v) or 10% (v/v) newborn 
calf serum for 24 hours lOng/ml human insulin was added to a proportion of the cells 
treated with both serum concentrations for the 24 hours. Cells were stimulated for the 
times indicated with either lOOnM bombesin or DBG. Result is representative of 3 
individual experiments with values presented as % basal ± s.d., which is equivalent to 
500 ± 55 dpm in all conditions. The conditions depicted are 2% stimulation ( • ) ,  2% 
control (O), 2% stimulation with insulin (■), 10% control (□) and 10% stimulated 
(A).
Figure 3.6(b) Effect of lysophosphatidic acid (LPA) upon
bombesin-stimulated intracellular pH ] arachidonate 
release in Swiss 3T3 fibroblasts quiesced in DMEM 
containing either 2% or 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when the medium was changed to DMEM containing l|xCi/ml 
[4,5,8,9,11,12,14,15-3H] arachidonic acid and either 2% (□) or 10% (■) (v/v) 
NBCS for 24 hours. To a proprtion of the cells under both quiescing conditions, 
lOjiM LPA was added for the 24 hour quiescing period. Cells were then stimulated 
for 1 minute with lOOnM bombesin. Result shown is representative of 2 individual 
experiments and values presented as % basal ± s.d., which was 450 ± 35 dpm.
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Figure 3.7 Dose-dependency of LPA attenuation of bombesin-
stimulated intracellular [^H] arachidonate release in 
Swiss 3T3 fibroblasts quiesced in DMEM containing 
either 2% or 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was changed to DMEM containing l|iC i/m l 
[4,5,8,9,11,12,14,15-%] arachidonic acid and either 2% (# )  or 10% (O) (v/v) 
NBCS for 24 hours. To a proportion of cells quiesced under both serum condition 
various concentrations of LPA were added for the quiescing period. Cells were then 
stimulated with l(X)nM bombesin for 1 minute. A basal value of 4(X) ± 35 dpm was 
obtained by stimulating with DBG for the times utilised. Result shown is 
representative of 2 individual experiments and values presented as % basal ± s.d., 
whereby the basal value is taken as 1200 ±130 dpm, corresponding to bombesin- 
stimulated arachidonate release at the times chosen. Therefore, all values presented are 
compared to the bombesin-stimulated response in the absence of preincubation by 
LPA.
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Figure 3.8(a) Dose-dependency of bombesin-stimulated
intracellular [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced in 2 % (v/v) NBCS.
Swiss 3T3 fibroblasts were quiesced in DMEM containing 2% (v/v) NBCS and 
IjiCi/ml [4,5,8,9,11,12,14,15-3H] arachidonic acid for 24 hours. Cells were then 
stimulated for 30 seconds with the concentrations of bombesin shown (#). Result 
shown is representative of 6 individual experiments with the values being presented as 
% basal ± s.d. corresponding to a basal value of 550 ±  40 dpm.
Figure 3.8(b) Dose-dependency of bombesin-stimulated
intracellular [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced in 10% (v/v)NBCS.
Swiss 3T3 fibrobalsts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was replaced by DMEM containing IpC i/m l 
[4,5,8,9,11,12,14,15-^H] arachidonic acid and 10% (v/v) NBCS for 24 hours. Cells 
were stimulated for 20 seconds with the concentrations of bombesin shown (#). 
Result is representative of 5 individual experiments with values being presented as % 
basal ± s.d. where the basal level is equivalent to 400 ± 30 dpm.
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Figure 3.9(a) Effect of GTP7 S upon submaximal bombesin- 
stimulated total pH ] arachidonate release in 
Streptolysin O-permeabilised Swiss 3T3 fibroblasts 
quiesced in 2 % (v/v) NBCS.
Swiss 3T3 fibroblasts cultured in 10% (v/v) NBCS until 80-90% confluent when 
medium was changed to DMEM containing IpCi/m l [4,5,8,9,11,12,14,15-%] 
arachidonic acid and 2% (v/v) NBCS for 24 hours. Cells were washed and 
permeabilised for 5 minutes using 0.6units/ml Streptolysin O in permeabilisation 
buffer. lOnM bombesin (#), 30pM GTPyS (O) and both together (■) were diluted 
in permeabilisation buffer and used to stimulate the cells for the times shown. Result 
shown represents 2 individual experiments with values being represented as % basal ± 
s.d., where basal value is equivalent to 8(X) ± 60 dpm.
Figure 3.9(b) Effect of GTPyS upon submaximal bombesin- 
stimulated total pH ] arachidonate release in 
Streptolysin O-permeabilised Swiss 3T3 fibroblasts 
quiesced in 10% (v/v) NBCS.
Swiss 3T3 fibroblasts cultured in DMEM containing 10% (v/v) NBCS until 80-90% 
confluent when medium was replaced with DMEM containing Ip C i/m l 
[4,5,8,9,11,12,14,15-^H] arachidonic acid and 10% (v/v) NBCS for 24 hours. Cells 
were then washed and permeabilised for 5 minutes with 0.6 units/ml Streptolysin O in 
permeabilisation buffer. lOnM bombesin (# ), 30|iM GTPyS (O) and both together 
(■) were diluted in permeabilisation buffer and used to stimulate the cells for the times 
shown. Result shown is representative of 2 individual experiments with the values 
being presented as % basal ± s.d., where the basal value is 850 ± 7 5  dpm.
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Figure 3.10(a) Effect of GTPyS upon maximal bombesin-stimulated
total [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced using 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when the medium was replaced with DMEM containing IpCi/ml 
[4,5,8,9,1 1,12,14,15-3H] arachidonic acid and 10% (v/v) NBCS for 24 hours. Cells 
were washed and permeabilised with 0.6units/ml Streptolysin O in permeabilisation 
buffer for 5 minutes at 37°C. Vehicle alone (O), lOOnM bombesin ( • ) ,  30pM 
GTPyS (□) and both together (■) were diluted in permeabilisation buffer and used to 
stimulate the cells for the times indicated. Result shown is representative of 2 
individual experiments with values presented as % basal ± s.d., where the basal level 
is equivalent to 900 ± 90 dpm.
Figure 3.10(b) Effect of GDPpS upon maximal bombesin-stimulated
total [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced using 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when the medium was changed to DMEM containing IpCi/m l 
[4,5,8,9,11,12,14,15-%] arachidonic acid and 10% (v/v) NBCS for 24 hours. Cells 
were washed and permeabilised usin 0.6units/ml Streptolysin O in permeabilisation 
buffer for 5 minutes at 37°C. Vehicle alone (O), lOOnM bombesin (# ), 2mM 
GDPps (□) and both together (■) were diluted in permeabilisation buffer and used to 
stimulate the cells for the times indicated. Result shown is representative of 3 
individual experiments with values presented as % basal ± s.d., where the basal level 
is equivalent to 1250 ± 135 dpm for each of the experiments performed.
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Figure 3.11(a) Effect of Pertussis toxin upon bombesin-stimulated
intracellular [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced using 10% (v/v) NBCS.
Cells were cultured in DMEM containing 10% (v/v) NBCS until 80-90% confluent 
when the medium was replaced with DMEM containing I jiC i/m l 
[4,5,8,9,11,12,14,15-3H] arachidonic acid and 10% (v/v) NBCS in the presence or 
absence of 25ng/ml pertussis toxin for 24 hours. Cells were then stimulated for the 
times indicated with lOOnM bombesin. Result shown is a representation of 3 
individual experiments and the values are presented as % basal ± s.d., where the basal 
value is equivalent to 800 ± 55 dpm. Vehicle alone (O), l(X)nM bombesin ( • )  and 
lOOnM bombesin after pertussis toxin treatment (■).
Figure 3.11(b) Aluminium Fluoride-stimulated intracellular pH]
arachidonate release in Swiss 3T3 fibroblasts 
quiesced using 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was replaced with DMEM containing IjLiCi/ml 
[4,5,8,9,11,12,14,15-%] arachidonic acid and either (i) 2% (v/v) or (ii) 10% (v/v) 
NBCS for 24 hours. Permeabilisation was achieved by preincubation with 
0.6units/ml Streptolysin O in permeabilisation buffer for 5 minutes at 37°C. Cells 
were stimulated for the times shown with vehicle (■), lOnM bombesin (□) or 20pM 
aluminium chloride/SOmM sodium fluoride (□) diluted in permeabilisation buffer and 
total arachidonate measured (iii) Whole cells quiesced in 10% (v/v) NBCS were 
stimulated with the same concentrations of agonists but diluted in DBG and 
intracellular arachidonate measured. Result is representative to 3 individual 
experiments with the values presented as % basal ± s.d., where the basal level is 
equivalent to vehicle-stimulated arachidonate release and is 900 ± 85 dpm.
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Figure 3.12(a) Effect of differentiation upon stimulated total pH ]
arachidonate release in HL60 cells.
HL60 ceils were seeded at 5x105 cells per ml in RPMI 1640 containing 15% (v/v) 
heat-inactivated foetal calf serum and 1.3% (v/v) dimethyl sulphoxide for the times 
indicated. 17hours prior to harvesting 0.25jiCi/ml [4,5,8,9,11,12,14,15-5H] 
arachidonic acid was added to the cell culture. On harvesting, cells were washed and 
resuspended at 10  ^cells/ml in RBG. 10^ cells were pretreated with 5pM cytochalasin 
B for 5 minutes prior to stimulation with either RBG (O), lOOnM TPA (■), 0.5mM 
perhydrovanadate (# ) for 10 minutes or lOOnM fMLP (A) for 5 minutes. Total 
arachidonate was measured. Result is representative of 3 individual experiments with 
values presented as % basal ± s.d., where the basal value is equivalent to 1200 ±115 
dpm.
Figure 3.12(b) Comparison of agonist-stimulated total [^H]
arachidonate release in cytochalasin B-primed and 
-unprimed 5 day DMSO-differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cell/ml in RPMI 1640 containing 15% (v/v) heat- 
inactivated foetal calf serum and 1.3% (v/v) DMSG for 5 days. 17 hours prior to 
harvesting 0.25|LtCi/ml [4,5,8,9,11,12,14,15-%] arachidonic acid was added. Cells 
were washed and resuspended in RBG at 10^ cells/ml. 10^ cells were preincubated 
for 5 minutes with either RBG (□) or 5p,M cytochalasin B (■) and stimulated with 
either RBG, lOOnM TPA, lOjiM platelet activating factor, 100p.M lysophosphatidic 
acid for 10 minutes or lOOnM fMLP for 5 minutes. Result is a representation of 3 
individual experiments with values being presented as % basal ± s.d., where the basal 
value is equivalent to a value of 400 ± 150 dpm for each experiment.
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Figure 3.13(a) fMLP-stimulated total [^H] arachîdionate release in
DMSO-differentiated, cytochalasin B-primed HL60 
cells.
HL60 cells were seeded at 5x10^ cells/ml in RPMI 1640 containing 15% (v/v) heat- 
inactivated foetal calf serum and 1.3% (v/v) DMSO. Cells were allowed to 
differentiate for 5 days with 0.25fiCi/ml [4,5,8,9,11,12,14,15-3h ] arachidonic acid 
being added 17 hours prior to harvesting. 10^ cells were used per sample which were 
incubated for 5 minutes with 5p.M cytrochalasin B at 37°C. The cells were stimulated 
with either RBG (O) or lOOnM fMLP ( • )  for the times indicated. Result shown is 
representative of 3 individual experiments with the values being presented as % basal 
± s.d., where the basal value is equivalent to 500 ± 45 dpm.
Figure 3.13(b) Dose-dependency of fMLP-stimulated total [^H]
arachidonate release in DMSO-differentiated, 
cytochalasin B-primed HL60 cells.
HL60 cells were seeded at 5x10^ cells/ml in RPMI 1640 containing 15% (v/v) heat- 
inactivated foetal calf serum and 1.3% (v/v) DMSO. Cells were allowed to 
differentiate for 5 days with 0.25|iCi/ml [4,5,8,9,11,12,14,15-3H] arachidonic acid 
being added 17 hours prior to harvesting. 10  ^cells were used per sample which were 
incubated with 5(iM cytochalasin B for 5 minutes at 37°C prior to stimulation for 5 
minutes with the various fMLP concentrations shown (#). Result is representative of 
3 individual experiments with the values presented as % basal ± s.d., where the basal 
level, as determined by incubating with RBG in place of fMLP for 5 minutes, is 
equivalent to an average value of 560 ± 45 dpm over the times taken.
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3 .3  DISCUSSION
3 . 3 . 1  Fatty acid product of CPLA2 activation.
The fatty acid product of CPLA2 activity has been widely thought to be 
arachidonate (20:4), due to the importance of this ci^-unsaturated fatty acid as the 
precursor of eicosanoid production. Many groups have reported agonist-stimulated 
[4,5,8,9,11,12,14,15-3H] arachidonate release, but as shown in Figure 3.3(b), it can 
also be measured chemically. The amount of material required to measure the 
physiological levels of arachidonate is much greater than that required for 
radiochemical analysis. With this in mind, Figure 3.3(a) demonstrates that a large 
amount of other fatty acids are released upon agonist stimulation. However, these are 
very difficult to identify and may not be due to cytosolic phospholipase A2 activity, 
but maybe due to other lipase actions, including the lysophospholipase activity that 
CPLA2 also exhibits (Leslie et al., 1991). In particular, most of the saturated species 
identified are generally found in the .sn-l position of the diacyl glycerol backbone of 
phospholipids, which would be the site of action of a lysophospholipase after the 
hydrolysis of the sn~2 position by phospholipase A2 activity (She et aL, 1994). 
Another factor to be taken into consideration is the abundance of these fatty acids 
within the phospholipid pools. It has been shown that arachidonate is one of the least 
abundant of the fatty acids found in eukaryotic cells, therefore, even though such a 
small amount is released, this maybe a very high proportion of the available 
arachidonate within the cell, whereas the proportion of other fatty acids released
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maybe minute in relation to their abundance within the cell (Buttke et aL, 1984). One 
fatty acid that was seen to be released was oleic acid (18:1) which has been reported to 
be required for maximal activity of certain isoforms of protein kinase C (McPhail et 
aL, 1984) and phospholipase D (PLD) (Chahfa et aL, 1990; Massenburg et aL, 1994). 
Using radiochemical analysis, Figure 3.1(a) demonstrates that endothelin 1 - 
stimulated, biphasic release of oleate in Rat-1 fibroblasts is very similar in kinetic 
terms to that observed for arachidonate release in Figure 3.2(a). This maybe via the
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same receptor since Figure 3.2(b) and 3.3(b) show that the EC50 for both initial 
phases was 3nM(± 2nM); however, the concentration of endothelin-1 required to 
produce maximum arachidonate release differs, which would suggest the occupation 
of diffferent receptor subtypes. This question could only be answered by receptor 
binding assays which have shown the existence of three such subtypes of endothelin 
receptor (for review see Miller et aL, 1993). Whether the endothelin-1-stimulated 
oleate release observed is due to CPLA2 activity remains to be determined. If it is the 
same enzyme responsible for both, there does seem to be a preference towards 
arachidonate-containing phospholipids, since the amount of arachidonate released 
from that available is high compared to the relative amount of oleate released.
However, this could also be explained by either different rates of hydrolysis at the sn-
'
1 and sn-2 position by the cytosolic phospholipase A2 activity and the same enzyme’s 
lysophospholipase activity or by different rates of reincorporation of the free fatty 
acids into the phospholipid pools.
3 . 3 . 2  Kinetics of arachidonate release
Due to these observations and their correlation with published work, 
arachidonate was chosen as the fatty acid most appropriate to study the regulation of 
agonist-stimulated cytosolic phospholipase A2 activity. Bombesin-stimulated 
arachidonate release in murine Swiss 3T3 fibroblasts has been previously reported 
(Currie et aL, 1992). In this published work, the cells were quiesced by contact 
inhibition in DMEM containing 10% (v/v) newborn calf serum. This was of 
relevance, since other phospholipases studied in bombesin-stimulated Swiss 3T3 
fibroblasts, have been quiesced by serum deprivation (DMEM containing 2% (v/v) 
newborn calf serum 24 hours prior to experimentation) (Cook & Wakelam, 1989).
The bombesin-stimulated arachidonate release in cells cultured in each condition is 
biphasic as shown in Figure 3.4(a) and (b), however, there were subtle differences in 
the kinetics. In 10% serum, the initial transient phase appeared to be of a smaller 
magnitude to that produced in 2% serum quiesced cells. Both initial phases return to
basal by 10 minutes, with the second sustained phase being evident at 20 minutes. 
The response in 10% cells is of a smaller magnitude of those in 2%, however, it 
appears to be kinetically faster, being maximal at 20 minutes and returning towards 
basal by 30 minutes. The second phase in cells quiesced in 2% is increasing at 30 
minutes, returning to basal by 60 minutes (result not shown). Therefore, it appears 
that the second phase is kinetically quicker but of a lower magnitude in contact 
inhibited cells compared to serum starved cells. This observation could be due to an 
effect of the quiescing method on a multitude of signalling enzymes. In the acute, 
initial transient phase of the response, however, only a phospholipase of the A2 type 
could be responsible and again, it appears that in 10% quiesced cells, the magnitude of 
the response is less than in 2% quiesced cells at the 30 second time point taken. This 
is not the true picture as Figure 3.5(a) and (b) demonstrates. Here it is apparent that in 
contact inhibited cells the onset of the bombesin-stimulated arachidonate release is 
quicker than in 2% quiesced cells, the magnitude and the duration of the response 
being identical in both cases. It appears that the cytosolic phospholipase A2 
responsible for the response is more reactive to subsequent bombesin stimulation in 
10% quiesced cells. This could be described as a priming event, since the higher 
concentration of serum used to quiesce the cells produces a more reactive enzyme, but 
does not activate it itself, as the basal levels of arachidonate are identical to, if not even 
slightly lower, than those in 2% quiesced cells.
3 . 3 . 3  Possible serum components responsible for priming effect
This data suggested that there is a component within serum which is at a high 
enough concentration to prime CPLA2 in 10% (v/v) NBCS. One such component 
maybe insulin or insulin-like growth factor 1 as Figure 3.6(a) demonstrates that 
quiescing in 2% (v/v) NBCS containing 10|ig/ml insulin, result in cells which respond 
to bombesin in a manner similar to cells quiesced by contact inhibition using DMEM 
containing 10% (v/v) NBCS. However, the response is more sustained, suggesting 
that other activators of CPLA2 are stimulated, in addition to those primed by the serum
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.1component responsible in 10% (v/v) NBCS. Inclusion of insulin in cells quiesced in 
10% (v/v) NBCS-containing medium had no effect upon the kinetics of subsequent 
bombesin-stimulated arachidonate release (Result not shown). |j
Another possible component of serum that may be responsible for priming is 
lysophosphatidic acid (LPA). Figure 3.6(b) shows that LPA itself produced a small 
arachidonate release in 2% quiesced cells, but also produced a potentiation of the 
bombesin-stimulated response in both quiesced conditions. This is probably due to 
the activation of MAP kinase by LPA as reported by Howe and Marshall (1993). The 
initial LPA-stimulated MAP kinase activation produced would phosphorylate cPLA2 
leading to the small amount of arachidonate released, but also the priming of the 
enzyme so as to be more sensitive to bombesin stimulation. The small LPA-stimulated 
arachidonate release was more apparent in 2% quiesced cells compared to 10% cells, 
probably due to the LPA present in the serum being at a high enough concentration to 
produce the priming response and thus desensitize the cell to further LPA stimulation.
The sensitivity of the cells quiesced under the two conditions to LPA was a
Idose dependent phenomenon (Figure 3.7). When cells quiesced in 2% were 
preincubated with various concentrations of LPA and then stimulated with lOOnM 
bombesin there was a small potentiation of the bombesin-stimulated arachidonate
■Irelease even at very low concentrations of LPA. Those quiesced in 10% serum |
showed no additional response at these lower LPA concentrations, suggesting the 
desensitization of the LPA receptor, due to the higher concentration of LPA in the 
serum. However, between IpM and 30|iM LPA there was an identical potentiation of |
bombesin-stimulated arachidonate release in both serum conditions. This may be due 
to the occupation of a higher number of receptors or of other lower affinity LPA 
receptors stimulating the same pathways, which may explain the overriding of the
' Ide sensitization seen at lower LPA concentrations in cells quiesced in 10% NBCS. IThe activation of additional CPLA2 regulators by these higher concentrations of LPA
could explain the very similar responses seen in both conditions. Therefore, it can be |
suggested that both LPA and insulin can prime cytosolic phospholipase A2 , probably 
through MAP kinase activation. This has still to be confirmed.
3 . 3 . 4  Role of GTP-bindlng proteins in both chronically primed
and unprimed Swiss 3T3 fibroblasts.
In order to identify the site of action of priming observed in Swiss 3T3 
fibroblasts quiesced in 10% (v/v) NBCS, the possible regulatory proteins of CPLA2 
were studied in isolation.
Receptors for a range of agonists can exist in both high and low affinity states 
(Prossnitz et aL, 1995(a)), It was thus possible that the affinity of the bombesin 
receptor was being affected by priming. There is apparently only one receptor subtype 
for bombesin expressed upon Swiss 3T3 fibroblasts (Shapira et aL, 1991) and as 
shown in Figure 3.8, the affinity of this receptor was unaffected by the quiescing 
method employed, with an EC50 value of 3nM (± 2nM) in both cases. Since the 
bombesin receptor is a classical 7 membrane spanning-G-protein linked receptor, the 
effect of priming upon the GTP-binding proteins involved in the regulation of CPLA2 
was studied.
Using maximal concentrations of bombesin (lOnM) as determined by the dose- 
dependency in the preceding figure and 30}xM GTPyS, the non-hydrolysable analogue 
of GTP, in streptolysin O permeabilised Swiss 3T3 fibroblasts, Figure 3.9(a) 
demonstrates that there was a potentiation of bombesin-stimulated arachidonate release 
in serum-starved cells. This potentiation was observed at 30 seconds and release 
remained elevated after 1 minute. There was no such potentiation observed in 10% 
quiesced cells as shown in Figure 3.9(b). A potentiation of agonist-stimulated 
arachidonate release has been observed in Swiss 3T3 fibroblasts, quiesced in 10% 
(v/v) NBCS (Currie et aL, 1992), but the method for isolating free arachidonate 
differed, however it is well known that there is a variation between clones of the same 
cell type. With this in mind, it appears that the GTP-binding protein involved in 
bombesin-stimulated arachidonate release is only able to bind GTPyS in 2% quiesced
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cells, suggesting that in 10% quiesced cells, the GTP-binding protein is already fully 
loaded with GTP. In both cases, there must be agonist-stimulation to produce a rapid 
response, with GTPyS producing a small, significant release of arachidonate after 5 
minutes (results not shown), corresponding to the basal GTP-GDP exchange rate 
within the cell.
GTP-binding proteins have a role in the activation of bombesin-stimulated 
arachidonate release in 10% quiesced cells, since the non-hydrolysable analogue of 
GDP, GDPPS, completely abolished the response as shown in Figure 3.10(b). This 
further substantiates the possibility that the GTP-binding protein involved in f
bombesin-stimulated arachidonate release in 10% quiesced cells is already loaded with 
GTP, but requires subsequent agonist stimulation to produce arachidonate release.
Due to the fact that a potentiation by GTPyS could not be produced by maximal 
bombesin concentrations in 10% quiesced Swiss 3T3 fibroblasts, the effect of 
supramaximal bombesin concentrations (lOOnM) used throughout the kinetic studies 
in this work was examined. Figure 3.10(a) shows an effect, but apparently an 
inhibition of bombesin-stimulated arachidonate release, rather than a potentiation.
This could be explained by the activation of a GTP-dependent feedback inhibition 
upon cPLA2 . The most probable pathway to be activated by GTPyS, that could inhibit
■;3
bombesin-stimulated arachidonate release, perhaps via an effect upon the MAP kinase 
pathway, is the production of cyclic AMP by activation of adenylyl cyclases (Millar &
Rozengurt, 1988).
The GTP-binding protein involved in bombesin-stimulated arachidonate 
release in Swiss 3T3 fibroblasts quiesced under both serum conditions was pertussis 
toxin insensitive as shown in Figure 3.11(a). To determine the type of GTP-binding #
protein involved, the heterotrimeric G-protein activator aluminium fluoride (AIF^-) 
was used on both streptolysin O permeabilised and intact cells. This ion mimics the 
terminal phosphate of GTP, binding to the GTP-binding site of the a-subunit of the 
heterotrimeric G-proteins, but cannot be hydrolysed by the intrinsic GTPase activtity.
This effect is not seen in small molecular weight GTP-binding proteins, suggesting a
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difference in the stoicheimetric binding of GTP and thus providing a tool to 
discriminate between the two types of agonist-stimulated GTP-binding proteins 
(Kahn, 1991). In permeabilised 2% quiesced cells (Figure 3.11(b)(i)), there was a 
small arachidonate release at 30 seconds AIF^- stimulation, whereas there was nothing 
in permeabilised 10% quiesced cells (Figure 3.11(b)(ii)). In whole cells (Figure
3.1 l(b)(iii)), arachidonate release was seen at 5 minutes, in response to AIF' '^. Taking 
all of these results together, it appears that there is an involvement of a heterotrimeric 
G-protein at later time points in both permeabilised and whole cells. The lack of GTP- 
input in the initial onset of bombesin-stimulated arachidonate release could be 
explained by the effect of endogenous GTP already bound to the GTP-binding protein 
involved, or the role of a small molecular weight GTP-binding protein, such as rac, in 
the response. These small molecular weight G-proteins have been suggested to be 
involved in various signalling pathways, including the regulation of CPLA2 (for 
review see Hall, 1994). However, more work would have to be carried out to try and 
elucidate which form of GTP-binding protein is involved.
3 .3 .5  HL60 cells as a model of acute priming.
To aid the study of the chronic priming observed in Swiss 3T3 fibroblasts, a 
well established model, HL60 cells, of acute priming was utilised. The premyeolocitic 
human leukemic cell line HL60 can be differentiated by such agents as the phorbol 
esters, dibutyryl cyclic AMP and retinoic acid, in order to observe various agonist- 
stimulated signalling pathways. One such agonist is the chemotactic peptide 
formlyMethylLeucinePhenylalanine (fMLP). The expression of the receptor for fMLP 
is induced when HL60 cells are differentiated to a neutrophil-like cell using 1.3% (v/v) 
dimethyl sulphoxide (DMSO) in the culture medium for 3-5 days (Collins, 1987). As 
well as differentiation, a requirement for priming with such agents as cytochalasin B 
has been reported in order to observe fMLP-stimulated signalling responses (for 
review see Cockcroft, 1992). Figure 3.12(a) demonstrates that cytochalasin B- 
primed, fMLP-stimulated arachidonate release was observed after 4 days of DMSO-
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differentiation. However, a tyrosine phosphorylated activator of cPLA^ was active 
after only 2 days of DMSO-differentiation as shown by the results using the tyrosine 
phosphophosphatase inhibitor perhydrovanadate (0.5mM) (Figure 3.12(a)). These 
results suggest a role for tyrosine kinases in the regulation of arachidonate release in 
DMSO-differentiated HL60 cells. At the time point chosen, there does not appear to 
be a role for protein kinase C in the stimulation of arachidonate release, as the phorbol 
ester TPA did not produce any arachidonate release even after 6 days of DMSO 
differentiation.
The observed fMLP-stimulated arachidonate release in 5 day DMSO- 
differentiated HL60 cells was dependent on preincubation with cytochalasin B as 
shown in Figure 3.12(b) an effect that was both time- and dose-dependent (Figure 
3.13(a) and (b)). The response was rapid, plateauing after 1 minute but remaining 
elevated for the 20 minutes fMLP treatment. This plateauing could be due to an 
equilibrium between arachidonate release and metabolism by the lipoxygenase and 
cyclooxygenase pathways, as these cells have been reported to produce high levels of 
the inflammatory mediators produced by these metabolic pathways. The response to 
fMLP was variable as can be seen for the fold stimulation differences in Figure 
3.13(a) and (b), which can be explained by the length of time the cells are in culture as 
these cells have been shown to lose agonist responsiveness over a certain period of 
time in ceU culture. However, it was only the magnitude of the response that differed, 
not the affinity of the receptor to fMLP.
In conclusion, this chapter demonstrates that arachidonate-containing 
phospholipids are the preferred substrate for CPLA2 in Swiss 3T3 fibroblasts, 
however other fatty acids can be detected both chemically and by radiolabelling upon 
bombesin-stimulation, but may not be due to cytosolic phospholipase A2 activation, 
but to the lysophospholipase activity that CPLA2 exibits. Bombesin-stimulated 
arachidonate release as measured by radiolabelling, differed depending on the method 
adopted to quiesce Swiss 3T3 fibrobalsts, prior to agonist treatment, where cells 
quiesced in 10% (v/v) NBCS exibited a higher sensitivity to bombesin stimulation.
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This priming of CPLA2 by a serum factor, such as insulin or lysophosphatidic acid, 
did not affect the affinity of the receptor, but the pertussis toxin-insensitive GTP- 
binding protein associated, appeared to be in a GTP-bound state. The activation of 
CPLA2 by GTP-binding proteins in the premyelocytic HL60 cell has been well 
documented and has been shown to require both differentiation and priming (for 
review see Cockcroft, 1992), The proposed G-protein-mediated fMLP-stimulated 
arachidonate release also required DMSO-differentiation and cytochalasin B priming, 
to produce a time- and dose-dependent response. However, at shorter periods of 
DMSO-differentiation, a tyrosine kinase-stimulated arachidonate release was evident, 
suggesting the involvement of a tyrosine phosphorylated protein in CPLA2 activation 
in these cells. Therefore, in the following chapter, the role of tyrosine 
phosphorylation in the regulation and priming of CPLA2 will be discussed.
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CHAPTER 4
THE ROLE OF TYROSINE PHOSPHORYLATION IN PRIMING OF 
CYTOSOLIC PHOSPHOLIPASE A%
4 .
4 .1  INTRODUCTION
The role of tyrosine phosphorylation as a key component of signalling 
pathways has been extensively studied in T- and B-cells (for review see Abraham et 
aL, 1992; Cushley & Harnett, 1993), human neutrophils (Torres et aL, 1993) and 
Rat-1 fibroblasts (Hordijk et aL, 1994). The proteins that have been shown to be 
phosphorylated upon tyrosine residues, following agonist stimulation, have a wide 
variety of effects within the cell including cytoskeletal rearrangement (Ridley & Hall, 
1994), in the case of focal adhesion kinase (FAK) (Saville et aL, 1994), receptor 
autophosphorylation, in the case of the PDGF receptor (for review see Williams, 
1989) and nuclear translocation as in the case of MAP kinase (Lenormand et aL, 
1993).
The diversity of agonist stimulated tyrosine phosphorylation and the regulation 
of the tyrosine kinases involved has been studied to great lengths. This opened a 
whole new field of regulation in signalling pathways, since the serine/threonine 
directed kinases were thought to be the main kinase regulators of both phospholipase 
D and A^ (Nishizuka, 1995). In the case of phospholipase D, a requirement for both 
protein kinase C phosphorylation and tyrosine kinase phosphorylation in activation 
has been demonstrated (Briscoe et aL, 1995). Cytosolic phospholipase A^ activation 
has been shown to be regulated by protein kinase C (Currie et aL, 1992), whilst 
recently an indirect role for tyrosine phosphorylation has become apparent. Recent 
evidence has demonstrated a MAP kinase phosphorylation site in the sequence of 
cloned cPLA2 and it has been shown that Ser 505 could be phosphorylated directly by 
MAP kinase in vitro. (Lin et aL, 1993)
Bombesin has been shown to stimulate an increase in tyrosine phosphorylation 
in Swiss 3T3 fibroblasts (Briscoe et aL, 1995). The results in this chapter, address 
the possible involvement of tyrosine phosphorylation in the chronic and acute priming 
of cytosolic phospholipase A2 outlined in Chapter 3.
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4 .2  RESULTS
The priming of cytosolic phospholipase A2 by cytochalasin B in DMSO- 
differentiated HL60 cells was shown in Chapter 3 to be essential for fMLP-stimulated 
arachidonate release. The mechanism by which cytochalasin B produces this priming 
effect is as yet unclear, however, as Figure 4.1(a) demonstrates, the agent increased 
overall tyrosine phosphorylation in 5 day DMSO-differentiated HL60 cells, suggesting 
that a tyrosine kinase maybe involved in the acute priming effects. In the chronic 
priming of Swiss 3T3 fibroblasts by serum, there was also an increase in basal levels 
of tyrosine phosphorylation as shown in Figure 4.1(b), where cells quiesced in 10%
(v/v) newborn calf serum (NBCS) showed a significant increase in overall tyrosine 
phosphorylation compared to cells quiesced by serum starvation in DMEM containing 
2% (v/v) NBCS.
The level of protein tyrosine phosphorylation can be elevated using the 
tyrosine phosphophosphatase inhibitor perhydrovanadate. Figure 4.2 (a) 
demonstrates that 0.5mM perhydrovanadate can stimulate arachidonate release in 
Swiss 3T3 fibroblasts quiesced in 10% serum. This was also the case in 2% quiesced 
cells (result not shown). This was also observed in DMSO-differentiated HL60 cells
■. .
(Figure 4.2(b)), suggesting a role for tyrosine kinases in the regulation of CPLA2 .
The kinetics of perhydrovanadate-stimulated arachidonate release corresponded to the 
second sustained phase of bombesin-stimulated arachidonate release in Swiss 3T3 
fibroblasts. However, this association cannot be taken as absolute, since the inhibitor 
has to overcome both the physical barrier of entry into the cell to inhibit the 
phosphatases and rely upon basal tyrosine kinase activity in order for any significant 
effect to be observed. Taking this into consideration, DMSO-differentiated HL60 cells 
preincubated with 0.5mM perhydrovanadate for 2 minutes which does not produce 
arachidonate release, permitted the measurement of fMLP-stimulated arachidonate 
release (Figure 4.3(a)). Using this 2 minute preincubation of perhydrovanadate, 
subsequent fMLP-stimulation produced identical time-dependent kinetics of
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arachidonate release (Figure 4.3(b)) to those seen when cytochalasin B was used as 
the priming agent.
As Figure 4.1(b) demonstrated, there was an increased basal level of tyrosine 
phosphorylation in Swiss 3T3 fibroblasts quiesced in DMEM containing the higher 
NBCS concentration. The serum factors insulin and lysophosphatidic acid (LPA) 
were shown to mimic the priming effect observed when they were added to 2 % 
quiesced Swiss 3T3 fibroblasts (Figure 3.6). Both of these serum factors increased 
basal tyrosine phosphorylation levels (Figure 4.4) with differing banding patterns
• S .which might explain the different effects they produce. Figure 4.5(a) clearly shows i
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that bombesin stimulated a transient increase in tyrosine phosphorylation in cells 
quiesced in 2% NBCS which was maximal at 30 seconds, reaching levels equivalent 
to the basal levels in cells quiesced in 10% NBCS. In these primed cells there did not
appear to be an increase in overall tyrosine phosphorylation until after 1 minute, 
however, there did appear to be a dephosphorylation of a 69kDa protein at earlier time 
points (Figure 4.5(b)). The chronic primimg of Swiss 3T3 fibroblasts by serum did 
not inhibit the effect upon tyrosine phosphorylation by other agonists as shown in 
Figure 4.6.
To further elucidate the role of tyrosine phosphorylation upon cytosolic 
phospholipase A%, an inhibitor demethoxyviridine (DMV) was employed. This 
analogue of the putative PI-3 kinase inhibitor wortmannin was shown to inhibit 
bombesin-stimulated tyrosine phosphorylation levels in Swiss 3T3 fibroblasts, 
markedly on a 69kDa protein, in a dose-dependent manner with an IC50 = lOnM (± 
2nM) (Figure 4.7). In an in vitro bilayer assay utilising baculovirus expressed
:
CPLA2 , there was a small inhibition (30%) of arachidonate release at O.lnM
wortmannin (Figure 4.8(a)), when the CPLA2 activity enhancer phosphatidylinositol- 
4,5-bisphosphate (PtdIns-4 ,5 -P2) (Figure 4.8(b)) was included in the micelle. This 
inhibition was not as complete as speculated at the lower concentrations of 
wortmannin, suggesting multiple modes of action upon the enzyme by wortmannin, 
since at the higher concentrations, there was also an inhibition of arachidonate release
in the absence of PtdIns-4,5-P2. Inhibition could not be detected in 
immunoprecipitated CPLA2 from Swiss 3T3 fibroblasts (Figure 4.9), suggesting that 
the site of action of wortmannin was perhaps blocked in the immunoprecipitated 
enzyme from the whole cell. In whole cell experiments, the wortmannin analogue, 
DMV, produced a dose-dependent inhibition of both bombesin- and fMLP-stimulated 
arachidonate release (Figure 4.10(a) and (b) respectively); the IC50 in Swiss 3T3 
fibroblasts was 2nM (± 2nM) and 200nM (± 20nM) in HL60 cells. These results 
suggested both direct and indirect effects of DMV and wortmannin upon CPLA2 .
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Figure 4.1(a) Western blot analysis of 5jj,M cytochalasin B- 
stimulated tyrosine phosphorylation In 5 day 
DMSO-differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium containing 15% 
(v/v) heat-inactivated foetal calf serum and 1.3% (v/v) dimethylsulphoxide (DMSO) and 
cultured for 5 days. The cells were washed and 10^ cells were used per sample. 
Samples were stimulated for 5 minutes at 37°C with either 5pM cytochalsin B or RBG 
and reactions were terminated by washing with ice-cold PBS. Lysis was carried out as 
described in Materials and Methods and lOjig total protein was loaded onto 10% (w/v) 
polyacrylamide gels and SDS-PAGE carried out as described in Chapter 2. Tyrosine 
phosphorylated proteins were visualised using ECL. Result is representative of 3 
individual experiments.
Figure 4.1(b) Western blot analysis of basal levels of tyrosine
phosphorylation in Swiss 3T3 fibroblasts quiesced 
either by serum starvation (2% (v/v) NBCS) or 
contact inhibition (10% (v/v) NBCS).
Cells cultured in DMEM containing 10% (v/v) newborn calf serum until 80-90% 
confluent when medium was replaced with DMEM containing either 10% (v/v) or 2% 
(v/v) NBCS for 24 hours. Cells were then washed 3 times with ice-cold PBS and lysates 
prepared as described in Materials and Methods. lOjxg total protein was loaded onto 10% 
(w/v) polyacrylamide gels and SDS-PAGE carried out as described in Chapter 2. 
Tyrosine phosphorylated proteins were visuahsed using ECL. Result is representative of 
3 individual experiments, which used freshly prepared lysates.
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Figure 4.2(a) Perhydrovanadate-stimulated intracellular [^H]
arachidonate release in Swiss 3T3 fibroblasts 
quiesced in DMEM containing 10% (v/v) newborn 
calf serum.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was replaced with DMEM containing 10% (v/v) NBCS and 
l|j,Ci/ml [4,5,8,9,11,12,14,15-3H] arachidonic acid for 24 hours. Cells were stimulted 
with 0.5mM perhydrovanadate (#) in DBG or DBG alone (O) for the times indicated. 
Result is representative of 3 individual experiments with values being presented as % 
basal ± s.d., where the basal level was lOOOdpm ± 200 dpm.
Figure 4.2(b) Perhydrovanadate-stimulated total pH] arachidonate
release in cytochalasin B-primed, 5 day DMSO- 
differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium containing 15% 
(v/v) heat-inactivated foetal calf serum and 1.3% (v/v) DMSO and cultured for 5 days. 
17 hours prior to the end of the culturing period, 0.25jiCi/ml [4,5,8,9,11,12,14,15-%] 
arachidonic acid was added. 10  ^ cells which had been preincubated for 5 minutes at 
37°C with 5|iM cytochalasin B, were stimulated for the times shown with either 0.5mM 
perhydrovanadate (# )  in RBG or RBG alone (O). Result represents 3 individual 
experiments with values presented as % basal ± s.d., where the basal level was 500dpm 
±100 dpm for all experiments.
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Figure 4.3(a) Perhydrovanadate-stimulated total pH] arachidonate
release in cytochalasin B-primed and -unprimed 5 
day DMSO-differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium containing 15% 
(v/v) heat-inactivated foetal calf serum and 1.3% (v/v) DMSO and cultured for 5 days. 
17 hours prior to the end of the culturing period, 0.25|iCi/ml [4,5,8,9,11,12,14,15-%] 
arachidonic acid was added. 10^ cells per sample were preincubated with either 5p.M 
cytochalasin B in RBG or RBG alone for 5 minutes at 37°C. Preincubated samples were 
then stimulated with either 0.5mM perhydrovanadate in RBG or RBG alone for a further 
5 minutes at 37°C. Result is representative of 3 individual experiments with values 
presented as % basal ± s.d., where the basal level was 800 ±150 dpm.
Figure 4.3(b) fMLP-stimulated total [^H] arachidonate release in
perhydrovanadate-primed, 5 day DMSO- 
differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium containing 15% 
(v/v) heat-inactivated foetal calf semm and 1,3% (v/v) DMSO and cultured for 5 days. 
17 hours prior to the end of the culturing period, 0.25[iCi/ml [4,5,8,9,11,12,14,15-%] 
arachidonic acid was added. 10  ^cells were used for each sample which were incubated 
with 0.5mM perhydrovanadate in RBG for 2 minutes at 37°C, prior to stimulation with 
either lOOnM fMLP (#) in RBG or RBG alone (O) for the times indicated. Result is 
representative of 3 individual experiments with values being presented as % basal ± s.d., 
where the basal level was 700 ± 160 dpm.
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Figure 4.4 Western blot analysis of insulin- and
lysophosphatidic acid (LPA)-stimulated tyrosine 
phosphorylation in Swiss 3T3 fibroblasts quiesced 
in 2% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent, when the medium was replaced by DMEM containing either 2% (v/v) or 
10% (v/v) NBCS for 24 hours. A proportion of the cells quiesced in 2% (v/v) NBCS 
had either IpM LPA or lOpg/ml insulin added to the quiescing medium. Quiesced cells 
were then stimulated with either lOOnM bombesin in DBG or DBG alone for 1 minute at 
37°C. Lysates were prepared as described in Materials and Methods and lOpg total 
protein was loaded onto 10% (w/v) polyacrylamide gels and SDS-PAGE carried out as 
described in Chapter 2. Tyrosine phosphorylated proteins were visualised using ECL 
and result is representative of 3 individual experiments.
Lysophosphatidk actd (LPA) - and insulin-stimulated tyrosine phosphorylation in Swiss 3T3 fibroblasts quiesced in 2% (v/v) NBCS
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Figure 4.5(a) Bombesin-stimulated tyrosine phosphorylation in
Swiss 3T3 fibroblasts quiesced in 2% (v/v) and 10% 
(v/v) newborn calf serum,
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% NBCS until 80-90% 
confluent when medium was replaced by DMEM containing either 2% (v/v) or 10% (v/v) 
NBCS for 24 hours. Quiesced cells were then stimulated with lOOnM bombesin or DBG 
for the times indicated and lysates prepared as described in Materials and Methods. lOpg 
total protein was then loaded onto 10% (w/v) polyacrylamide gels and SDS-PAGE 
carried out as described in Chapter 2. Tyrosine phosphorylated proteins were visualised 
using ECL and result is representative of 3 individual experiments.
Figure 4.5(b) Western blot analysis of bombesin-stimulated
tyrosine phosphorylation in Swiss 3T3 fibroblasts 
quiesced in 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was replaced with fresh culture medium for 24 hours. 
Quiesced cells were stimulated with either lOOnM bombesin in DBG or DBG alone for 
the times indicated. Lysates were prepared as described in Materials and Methods and 
10p,g total protein was loaded onto 10% (w/v) polyacrylamide gels and SDS-PAGE 
carried out as described in Chapter 2. Tyrosine phosphorylated proteins were detected 
using an anti-phosphotyrosine, HRP-linked conjugate antibody, which was modelled on 
the monoclonal used for all other Phosphotyrosine western blots. Recognised proteins 
were visualised using ECL and result is representative of 2 individual experiments.
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Figure 4.6 Agonist-stimulated tyrosine phosphorylation in
Swiss 3T3 fibroblasts quiesced in 2% (v/v) and 10% 
(v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was replaced with DMEM containing either 2% (v/v) or 
10% (v/v) NBCS for 24 hours. Cells quiesced under both conditions were then 
stimulated for 20 minutes at 37<^ C with either lOOnM phorbol ester (TPA), 30|iM 
lysophosphatidic acid (LPA), lOng/ml insulin, 30ng/ml platelet derived growth factor 
(PDGF) in DBG or DBG alone. Lysates were prepared as described in Materials and 
methods with lOpg total protein being loaded onto 10% (w/v) polyacrylamide gels and 
SDS-PAGE carried out as described in Chapter 2. Tyrosine phosphorylated proteins 
were visualised using ECL and result is representative of 2 individual experiments.
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Figure 4.7 Effect of demethoxyviridlne (DMV) upon bombesin-
stimulated tyrosine phosphorylation in Swiss 3T3 
fibroblasts.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was replaced by DMEM containing 2% (v/v) NBCS for 24 
hours. Cells were preincubated for 5 minutes at 37°C with the concentrations of DMV 
shown. Control cells were preincubated with a vehicle control containing the same 
amount of DMSO present in the inhibitor samples. Preincubated cells were then 
stimulated with either lOOnM bombesin in DBG or DBG alone for 2 minutes at 37®C. 
Lysates were prepared as described in Materials and Methods and lOpg total protein was 
loaded onto 10% (w/v) polyacrylamide gels and SDS-PAGE carried out as described in 
Chapter 2. Tyrosine phosphorylated proteins were visualised using ECL and result is 
representative of 4 individual experiments.
M.J. Cross is greatfully acknowledged for this initial inhibitor work.
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Figure 4.8(a) Effect of wortmannin upon baculovirus expressed
cPLA 2 activity in an in vitro bilayer assay.
Bilayer micelles were prepared including and excluding phosphatidylinositol-4,5- 
bisphosphate (PIP2 ) and utilised as described in Materials and Methods. Prepared 
micelles were incubated for 5 minutes at 37°C with the concentrations of DMV shown 
and either 13 p-g/ml in the absence of PIP2 (O) or 3.25 pg/ml in the presence of PIP2 
( • ) ,  of baculovirus-expressed CPLA2 . Reactions were terminated by the addition of 
stopping buffer containing O.OlpCi/ml [4,5,8,9,11,12,14,15-^H] arachidonic acid. Free 
arachidonate was extracted and the [^H] and [^^C] levels measured by liquid scintillation 
spectrophotometry. Results is representative of 2 individual experiments.
Figure 4.8(b) Effect of phosphatidylinositol-4,5-bisphosphate
(PIP2 ) upon baculovirus-expressed CPLA2 activity 
in an in vitro bilayer assay.
Micelles containing l-stearyl-2-[l^C] arachidonyl phosphatidyl choline were prepared as 
described in Materials and Methods with PIP2 present (■) or excluded (□) from the final 
micelle. Different concentrations of baculovirus-expressed CPLA2 was then incubated for 
5 minutes at 37°C with both forms of the micelle prepared. Reactions were terminated by 
the addition of stopping buffer containing 0.01p.Ci/ml [4,5,8,9,1 1,12,14,15-3H] 
arachidonic acid. [^H] and [^^C] labelled arachidonate was then extracted and quantified 
using liquid scintillation spectrophotometry. Result is representative of 2 individual 
experiments carried out on freshly prepared micelles.
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Figure 4.9 Effect of wortmannin upon in vitro arachidonate release 
produced by immunoprecipitated CPLA2 activity from 
Swiss 3T3 fibroblasts quiesced in 2% (v/v) NBCS.
Swiss 3T3 fibroblasts were seeded in 75cm^ culture flasks in DMEM containing 10% 
(v/v) NBCS until 80-90% confluent, when medium was replaced by DMEM containing 
2% (v/v) NBCS for 24 hours. Quiesced cells were washed 3 times with DBG at 37°C 
and reactions terminated by washing with ice-cold PBS and placing on ice. Lysates were 
prepared and immunoprécipitation carried out as described for MAP kinase in vitro 
studies, using a 1:50 dilution of a rabbit anti-cPLA2 antibody. Washed pellets were 
resuspended in 35p,l assay buffer (50mM Tris/HCl (pH7.4)) and incubated for 10 
minutes at room temperature with the concentrations of wortmannin shown. The micelle 
containing PIP2 suspended in lOfiM CaCl2 and lOOmM KCl was then added and the total 
reaction mixture incubated for a further 10 minutes at 37°C. Reaction was stopped and 
arachidonate release quantified as described in Materials and methods. Result is 
representative of a single experiment, with duplicate points. Lane 1-control; 
2=baculovirus expressed CPLA2 ; 3=baculovirus expressed CPLA2 with 10 minute 
wortmannin pretreatment; 4=immunoprecipitate; 5=immunoprecipitate with wortmannin 
pretreatment; 6 =total cell lysate; 7=total cell lysate with wortmannin pretreatment.
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Figure 4.10(a) Effect of DMV upon bombesin-stimulated
intracellular [^H] arachidonate release in Swiss 3T3 
fibroblasts quiesced in 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were cultured in DMEM containing 10% (v/v) NBCS until 80- 
90% confluent when medium was replaced with DMEM containing 10% (v/v) NBCS and 
l}j,Ci/mi [4,5,8,9,11,12,14,15-3H] arachidonic acid. Cells were preincubated wth the 
concentrations of DMV shown for 5 minutes at 37°C and then stimulated with lOOnM 
bombesin for I minute (# ). Intracellular arachidonate was quantified by liquid 
scintillation spectrophotometry and result is representative of 6  individual experiments. 
Results are presented as % maximum stimulation ± s.d., which is equivalent to 3500 ± 
2 0 0  dpm and represents bombe sin-stimulated arachidonate release in the absence of any 
inhibitor. The basal level is equivalent to 800 ±150 dpm.
Figure 4.10(b) Effect of DMV upon fMLP-stimulated total [^H]
arachidonate release in 5 day DMSO-differentiated 
HL60 cells.
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium containing 15% 
(v/v) heat-inactivated foetal calf serum and 1.3% (v/v) DMSO and cultured for 5 days. 
17 hours prior to the end of the culturing period 0.25|iCi/ml [4,5,8,9,11,12,14,15-%] 
arachidonic acid was added. 10^ cells per sample were preincubated for 5 minutes at 
37°C with the concentrations of DMV shown, prior to a 5 minute stimulation with 
lOOnM fMLP (# )  at 37°C. Arachidonate was quantified using liquid scintillation 
spectrophotometry and results are presented as % maximum stimulation ± s.d., which is 
equivalent to 4500 ± 230 dpm. The basal level is 800 ± 1 5 0  dpm and the result is 
representative of 2  individual experiments.
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4 .3  DISCU SSIO N
The work presented in this chapter was performed to elucidate the role of 
protein tyrosine phosphorylation in the priming of CPLA2 activity in the models 
presented in Chapter 3.
Published data has suggested that, in differentiated HL60 cells and human |
neutrophils, the priming agent cytochalasin B increases the activity of a tyrosine kinase 
leading to increased responsiveness to subsequent agonist stimulation. Figure 4.1 (a) 
supports this finding since a 5 minute preincubation of 5 day DMSO-differentiated 
HL60 cells with 5|lIM cytochalasin B increased overall tyrosine phosphorylation as 
measured by western blotting. This preincubation did not increase basal levels of free 
arachidonate as described in Chapter 3. This increase in tyrosine phosphorylation is -j;
also visible in Swiss 3T3 fibroblasts chronically primed, i.e. when grown in DMEM 
containing 10% as opposed to 2% (v/v) NBCS (Figure 4.1(b)). Therefore, it appears 
that an increase in tyrosine phosphorylation maybe responsible for both acute and 
chronic priming, as in both cases there is no increase in basal levels of arachidonate, 
but the responsiveness to subsequent agonist stimulation is enhanced. The role of II
tyrosine phosphorylation in the activation of CPLA2 was further investigated using the 
general tyrosine phosphophosphatase inhibitor perhydovanadate. By inhibiting the 
dephosphorylation of tyrosine phosphorylated proteins, a chronic stimulation of 
arachidonate release was observed in Swiss 3T3 fibroblasts (Figure 4.2(a)) quiesced 
under both conditions (the data for 10% NBCS-quiesced cells is shown). The kinetics 
of this response correlated to the second sustained phase of bombesin-stimulated 
arachidonate release in Swiss 3T3 fibroblasts, but care must be taken in drawing any 
conclusions from this because of the time taken for the inhibitor to penetrate the cell 
and to inhibit the phosphatases. With this in mind, Figure 4.2(b) demonstrates that 
0.5mM perhydrovanadate can stimulate arachidonate release in 5 day DMSO- n;
differentiated HL60 cells lending further evidence for a tyrosine phosphorylated 
protein being involved in the activation of CPLA2 , however the kinetics of the 
response was much slower than those seen in response to fMLP-stimulation. Taking
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a 2  minute time point from this data, where there is no detectable perhydrovanadate- 
stimulated arachidonate release, Figure 4.3(a) shows that the cells are primed for 
subsequent fMLP stimulation. The kinetics of this response (Figure 4.3(b)) are very 
similar to those seen in the previous chapter, where cytochalasin B was used as the 
priming agent. Therefore, perhydrovanadate can be substituted for cytochalasin B 
suggesting that it is indeed a tyrosine phosphorylated protein that is responsible for the 
acute priming effect observed in HL60 cells. This is not the only enzyme which has 
been shown to be primed by tyrosine phosphorylation in neutrophils, for instance an 
involvement in the priming of NADPH oxidase in human neutrophils has been 
reported (Lloyds & Hallett, 1995; Phillips & Hamilton, 1990). The kinases affected 
by perhydrovanadate remain to be identified, however, an increase in the 
phosphorylation of both ERKl, ERK2 and a 74kDa protein has been demonstrated 
(Lloyds er tz/., 1995).
In chapter 3, the role of the serum factors insulin and lysophosphatidic acid in 
the chronic priming of Swiss 3T3 fibroblasts was discussed. These data suggested 
that both could prime 2% (v/v) NBCS quiesced cells for subsequent agonist 
stimulation, however the effects varied. Insulin-pretreatment of Swiss 3T3 fibroblasts 
quiesced in 2% (v/v) NBCS did not stimulate CPLA2 , but produced the same kinetics 
of bombesin-stimulated arachidonate release as seen in Swiss 3T3 fibroblasts quiesced 
in 10% (v/v) NBCS, whilst LPA produced a dose-dependent potentiation of 
bombesin-stimulated arachidonate release. This kinetic effect can be explained by an 
increase in tyrosine phosphorylation as shown in Figure 4.4. Both insulin and LPA 
induced an increase in tyrosine phosphorylation similar to that observed in 1 0% 
quiesced cells. However, the proteins that are tyrosine phosphorylated differed 
between the 2  agonists, which might partly explain the differences in the kinetics 
observed. Bombesin stimulation does not visibly increase the overall level of tyrosine 
phosphorylation of pretreated cells. This phenomenon was also evident in cells 
quiesced in 10% (v/v) NBCS as shown in Figure 4.5(a). In this Figure, bombesin-
,1
stimulated tyrosine phosphorylation in 1 0% quiesced cells was only increased after 1
-ils.
minute. However, bombesin had an effect at the earlier time points upon the tyrosine 
phosphorylation in 10% quiesced cells as shown in Figure 4.5(b), where there 
appeared to be a dephosphorylation of an approximately 69kDa protein following 
bombesin-stimulation. This dephosphorylation upon bombesin stimulation could only 
be visualised using a 12.5% (w/v) polyacrylamide gel which produced a better 
resolution of the protein bands around this molecular weight and an HRP-conjugate of 
the monoclonal anti-phosphotyrosine used in all the other phosphotyrosine western 
blots presented. In 2% quiesced cells a transient increase in bombesin-stimulated 
tyrosine phosphorylation was visible, which was maximum at 30 seconds and 
correlated with the kinetics of bombesin-stimulated arachidonate release under these 
quiescing conditions. The level of maximum tyrosine phosphorylation in 2% quiesced 
cells was comparable to the basal level in 1 0 % quiesced cells, suggesting that the 
tyrosine phosphorylated protein involved in the activation of CPLA2 was already 
phosphorylated in 10% quiesced cells, i.e. primed, with agonist stimulation producing 
the additional signal required to fully activate CPLA2 . In 2% quiesced cells, agonist 
stimulation was required for the tyrosine phosphorylation of this putative activating 
protein in addition to the additional signal required for maximal arachidonate release.
This could, therefore, explain the slower kinetics of bombesin-stimulated arachidonate 
release.
Other agonists also show a differential pattern of protein tyrosine 
phosphorylation in 2% and 10% quiesced cells (Figure 4.6). The receptor tyrosine 
kinase agonists insulin (Goldstein, 1992) and platelet derived growth factor (Williams,
1989), significantly increased tyrosine phosphorylation. The lipid agonist 
lysophosphatidic acid (LPA), which is reported to mediate its effects via a G-protein 
coupled receptor (van der Bend et ah, 1992) also increased the overall level.
However, the phorbol ester TPA appeared to stimulate a decrease in basal tyrosine 
phosphorylation in 2 % quiesced cells, but an increase in 1 0 % quiesced cells, 
suggesting that activation of protein kinase C has different effects depending upon the 
state of the cells. This could not be studied in greater detail in the time available, but it |
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can be concluded that the level of tyrosine phosphorylation is higher in 1 0% quiesced 
Swiss 3T3 fibroblasts, irrespective of the agonist used. As shown for bombesin- 
stimulated arachidonate release, an additional signal maybe required for maximal
arachidonate release and since the bombesin receptor has been shown to couple to 
PLCy (Plevin et al„ 1990) and that CPLA2 requires calcium for activation (Kramer et 
al., 1986), the additional signal required here may be inositol-1,4,5-trisphosphate 
(IP3)-stimulated intracellular calcium release. This will be discussed in Chapter 5.
Therefore, from work presented in this chapter so far, it appears that a tyrosine 
phosphorylated protein is responsible for both the acute and chronic priming of CPLA2 
observed. However, there is also a tyrosine phosphorylated protein involved in the 
agonist-stimulated arachidonate release. To further elucidate this, the inhibitor 
demethoxyviridin (DMV) was utilised. This compound inhibited bombesin-stimulated 
tyrosine phosphorylation in a dose-dependent manner with an IC;o=10nM (± 2nM)
(Figure 4.7, experiment performed by M.J.Cross). This inhibitor is an analogue of
3the putative potent phosphatidylinositol-3 kinase (PI-3K) inhibitor wortmannin,
,■1
however, the effect upon bombesin-stimulated tyrosine phosphorylation cannot be due 
to inhibition of PI-3 kinase, since there is no bombesin-stimulated PI-3 kinase activity 
in Swiss 3T3 fibroblasts (Cross et a l, 1995). There was a small direct inhibition by 
O.lnM wortmannin of baculovirus expressed CPLA2 activity as shown in Figure 
4.8(a), but only when phosphatidylinositol-4,5-bisphosphate (PtdIns-4 ,5 -P2) was 
included in the micelle adopted in the in vitro assay used. PtdIns-4 ,5 -P2 was a very 
potent activator of CPLA2 , producing a response 5 fold over that observed in the 
absence of PtdIns-4 ,5 -P2 with identical levels of enzyme present (Figure 4.8(b)).
This may suggest that wortmannin has more than one mode of action upon CPLA2 and 
that perhaps, the conformation of the enzyme determines whether or not there is an 
inhibition, as the presence of PtdIns-4 ,5 -P2 in the micelle appeared to allow inhibition 
at the lower wortmannin concentrations. This cannot be the only answer, as CPLA2 -
immunoprecipitated from whole cells was not inhibited by wortmannin (Figure 4.9),
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but in the whole cell, bombesin-stimulated arachidonate release was inhibited in a
:dose-dependent manner to a far greater extent, to that seen for baculovirus expressed
;
cPLA2 (MJ.Cross, personal communication). This suggests that there was both 
direct and indirect inhibitory effects exerted upon CPLA2 by wortmannin. In Swiss 
3T3 fibroblasts (Figure 4.10(a)), bombesin-stimulated arachidonate release was totally 
inhibited by the wortmannin analogue, demethoxyviridlne (DMV), with an IC50 value 
of 2nM (± 2nM), whereas fMLP-stimulated arachidonate release in 5 day DMSO- 
differentiated HL60 cells (Figure 4 .10(b)) was inhibited by 60% with an IC50 value of 
200nM (± 20nM). This suggests that a different regulatory element, maybe a tyrosine 
phosphorylation-regulated protein, was affected to a differing degree in the 2  cell 
types, or that it was affecting a multitude of possible cPLA2-regulatory proteins.
However, western blotting was not sensitive enough to isolate any inhibition at these 
very low concentrations of DMV. One of the main proteins regulated by tyrosine 
phosphorylation, which has been shown to phosphorylate and activate CPLA2 in vitrOy 
is MAP kinase (Lin et a t, 1993), the role of which will be discussed in detail in "9;
Chapter 5.
#
CHAPTER 5
REGULATION OF cPLAi BY MAP KINASE AND INCREASED
■"'114#:
INTRACELLULAR CALCIUM CONCENTRATION
5 .1  Introduction
In chapter 4, it was shown that both acute priming by cytochalasin B in HL60 
cells and chronic priming of Swiss 3T3 fibroblasts by serum, resulted in an increase in 
tyrosine phosphorylation. One of the main signalling enzymes regulated by a tyrosine 
kinase cascade is MAP kinase (Anderson et aLy 1990). This enzyme is activated by 
phosphorylation upon tyrosine and threonine residues (Haystead et al.y 1992), but 
exibits activity by phosphorylating its target substrates on serine/threonine residues, 
located within a specified recognition sequence (Rao & Reddy, 1993). In vitro studies 
have shown that CPLA2 can be directly phosphorylated on serine 505 by activated 
MAP kinase (Lin et a l ., 1993), The regulation of MAP kinase has been shown to 
involve the ras target raf-1 which is a MAP kinase kinase kinase (Kyriakis et aLy 
1992). MAP kinase is a convergence point for both tyrosine kinase and protein kinase 
C-mediated pathways (Morrison et a l, 1993).
CPLA2 has been shown to contain a CaLB domain (Shaq) et aLy 1991), which 
has been proposed to bind calcium and potentiate the binding of CPLA2 to the 
membrane (Masuda et at., 1991). It has been shown that calcium is essential for 
CPLA2 activity (Leslie et aLy 1988) and it has been proposed that it is required for the 
translocation of the enzyme to its membrane substrate (Channon & Leslie, 1990). 
However, the mechanism involved has yet to be clarified.
In this chapter the role of MAP kinase activation and increased intracellular 
calcium concentrations upon CPLA2 activation and priming are described.
134
I'
5 .2  RESULTS
5 .2 .1  Manipulation of MAP kinase activity using Rat-1
fibroblasts transfected with an estradiol-regulated plasmid 
expressing phosphorylated MAP kinase kinase kinase 
{raf).
In Rat-1 Raf ER4 fibroblasts, the cDNA for the kinase domain of p74^^I was 
fused to the hormone binding domain cDNA of the human estrogen receptor to
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generate the fusion gene product Raf ER (Samuels et aLy 1993). Upon addition of 
l|iM  p-estradiol for 1 hour, the activated raf-1 causes complete phosphorylation of 
ERK 1 and ERK 2 as demonstrated by western blotting (Figure 5.1). This figure also 
demonstrates that a 1 minute stimulation with the complete mitogen for Rat-1 
fibroblasts, lysophosphatidic acid (LPA), did not affect the phosphorylation of either 
MAP kinase isoform, in both estradiol-treated and -untreated Rat-1 Raf ER4 
fibroblasts. Figure 5.2 shows that MAP kinase was not the only tyrosine 
phosphorylated potein affected by raf-1 over expression, since anti-phosphotyrosine 
western blotting showed increased phosphorylation of various proteins. Since in vitro 
analysis has demonstrated the direct phosphorylation of cPLA^ by MAP kinase (Lin et
%aLy 1993), the effect of increased MAP kinase phosphorylation upon LPA-stimulated 
arachidonate release was studied. Figure 5.3(a) demonstrates that estradiol-induced 
Raf-1 expression and thus, MAP kinase phosphorylation, produced an enhanced and 
rapid onset of LPA-stimulated arachidonate release. In estradiol-pretreated Raf ER4 
fibroblasts, LPA-stimulated arachidonate release was detectable at 10 seconds and 
maximal at 30 seconds, 5-6 fold above basal. The cells responded to LPA in the 
absence of estradiol pretreatment, with the same kinetics, but to only 2-3 fold above 
basal- In both cases, the response was still elevated at 5 minutes. Estradiol treatment
Iincreased the efficacy of LPA-stimulated arachidonate release, but did not alter the 
affinity of the LPA-receptor, as the EC50 in both estradiol-treated and -untreated Raf 
ER4 fibroblasts was 200nM ±25nM (Figure 5.3(b)).
5 .2 .2  Effect of acute and chronic priming upon MAP kinase
phosphorylation state and activity.
Figure 5.4 shows that chronic priming of Swiss 3T3 fibroblasts by serum 
apparently increased the level of both MAP kinase isoforms (ERK 1 and ERK 2) 
within the cells, compared to that in cells quiesced in 2% (v/v) NBCS. Whilst there 
was no difference in the ratio of phosphorylated to non-phosphorylated enzyme.
bombesin stimulated a marked increase in the ratio over time, in cells quiesced under 
both conditions.
When 5 day DMSO-differentiated HL60 cells were examined, only ERKl
(44kDa) was recognised (Figure 5.5). When lysates from estradiol-treated and
-untreated Raf ER4 fibroblasts were examined as a comparison, it was clear that
ERKl in DMSO-differentiated HL60 cells was fully phosphorylated, with 5pM
cytochalasin B, lOOnM fMLP and both in conjunction, having no effect upon the
phosphorylation state. The tyrosine phosphophosphatase inhibitor perhydrovanadate
.(0.5mM) produced hyper-phosphorylation of ERKl, which was unaffected by 
cytochalasin B priming.
In order to correlate the phosphorylation of MAP kinase to activity, an in vitro 
assay was utilised. Using myelin basic protein as the substrate, immunoprecipitated 
MAP kinase activity was assayed (Table 5.1). In HL60 cells, which can be primed by 
either cytochalasin B or perhydrovanadate, only the latter produced a significant 
increase in MAP kinase activity. As expected, estradiol-treated Raf ER4 cells showed 
an increased basal level of MAP kinase activity, which was not further increased in 
response to LPA. In the case of Swiss 3T3 fibroblasts, even though there was 
apparently a higher level of both ERKl and ERK2 in 10% (v/v) quiesced cells, there 
was no significant increase in the level of basal MAP kinase activity, compared to cells 
quiesced in 2% (v/v) NBCS. However, in cells quiesced in 10% (v/v) NBCS, there 
was a biphasic MAP kinase activity, which was not detectable in 2% (v/v) quiesced 
cells (Figure 5.6).
136
which may be attributed to PIC-stimulated IP3 generation, which has been previously
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5 .2 .3  Role of agonist-stimulated increased intracellular calcium
concentrations in the activation and priming of cPLA^.
Cytochalasin B has been reported to induce its priming effects by stimulating
.the release of intracellular calcium (Forehand et al., 1989). However, this was not the 
case in 5 day DMSO-differentiated HL60 cells (Figure 5.7(a)). The cells did produce 
receptor-stimulated intracellular calcium release, with a calcium trace being obtained in 
response to lOOnM fMLP. The intracellular calcium concentration increased from 
150nM to approximately 450nM. This showed that the lack of cytochalasin B- 
stimulated intracellular calcium release was not due to the non-viability of the cells.
The other priming agent of 5 day DMSO-differentiated HL60 cells, perhydrovanadate, 
was also without effect upon the level of intracellular calcium concentration, as shown 
in Figure 5.7(b). Therefore, an increase in the intracellular calcium concentration was 
not responsible for the acute priming effects observed in 5 day DMSO-differentiated 
HL60 cells.
The effect of an increased intracellular calcium concentration upon bombesin-
stimulated arachidonate release in Swiss 3T3 fibroblasts quiesced in 10% (v/v) NBCS
was studied using the calcium chelator BAPTA-AM(10fi.M). This compound enters
the cell, where it is cleaved by non-specific lipases, to produce the active chelator
.BAPTA. Figure 5.8(a) demonstrates that preincubation with B APT A-AM inhibited 
bombesin-stimulated arachidonate release by 40-50%. LPA-stimulated arachidonate 
release in both estradiol-treated and -untreated Raf ER4 fibroblasts was totally 
inhibited after preincubation with this intracellular calcium chelator (Figure 5.8(b)).
These observations demonstrate that calcium plays a major role in the activation of 
CPLA2 in chronically primed cells, but do not point to a role in the priming per se.
Agonist-stimulated increased intracellular calcium concentrations were 
measured in Swiss 3T3 and Raf ER4 fibroblasts, which had been loaded with the 
fluorescent dye Indo-1. In Swiss 3T3 fibroblasts quiesced in both 2% (v/v) and 10%
:(v/v) NBCS, bombesin stimulated a rapid rise in intracellular calcium concentrations.
I
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idemonstrated in bombesin-stimulated Swiss 3T3 fibroblasts (Cook et al.,
1990)(Figure 5.9). The basal levels did not vary between the quiescing methods, 
suggesting that changes in calcium levels are not involved in the serum-induced 
priming event observed. However, an increase in intracellular calcium concentration 
does have a role in bombesin-stimulated arachidonate release in primed cells, as 
disscused earlier, where BAPTA-AM was shown to inhibit this response by 40-50%.
To rule out the possibility that the partial inhibition by BAPTA of bombesin-stimulated 
arachidonate release was due to incomplete chelation of calcium, the effect of BAPTA 
upon the intracellular calcium concentration was measured. Figure 5.10 demonstrates 
that BAPTA-AM was able to compete with Indo-1, resulting in a total loss of 
bombesin-stimulated increased intracellular calcium fluxes. This data suggests that an 
additional mechanism to calcium changes must be involved in the activation of cPLA^.
BAPTA-AM also effectively chelated LPA-stimulated intracellular calcium 
release in Raf ER4 fibroblasts (results not shown), explaining the total inhibition of 
LPA-stimulated, arachidonate release. The LPA-stimulated increased intracellular 
calcium concentration in estradiol treated- and -untreated Raf ER4 fibroblasts was 
presumably due to an IPg-mediated response (Figure 5.11(a) and (b)). However, the 
increase in [calcium] in estradiol-treated Raf ER4 cells was greater than in the control 
(Figure 5.11(b)), which could not be explained by an estradiol-stimulated release of 
intracellular calcium (Figure 5.12). The LPA-receptor is proposed to be a 7-
■ ■- ■:membrane spanning, G-protein linked receptor which is coupled to IP3-mediated 
intracellular calcium release (van der Bend et a l, 1992; van Corven et a l, 1993), thus 
the effect of estradiol-pretreatment upon LPA-stimulated inositol phosphate generation
was studied. Figure 5.13 shows that estradiol-pretreatment had no effect upon LPA-
■
stimulated inositol-phosphate (IPi) and inositol-1,4-bisphosphate (IP2) generation.
However, the level of LPA-stimulated inositol-1,4,5-trisphosphate (IP3) was greater 
in estradiol-treated Raf ER4 fibroblasts, which could explain the enhanced intracellular 
calcium concentration measured. The total IP4 , IP5 and IPg isoforms appeared to be at 
a lower level in estradiol-treated, compared to estradiol-untreated, Raf ER4
138
139
fibroblasts, suggesting that estradiol may have had an effect on the metabolism of 
inositol-1,4,5-trisphosphate (IP3).
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Figure 5.1 Western blot analysis of estradiol- and LPA-stimulated
phosphorylation of ERKl and 2 in Rat-1 Raf ER4 
fibroblasts.
Raf ER4 fibroblasts were seeded at 2x10^ cells per ml and cultured in DMEM containing 
10% (v/v) NBCS and 400pg/ml geneticin until 80-90% confluent, when medium was 
replaced with DMEM for 48 hours. Cells were washed with DBG and then incubated for 
1 hour at 37°C with either DBG alone or DBG containing IpM p-estradiol. Preincubated 
cells were then stimulated with either DBG or 30p,M LPA in DBG for 30 seconds at 
37°C. Cells were then washed with ice-cold PBS and lysed as described in Materials and 
methods. 40jig total protein was loaded onto 12.5% (w/v) polyacrylamide gels and 
SDS-PAGE carried out. Detection of ERK 1 and ERK 2 was carried out as described in 
Chapter 2, with recognised proteins being visualised by ECL. Result is demonstrative of 
3 individual experiments.
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Figure 5.2 Western blot analysis of estradiol- and LPA-stimulated
tyrosine phosphorylation in Rat-1 Raf ER4 fibroblasts.
Cells were cultured and treated exactly as described in Figure 5.1, with 10|ig total protein 
being loaded onto 10% (w/v) polyacrylamide gels and SDS-PAGE being carried out. 
Tyrosine phosphorylated proteins were detected as described in Materials and methods 
and visualised using ECL. Result is representative of 3 individual experiments.
Kstradiol- and LPA-stimulated tyrosine phosphorylation in Rat I Raf ER4
nbrohlasts
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Figure 5.3(a) Effect of estradiol-pretreatment upon LPA-stimulated
intracellular [^H] arachidonate release in Rat-1 Raf 
ER4 fibroblasts.
Cells were seeded at 2x10^ cells per/ml in DMEM containing 10% (v/v) NBCS and 
400p.g/ml geneticin until 80-90% confluent. The medium was then replaced with DMEM 
containing IjiCi/ml [5,6,8,9,11,12,14,15-^H] arachidonic acid for 48 hours. After this 
time, cells were washed with DBG and then incubated for 1 hour with either DBG alone 
or DBG containing l|iM  p-estradiol. Pretreated cells were then stimulated with either 
30|iM LPA or DBG alone for the times shown. Control values (□) represent those 
obtained for both DBG and estradiol-pretreated cells. The figure represents LPA- 
stimulated intracellular arachidonate release in estradiol-treated (#) and -untreated cells 
(O) and is representative of 3 individual experiments, with the results being presented as 
% basal ± s.d. which is equivalent to 800 ± 35 dpm.
Figure 5.3(b) Dose-dependency of LPA-stimulated intracellular [^H]
arachidonate release in estradiol-treated and -untreated 
Rat-1 Raf ER4 fibroblasts.
Rat-1 Raf ER4 fibroblasts were seeded at 2x10^ cells/ml in DMEM containing 10% (v/v) 
NBCS and 400}ig/ml geneticin until 80-90% confluent. Medium was replaced with 
DMEM containing l|iCi/ml [5,6,8,9,11,12,14,15-^H] arachidonaic acid for 48 hours. 
Labelled cells were then washed with DBG and preincubated with either DBG alone or 
DBG containing IjiM p-estradiol for 1 hour at 37°C. Pretreated cells were stimulated 
with the concentrations of LPA shown for 30 seconds. Result represents LPA-stimulated 
intracellular arachidonate release in (i)control (O) and (ii)estradiol-treated(#)cells. The 
results are presented as % basal ± s.d, which is equivalent to 500±30 dpm and is 
representative of 3 individual experiments.
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Figure 5.4 Western blot analysis of bombesin-stimulated ERKl
and ERK2 phosphorylation in Swiss 3T3 fibroblasts.
Swiss 3T3 fibroblasts were seeded at 2x10^ cells/ml in DMEM containing 10% (v/v) 
NBCS until 80-90% confluent, when medium was replaced with DMEM containing 
either 10% (v/v) or 2 % (v/v) NBCS for 24 hours. Cells were then washed with DBG 
and stimulated with either DBG or lOOnM bombesin for the times shown. Stimulated 
cells were then washed with ice-cold PBS and lysed as described in Materials and 
methods, 40fig total protein was loaded onto 12.5% (w/v) polyacrylamide gels and 
SDS-PAGE electrophoresis carried out. ERKl and ERK2 were identified as described in 
Chapter 2 and visualised using ECL. Result is representative of 3 individual experiments 
where freshly stimulated cells were utilised.
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Figure 5.5 Western blot analysis of MAP kinase isoforms present
in 5 day DMSO-differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cells/ml in RPMI 1640 medium containing 15% (v/v) 
heat-inactivated foetal calf serum and 1.3% (v/v) DMSO and cultured for 5 days. 
Differentiated cells were then washed in RBG prior to the stimulation of 10^ cells with 
either RBG, 5|iM cytochalasin B, lOOnM fMLP or both cytochalasin B and fMLP. 
Stimulated cells were washed with ice-cold PBS and lysed as described in Materials and 
methods. 40pg total protein was loaded onto 12.5% (w/v) polyacrylamide gels and 
SDS-PAGE carried out. MAP kinase isoforms were detected as described in Chapter 2 
and visualised using ECL. Result is representative of 3 individual experiments.
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Table 5.1 In vitro MAP kinase activity in the cell types studied.
Swiss 3T3 fibroblasts were seeded at 2x10^ cells/ml in DMEM containing 10% (v/v) 
NBCS and cultured until 80-90% confluent. Medium was then replaced with DMEM 
containing either 2% (v/v) or 10% (v/v) NBCS for 24 hours. Rat-1 Raf ER4 fibroblasts 
were seeded and cultured in the same way as Swiss 3T3 fibroblasts, but in the presence 
of 400jig/ml geneticin. When 80-90% confluent the medium was replaced with DMEM 
for 24 hours. Quiesced cells were washed with DBG and then stimulated with either 
DBG alone or DBG containing l|iM  (3-estradiol for 1 hour at 37°C. Pretreated cells were 
stimulated with either DBG alone or DBG containing 30|iM LPA for 30 seconds at 3 7 ^ . 
HI.60 cells were seeded at 5x10^ cells/ml in RPMI1640 medium containing 15% (v/v) 
heat-inactivated foetal calf serum and 1.3% (v/v) DMSO and cultured for 5 days. 
Differentiated cells were washed in RBG and resuspended at 10^ cells per ml in RBG. 
10^ cells were used per sample which were pre treated with either RBG alone, RBG 
containing 5pM cytochalasin B for 5 minutes at 37°C or RBG containing 0.5mM 
perhydrovanadate for 2 minutes at 37°C. Preincubated cells were then stimulated with 
either RBG alone or RBG containing lOOnM fMLP for 5 minutes at 37°C. Reactions 
were terminated by washing with ice-cold PBS and lysates prepared as described in 
Materials and methods. Result is representative of 3 individual experiments and is 
presented as cpm of ^ ^P incorporated into myelin basic protein, ± standard deviation, as 
described in section 2.6.2.
Table 5.1
Swiss 3T3,.cell^
2% serum  
10% serum
9 4 0 7 .1
9 0 4 2 .3
±  60.6 
± 424.6
S day ÜMSO-diffgrentiated HL60 çglls
Control 
Cytochalasin B 
Perhydrovanadate
7 4 1 3 .9
7 0 2 2 .8
8 9 9 2 .4
±  208.0 
± 200.0 
±  94.4
Rat-1 Raf ER4 fibroblasts
Control
Estradiol
LPA
Estradiol+LPA
2 3 0 3 .6
4 2 4 0 .6  
2 3 8 8 .2  
4 3 3 6 .0
± 87.4
±  320.0 
± 295.5 
± 100.0
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Figure 5.6 In vitro MAP kinase activity in bombesin-stimulated
Swiss 3T3 fibroblasts quiesced in 10% (v/v) NBCS. 
Swiss 3T3 fibroblasts were seeded at 2x10^ cells/ml in DMEM containing 10% (v/v) 
NBCS and cultured until 80-90% confluent, when medium was replaced with DMEM 
containing either 2% (v/v) or 10% (v/v) NBCS for 24 hours. After quiescing cells were 
washed with DBG and stimulated with either DBG (O) or DBG containing lOOnM 
bombesin (#) for the times indicated. Reactions were terminated by washing with ice- 
cold PBS and lysates prepared as described in Materials and methods. The measure of in 
vitro MAP kinase activity was determined as described in chapter 2, using myelin basic 
protein as the substrate. Result is presented as % basal of cpm of ^^P incorporated into 
myelin basic protein ± s.d. with a basal representing 9000±250 cpm and is representative 
of 3 individual experiments.
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Figure 5.7(a) Cytochalasin B- and fMLP-stimulated intracellular
calcium concentrations in 5 day DMSO-differentiated 
HL60 cells.
HL60 cells were seeded at 5x10^ cells/ml in RPMI 1640 medium containing 15% (v/v) 
heat inactivated foetal calf serum and 1.3% (v/v) DMSO and cultured for 5 days. DMSO- 
differentiated HL60 ceils were washed in RBG (phenol red free) and then incubated at 
37^C for 45 minutes in RBG (phenol red free) containing l|iM  Fura-2-am. 10^ Fura-2 
loaded HL60 cells were treated with 5|iM cytochalasin B or lOOnM fMLP for the time 
indicated and the ratio of calcium-bound and -unbound Fura-2 measured as described in 
Materials and methods. Result is representative of 3 individual experiments and the time 
scale represents the duration of the experiment.
Figure 5.7(b) Perhydrovanadate-stimulated intracellular calcium
concentrations in 5 day DMSO-differentiated HL60 
cells.
Cells were cultured and loaded with Fura-2 as described in Figure 5.7(a). 10  ^cells were 
stimulated with 0.5mM perhydrovanadate for the time shown and the ratio of calcium- 
bound and -unbound Fura-2 measured as described in Materials and methods. Result is 
representative of 3 individual experiments. Time recorded was the duration of the 
experiment.
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Figure 5.8(a) Effect of preincubation with BAPTA-AM, upon
bombesin-stimulated intracellular [^HJarachidonate 
release in Swiss 3T3 fibroblasts quiesced in 10% (v/v) 
N BC S.
Swiss 3T3 fibroblasts were seeded and labelled as previously described in Chapter 3, 
Radiolabelled cells were then washed with DBG and preincubated with either DBG alone 
or DBG containing lOjiM BAPTA-AM for 1 hour at 37®C. Preincubated cells were 
stimulated with either DBG or DBG containing lOOnM bombesin for the times shown, 
resulting in the study of arachidonate levels in contol, non-BAPTA pretreated(O); 
control, BAPTA pretreated(Q); bombesin-stimulated, non-BAPTA pretreated(#) and 
bombesin-stimulated, BAPTA pretreated(B) Swiss 3T3 fibroblasts. Result is 
representative of 2 individual experiments and presented as % basal ± s.d, which is a 
value equivalent in all cases to 800 ± 45 dpm.
Figure 5.8(b) Effect of preincubation with BAPTA-AM upon LPA- 
stimulated intracellular arachidonate release in 
estradiol-treated and -untreated Rat-1 Raf ER4 
fibroblasts.
Raf ER4 fibroblasts were seeded and labelled as previously described in Materials and 
methods. Radiolabelled cells were washed with DBG and preincubated for 1 hour at 
37*^0 with either DBG alone, DBG containing lOjiM BAPTA-AM or DBG containing 
IjiM p-estradiol and 10|iM BAPTA-AM. Pre treated cells were then stimulated with 
either DBG alone or DBG containing SOjaM lysophosphatidic acid (LPA) for the times 
shown at 37°C. This allowed the study of arachidonic acid levels in control, estradiol- 
treated(A); LPA-stimulated(O); LPA-stimulated, BAPTA-treated(#); LPA-stimulated, 
estradiol-treated(Q) and LPA-stimulated, estradiol- and BAPTA-treated(B) Rat-1 Raf 
ER4 fibroblasts. Result is representative of 2 individual experiments and is presented as 
% basal ± s.d. which has a value equivalent to 1000 ± 200 dpm.
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Figure 5.9 Bombesin-stimulated intracellular calcium
concentrations in Swiss 3T3 fibroblasts quiesced in 
either 2%  (v/v) or 10% (v/v) NBCS.
Swiss 3T3 fibroblasts were seeded at 2x10^ cells/ml in DMEM containing 10% (v/v) 
NBCS and cultured on glass coverslips until 80-90% confluent, when medium was 
replaced with DMEM containing either 2% (v/v) or 10% (v/v) NBCS for 24 hours. 
Quiesced cells were washed in DBG (phenol red free) and then incubated for 30 minutes 
at 37°C with DBG (phenol red free) containing IjiM Indo-L Indo-1 loaded Swiss 3T3 
fibroblasts were then stimulated with lOOnM bombesin and the consequent increase in 
intracellular calcium concentrations were measured as described in Materials and 
methods. Result is representative of 3 individual experiments and is presented as the 
ratio of the fluorescence obtained for calcium-bound and -unbound Indo-1 at the time 
shown. Each trace shown is from a single cell measurement and the time scale represents 
the length of the experiment.
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Figure 5.10 Effect of preincubation with BAPTA-AM upon
bombesin-stimulated intracellular calcium 
concentrations in Swiss 3T3 fibroblasts quiesced in 
10% (v/v) NBCS.
Swiss 3T3 fibroblasts were seeded at 2x10^ cells/ml in DMEM containing 10% (v/v) 
NBCS and cultured on glass coverslips until 80-90% confluent, at which time the 
medium was replaced with fresh culture medium. Cells were then washed with DBG 
(phenol red free), prior to incubation for 1 hour with DBG (phenol red free) containing 
lOpM BAPTA-AM at 37®C. 30 minutes prior to the end of the incubation period, IpM 
Indo-1 was added. Preincubated cells were stimulated with lOOnM bombesin for the 
time shown and the intracellular calcium concentration measured as described in Materials 
and methods. Result is representative of 3 individual experiments, which utilised freshly 
cultured Swiss 3T3 fibroblasts, and is presented as the ratio of the fluorescence measured 
for calcium-bound and -unbound Indo-1. Each trace shown is from an individual cell 
measurement and the time scale represents the length of the experiment.
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Figure 5.11(a) LPA-stimulated intracellular calcium concentrations
in Rat-1 Raf ER4 fibroblasts.
Rat~l Raf ER4 fibroblasts were seeded onto glass coverslips at 2x10^ cells/ml in DMEM 
containing 10% (v/v) NBCS and 400|ig/ml geneticin. When 80-90% confluent, medium 
was replaced with DMEM for 24 hours. Quiesced cells were washed with DBG (phenol 
red free) and preincubated for 30 minutes at 37°C with l}xM Indo-1, prior to stimulation 
with DBG (phenol red free) containing 30mM LPA for the time shown. Intracellular 
calcium concentrations were measured as described in Materials and methods. Result is 
representative of 3 individual experiments and presented as the ratio of fluorescence 
measured for calcium-bound and -unbound Indo-1 over the time shown. Each trace is 
from an individual cell measurement and the time scale represents the length of the 
procedure.
Figure 5.11(b) LPA-stimulated intracellular calcium concentrations
in estradiol-treated Rat-1 Raf ER4 fibroblasts.
Rat-1 Raf ER4 fibroblasts were seeded at 2x10^ cells/ml onto glass coverslips and 
cultured until 80-90% confluent. Medium was then replaced with DMEM for 24 hours. 
Quiesced cells were washed with DBG (phenol red free) and preincubated with DBG 
(phenol red free) containing IfiM p-estradiol for 1 hour at 37®C. 30 minutes prior to the 
end of the incubation period, l|iM  Indo-1 was added. Cells were stimulated with DBG 
(phenol red free) containing 30jiM LPA for the time shown and the intracellular calcium 
concentration measured as described in Materials and methods. Result is representative 
of 3 individual experiments and is presented as the ratio of the fluorescence measured for 
calcium-bound and -unbound Indo-1. Each trace is from an individual cell measurement 
and the time scale represents the length of the experiment.
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Figure 5.12 P-estradiol stimulated intracellular calcium
concentrations in Rat-1 Raf ER4 fibroblasts.
Rat-1 Raf ER4 fibroblsts were seeded at 2x10^ cells per ml onto glass coverslips in 
DMEM containing 10% (v/v) NBCS and 400)j.g/ml geneticin and cultured until 80-90% 
confluent. Medium was then replaced with DMEM for 24 hours. Quiesced cells were 
washed with DBG (phenol red free), then incubated with DBG (phenol red free) 
containing l\xM Indo-1 for 30 minutes at 31°C, prior to stimulation with 1|liM p-estradiol 
for the time shown. Intracellular calcium concentrations were measured as described in 
Materials and methods. Result is representative of 3 individual experiments and is 
presented as the ratio of the fluorescence for calcium-bound and -unbound Indo-1. Each 
trace is from an individual cell measurement and the time scale represents the length of the 
experiment
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Figure 5.13 LPA-stimuIated intracellular pH]inositol phosphate
release in estradiol-treated and -untreated Rat-1 Raf 
ER4 fibroblasts.
Rat-1 Raf ER4 fibroblasts were seeded at 2x10^ cells per ml in DMEM containing 10% 
(v/v) NBCS and 400|ig/ml geneticin and cultured until 80-90% confluent. Medium was 
then replaced with DMEM containing 4|iCi/ml inositol for 48 hours.
Radiolabelled cells were washed with DBG and preincubated for Ihour at 37°C with 
either DBG alone or DBG containing IjiM p-estradiol. Pretreated cells were then 
stimulated with either DBG alone or DBG containing 30|iM LPA for the times shown. 
The inositol phosphate groups were separated as described in Materials and methods and 
quantified using liquid scintilation spectrophotometry. Results for control(O); control, 
estradiol-treated(Q); LPA-stimuiated(#) and LPA-stimulated, estradiol-treated(B) Rat-1 
Raf ER4 fibroblasts are representative of 2 individual experiments and presented as dpm 
± s.d.
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5 .3  DISCUSSION
5 . 3 . 1  Manipulation of MAP kinase using Rat-1 fibroblasts
transfected with an estradiol-regulated plasmid expressing 
activated MAP kinase kinase kinase, p74^ /^' .^
When discussing the regulation of MAP kinase, all isoforms must be taken 
into consideration. The isoforms of importance in this work are ERKl (44kDa) and 
ERK2 (42kDa) which are both activated by phosphorylation on tyrosine and threonine 
residues (Hanks etaL, 1988). Using western blotting techniques this phosphorylation 
can be visualised by what is termed the 'band-shift' assay, whereby the 
phosphorylated MAP kinase isoforms are retarded in the gel, thus running at an 
apparently higher molecular weight than their non-phosphorylated counterparts 
(McLees et aL, 1995). This bandshift technique has been widely utilised to study 
many enzymes regulated by phosphorylation. MAP kinase is phosphorylated by MAP 
kinase kinase (Posada & Cooper, 1992), which is in turn phosphorylated by a MAP 
kinase kinase kinase, termed raf~l (Kyriakis et al., 1992). This 74kDa protein is itself 
activated by ras which has been shown to be activated by many agonists upon receptor 
activation (Moodie et aL, 1993). The dual phosphorylation of MAP kinase on both 
tyrosine and threonine residues provides a convergence point for both a tyrosine 
kinase cascade, such as that stimulated by insulin (for review see White & Kahn,
1994) and the classical PKC-mediated response stimulated by agonists which work 
via 7 membrane spanning receptors and src kinases, such as bombesin (Cook etal., 
1990). Therefore, the manipulation of raf-1 is a good tool to study the regulation of 
MAP kinase, and thus, its effects upon its substrates. One such substrate has been 
shown to be cytosolic phospholipase A2 when studied in an in vitro system (Lin et at., 
1993).
Rat-1 Raf ER4 cells are Rat-1 fibroblasts transfected with a plasmid containing 
the kinase domain of p74^«/"  ^ fused to the hormone binding domain of the human 
estrogen receptor, resulting in the fusion gene product Raf ER (Samuels et al., 1993). 
Upon incubation with (3-estradiol, the increased expression of the kinase domain of
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p7 4 '*4/U^ results in fully phosphorylated ERKl and ERK2 (Figure 5.1). This 
construct permits the examination of the role of MAP kinase activation in the absense 
of an input from either p2K^'^ or receptor activation. The full mitogen for Rat-1 
fibroblasts, lysophosphatidic acid (LPA), did not alter the phosphorylated state of 
either ERK isoform after a 1 minute stimulation, irrespective of prior estradiol 
pretreatment (Figure 5.1). This is probably due to the time point chosen for LPA- 
stimulation, as a 5 minute stimulation by LPA has been shown to stimulate the 
phosphorylation of MAP kinase in these cells (Hordijk et a l,  1994). The increased 
MAP kinase phosphorylation correlates with an increase in MAP kinase activity as 
shown in Table 5.1. However, the pretreatment with l|iM  (3-estradiol also increases 
overall tyrosine kinase activity, as various proteins have increased tyrosine 
phosphorylation, as shown by western blotting in Figure 5.2, which maybe due to the 
activation of various proteins involved in the tyrosine kinase cascade initiated by raf-1, 
including MAP kinase. This increase in tyrosine phosphorylation may have an effect 
upon the activation of CPLA2 , but MAP kinase is activated to such an extent that it will
probably be the major kinase involved in the regulation of CPLA2 . Estradiol-treated I
Raf ER4 fibroblasts produced a substantial increase in LPA-stimulated arachidonate 
release, compared to untreated cells (Figure 5.3(a)). In untreated cells, there was a 
monophasic release of arachidonate, which was maximum at 30 seconds, 2-3 fold 
above basal. In estradiol-treated cells, this response was enhanced in magnitude, with 
a maximum response at 30 seconds, 5-6 fold above basal. This demonstrates that 
phosphorylated MAP kinase can increase LPA-stimulated CPLA2 activity but, since the 
basal level of arachidonate is identical in both the estradiol-treated and -untreated Rat-1 
Raf ER4 fibroblasts, does not produce the release of arachidonate alone. This 
suggests that the reported activation of CPLA2 by MAP kinase in vitro, is not the case 
in vivo and that an additional factor in conjunction with MAP kinase phosphorylation 
is required for arachidonate release. This enhanced magnitude of response is mirrored 
in the dose-dependency of LPA-stimulated arachidonate release, but does not effect the 
affinity of the receptor as the EC50 is unaffected (Figure 5.3(b)).
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5 . 3 .2  Effect of acute and chronic priming upon MAP kinase
phosphorylation and activity.
It has been shown that CPLA2 can be primed by the phosphorylation of MAP 
kinase by a ra/-7-mediated cascade. This lead to the possibility that the activation of 
MAP kinase by either or both of the chronic priming agents in serum and cytochalasin 
B, could be involved in the subsequent priming of CPLA2 .
Figure 5.4 demonstrates that Swiss 3T3 fibroblasts quiesced in DMEM 
containing 10% (v/v) NBCS, have a higher level of both ERKl and ERK2, compared 
to cells quiesced in 2% (v/v) NBCS. The ratio of phosphorylated to non- 
phosphorylated ERK 1/2 at basal levels was identical under both quiescing conditions 
and the increase in MAP kinase phosphorylation in response to bombesin, was I
unaffected by the quiescing method employed. Therefore, chronic priming by serum 
does not appear to affect the phosphorylation state of MAP kinase, but does appear to 
enhance the level expression of the MAP kinase isoforms. The higher level of MAP 
kinase in 10% quiesced cells, does not result in a higher level of basal MAP kinase 
enzyme activity as determined by in vitro measurements (Table 5.1), providing further 
evidence that MAP kinase is not involved in the priming event induced by serum in 
Swiss 3T3 fibroblasts. In 10% (v/v) NBCS, there was a biphasic in vitro MAP 
kinase activity. The initial, transient phase was maximum at 10 seconds, returning to 
basal by 30 seconds, the second phase was sustained, maximal at 1 minute and f
remaining elevated at 5 minutes (Figure 5.6). Only the second phase was detectable in 
cells quiesced in 2% (v/v) NBCS (results not shown), suggesting that MAP kinase is 
also primed by semm. This may be one of the factors involved in the priming event of 
CPLA2 observed, but the results highlight the inacuracy of western blot ’band-shifts’ 
as a measure of MAP kinase activity.
In the case of acute priming of CPLA2 by cytochalasin B in 5 day DMSO- 
differentiated HL60 cells, there was no increased phosphorylation of MAP kinase, in 
response to the priming agent, the agonist fMLP or both used in conjunction (Figure 
5.5). However, when compared to the ERKl and ERK2 in control and estradiol-
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treated Rat-1 Raf ER4 fibroblasts, it was clear that only the phosphorylated ERKl was 
present in 5 day DMSO-differentiated HL60 cells. The phosphorylation of ERKl was 
enhanced by the other possible priming agent, perhydrovanadate, suggesting that the 
hyperphosphorylation observed is due to tyrosine phosphorylation. Therefore, in 5 
day DMSO-differentiated HL60 cells a number of tyrosine or other kinases can 
phosphorylate MAP kinase and some of these are active prior to priming. 
Cytochalasin B priminjg does not appear to be mediated through MAP kinase, as it 
does not increase its phosphorylation state, however, the priming event mediated by 
perhydrovanadate, may be due to increased MAP kinase activity. This activity 
increase was confirmed by in vitro measurements (Table 5.1). Therefore, it appears 
that in both serum-primed Swiss 3T3 fibroblasts and cytochalasin B-primed DMSO- 
differentiated HL60 cells, MAP kinase activation is not involved. This may not be the 
case in perhydrovanadate-primed HL60 cells, as this was able to phosphorylate MAP 
kinase, providing the possibility that the priming of differentiated HL60 cells maybe 
via MAP kinase-dependent and -independent pathways. ■
cPLA2 to the membrane upon agonist-stimulated increased intracellular calcium 
concentrations (Channon & Leslie, 1990). Therefore, any manipulation of
5 . 3 . 3  Role of agonist-stimulated intracellular calcium
concentrations in the activation and priming of cPLA^.
cPLA2 can be activated by increased intracellular calcium concentrations 
(Leslie et al., 1988). From the sequence of cPLA2 , a Ca^+-lipid-binding domain 
(CaLB) was identified (Sharp et al., 1991) and may mediate the translocation of
I
intracellular calcium concentration would have an effect upon subsequent cytosolic 
phospholipase A2 activity.
'■iIt was suggested that cytochalasin B treatment increased intracellular calcium, 
however, this was not the case in 5 day DMSO-differentiated HL60 cells. The cells 
used were able to induce a Ca^+ signal as the agonist fMLP produced an apparently 
IPg-mediated intracellular calcium release (Figure 5.7(a)). Figure 5.7(b) demonstrated
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that the alternative priming agent in 5 day DMSO-differentiated HL60 cells, 
perhydrovanadate, did not effect the concentration of intracellular calcium. Therefore, 
it can be concluded that the priming of CPLA2 in 5 day DMSO-differentiated HL60 
cells, is not mediated via increased intracellular calcium concentrations, but that 
agonist-stimulated intracellular calcium release is essential for CPLA2 activity.
This calcium requirement for CPLA2 activity was also shown in Swiss3T3 and 
Rat-1 Raf ER4 fibroblasts. In the presence of the intracellular calcium chelator
BAPTA, bombesin-stimulated arachidonate release in Swiss 3T3 fibroblasts quiesced 
in 10% (v/v) NBCS was inhibited by 40-50% (Figure 5.8(a)), whereas LPA- 
stimulated arachidonate release in both estradiol-treated and -untreated Raf ER4 I
fibroblasts, was totally inhibited (Figure 5.8(b)). The incomplete inhibition of 
bombesin-stimulated arachidonate release in Swiss 3T3 fibroblasts cannot be attributed 
to incomplete chelation of intracellular calcium by BAPTA, as there was a complete 
abolition of bombesin-stimulated increased intracellular concentrations in the presence 
of BAPTA (Figure 5.10). ' Therefore, agonist-stimulated intracellular calcium release 
is essential for LPA-stimulated arachidonate release in Rat-1 Raf ÉR4 fibroblasts, but ";'ï.
there is another factor in conjunction with calcium required for maximal bombesin- 
stimulated aracidonate release in Swiss 3T3 fibroblasts. This additional regulator may 
be a GTP-binding protein as in 10% quiesced Swiss 3T3 fibroblasts, bombesin-
■tstimulated arachidonate release was totally inhibited by GDPpS (Figure 3.10(b)). iHowever, the GTP-binding protein involved appeared to be in the GTP-bound state 
under the exprimental conditions and, since the non-hydrolyzable analogue GTPyS, 
did not potentiate bombesin-stimulated arachidonate release in streptolysin O- 
permeabilised Swiss 3T3 fibroblasts (Chapter 3).
Calcium, however, does not appear to play a role in the priming of CPLA2 by 
serum. In Swiss 3T3 fibroblasts quiesced under both conditions, the basal 
concentration of intracellular calcium was identical, suggesting that serum does not
■induce a sustained elevation of the intracellular calcium concentrations. Nevertheless, 
the bombesin-stimulated intracellular calcium concentration was greater in 10%
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quiesced cells (Figure 5.9), suggesting that PLCy is also affected by serum, since it 
has been well documented that bombesin-stimulated intracellular calcium release is 
mediated via an IPg-stimulated response (Cook et al., 1990). In the case of estradiol- 
treated and -untreated Rat-1 Raf ER4 fibroblasts, the LPA-stimulated increased 
intracellular calcium concentration also appeared to be IP3-mediated (Figure 5.11(a) 
and (b)), from the trace obtained. Of interest, was the apparent elevation of LPA- 
stimulated intracellular calcium release in estradiol-treated Raf ER4 fibroblasts. This 
elevation was not due to estradiol stimulating intracellular calcium release (Figure 
5.12), but may be due to a similar priming effect upon PLCy as observed in Swiss 
3T3 fibroblasts in response to serum. The chronic priming of Rat-1 Raf ER4 
fibroblasts by estradiol elevated LPA-stimulated IP3 production, which was detected
immediately upon the addition of LPA (Figure 5.13). LPA-stimulated IP4 levels were
.also enhanced in estradiol-treated Raf ER4 cells, but were detected at a later time point 
compared to the LPA-stimulated increase in intracellular calcium, which was 
instantaneous. This suggests that IP4-stimulated extracellular calcium entry does not 
play a role in the onset of LPA-stimulated increased intracellular calcium
"•concentrations, however, this is rather ambiguous as all species of IP4 are measured, 
not just that responsible for stimulating extracellular calcium influx.
In conclusion, cytochalasin B-stimulated MAP kinase activity and intracellular 
calcium release does not play a role in the acute priming of cPLA^ in 5 day DMSO- 
differentiated HL60 cells. The chronic priming of Swiss 3T3 fibroblasts is not 
mediated via an increased basal concentration of calcium or MAP kinase activity, but 
calcium is required for maximal CPLA2 activity. The activation of MAP kinase by 
estradiol-pretreatment in Rat-1 Raf ER4 fibroblasts, enhances LPA-stimulated 
arachidonate release, but does not increase the basal levels of arachidonate release, 
suggesting that another factor is required to stimulate CPLA2 . This factor is calcium, 
as BAPTA-pretreatment totally inhibits LPA-stimulated arachidonate release in 
estradiol-treated cells. Chronic priming by serum in Swiss 3T3 fibroblasts and by 
estradiol in Rat-1 Raf ER4 fibroblasts, enhances the concentration of intracellular
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calcium released upon agonist stimulation, suggesting that PLCy is perhaps also 
primed under these conditions. This priming of PLCy was demonstrated by an 
elevation of LPA-stimulated IP3 levels in estradiol-treated Rat-1 Raf ER4 fibroblasts. 
Therefore, chronic and acute priming appears to be due to a tyrosine phosphorylated 
protein (Chapter 3), which is not involved in the MAP kinase cascade. In the case of 
Swiss 3T3 fibroblasts, this protein may feed into CPLA2 activation via a non-MAP 
kinase mediated pathway, or affect the cytoskeletal network as shown for cytochalasin 
B. This possible involvement of the cytoskeleton allows CPLA2 easier access to the 
substrate, bypassing any agonist-stimulated translocation mechanisms that maybe 
required for maximal activity. In this new configuration the enzyme would be more 
susceptible to subsequent agonist-stimulated calcium release, which is essential for 
activity.
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CHAPTER 6
LOCALISATION AND PHOSPHORYLATION STATE OF 
CYTOSOLIC PHOSPHOLIPASE Az UNDER THE CONDITIONS
STUDIED.
• i ''LC, - ' -V J-r -  •
6 .1  INTRODUCTION
In the previous chapters it has been shown that cytosolic phospholipase A2 
activity can be acutely primed by cytochalasin B in 5 day DMSO-differentiated HL60 
cells and chronically primed by serum in Swiss 3T3 fibroblasts. Neither cytochalasin 
B nor serum stimulated phospholipase A2 activity, as shown by arachidonate release, 
but their effect produced enhanced agonist-stimulated arachidonate release (Chapter 3).
Both cytochalasin B and serum induced an increase in tyrosine phosphorylation, 
implying that a tyrosine phosphorylated protein was activated, which did not stimulate 
CPLA2 alone, but enhanced the enzyme's activity to subsequent agonist stimulation 
(Chapter 4). Tyrosine phosphorylation induced by the priming agents, did not *
stimulate MAP kinase activity in vitro, but rq/^7-stimulated MAP kinase activity 
enhanced LPA-stimulated arachidonate release, demonstrating that MAP kinase was a 
positive regulator of CPLA2 (Chapter 5). However, basal levels of CPLA2 activity 
were not affected, therefore, an additional agonist-stimulated signal was required for 
the enhanced activation of cytosolic phospholipase A2 in cytochalasin B-primed HL60 
cells, serum-primed Swiss 3T3 fibroblasts and [3-estradiol-treated Rat-1 Raf ER4 
fibroblasts.
Cytosolic phospholipase A2 activity has been shown to be regulated by various 
factors including protein kinase C (Gronich et aL, 1988) and GTP-binding proteins 
(Cockcroft, 1992). Both Gi2 (Winitz et al., 1994) and rac (Peppelenbosch et al.,
1995) have been implicated in the regulation of CPLA2 activity. The enhancement of 
agonist-stimulated arachidonate release by GTPyS, the non-hydrolysable analogue of 
GTP, was initially thought to be due to the chronic activation of phospholipase C 
(PIC), producing increased intracellular levels of the protein kinase C activator 
diacylglycerol (DAG) and the intracellular calcium mobiliser inositol-1,4,5- 
trisphosphate (IP3). The IP3-mediated response was of more importance when 
studying the acute agonist-stimulated arachidonate release, as PKC only effects the 
second sustained phase of arachidonate release (Currie et al., 1992). IP3 levels 
increase rapidly and transiently in response to bombesin in Swiss 3T3 fibroblasts
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(Cook et a l,  1990), producing an immediate increase in intracellular calcium 
concentrations, which was required for maximal CPLA2 activity (Chapter 5), as 
bombesin-stimulated arachidonate release was inhibited by 50% by the calcium 
chelator BAPTA (Figure 5.8(a)). The regulation of CPLA2 by calcium is through the 
calcium-phospholipid (CaLB) binding site and is thought to confer an active 
conformational state of the enzyme upon calcium binding (Sharp et al., 1991). This 
may result in the translocation of the enzyme from the cytosol to the membrane, which
has been demonstrated by western blotting upon increased intracellular calcium■
concentrations (Channon & Leslie, 1990). Using a 'band-shift' SDS-PAGE system, 
it was shown that it was only phosphorylated CPLA2 that was translocated to the 
membrane upon calcium binding. This phosphorylated form of CPLA2 has been 
shown in vitro to be the more active state of the enzyme (Kramer et al., 1993(a)), 
which would be logical as the membrane contains the enzymes natural substrate, as 
well as many of the suggested regulators of CPLA2.
This chapter addressed the translocation of CPLA2 in response to the priming 
agents and agonists studied throughout this work. The phosphorylation state of the 
enzyme was also examined in order to correlate the location of cytosolic phospholipase 
A2 with its activity.
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6 .2  RESULTS
6 . 2 . 1  Localisation and phosphorylation state of cytosolic
phospholipase A2 in chronically primed Swiss 3T3 and p- 
estradiol treated Rat-1 Raf ER4 fibroblasts.
In Swiss 3T3 fibroblasts quiesced in 10% (v/v) NBCS, the initial, transient, 
bombesin-stimulated arachidonate release was shown to be kinetically quicker than in 
cells quiesced in 2% (v/v) NBCS (Figure 3.4). This phenomenon was attributed to 
priming of cytosolic phospholipase A2 by some factor which was at a high enough 
concentration in 10% serum, to enhance the activity of the enzyme to a subsequent y
agonist stimulation. To examine the localisation and phosphorylation state of CPLA2 
under these conditions, samples were blotted with a rabbit anti-peptide, anti-cytosolic 
phospholipase A2 antibody. Figure 6.1(a) demonstrates that most of the CPLA2 was 
present in the cytosolic fraction when Swiss 3T3 fibroblasts were quiesced in either 
2% or 10% (v/v) NBCS. However, Figure 6.1(a) also demonstrates that in cells 
quiesced in 10% (v/v) NBCS more of the enzyme was in the membrane fraction under 
basal conditions. Only non-phosphorylated CPLA2 was detected in the cytosol and the
.«;i
y|'
ratio of phosphorylated to non-phosphorylated enzyme in the membrane fraction under
: tbasal conditions, was greater in cells quiesced in 10% serum. Upon stimulation with M
i-lOOnM bombesin for 20 or 30 seconds, a translocation of CPLA2 from the cytosolic 
fraction to the membrane fraction was observed in cells quiesced under both 
conditions (Figure 6.1(b)). To determine which membrane compartment the enzyme 
was located confocal microscopy using the same antibody utilised for western blotting 
was performed, with antibody binding being detected using an anti-rabbit fiuorescene 
conjugate. Figure 6.2(a) demonstrates that in cells quiesced in DMEM containing 2%
(v/v) NBCS, the majority of the enzyme is located in the cytosol and extranuclear 
compartment. In cells quiesced in DMEM containing 10% (v/v) NBCS, the enzyme 
was in both the extra- and intra-nuclear regions (Figure 6.2(b)). Therefore, there is an 
apparent difference in the localisation of the enzyme within the cell, depending on the 
quiescing conditions used.
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As MAP kinase activation has been shown to phosphorylate CPLA2 directly in 
vitro, the effect upon the phosphorylation state and localisation of CPLA2 by the 
activation of MAP kinase in Rat-1 Raf ER4 fibroblasts was examined. In Figure 5.1 it 
was shown that MAP kinase in Rat-1 Raf ER4 fibroblasts was in the fully 
phosphorylated form after a 1 hour treatment with l|iM  p-estradiol. Figure 6.3(a) 
demonstrates that in control Rat-1 Raf ER4 fibroblasts, CPLA2 was mainly in the non- 
phosphorylated form. After a 1 hour pretreatment with IfiM p-estradiol a clear 
retardation in the mobility of the enzyme was visualised, corresponding to the 
phosphorylation of CPLA2 . This phosphorylation was confirmed using phosphatase ||
treatment, where the 'band-shift' was abolished and only dephosphorylated enzyme
was detected (results not shown). This figure also demonstrates that a 30 second
.
stimulation with 30jiM lysophosphatidic acid, did not alter the phosphorylation state 
of CPLA2 in either estradiol-treated or -untreated Rat-1 Raf ER4 fibroblasts. This 
phosphorylation of CPLA2 by estradiol-stimulated MAP kinase phosphorylation, was 
due to a direct effect on CPLA2 by the kinase cascade initiated by raf-1, as both 
inhibition of protein kinase C by a PKC-specific inhibitor, RO-31-8220 and chelation 
of intracellular calcium by BAPTA had no effect upon estradiol-stimulated 
phosphorylation (results not shown). Estradiol pretreatment caused a substantial 
phosphorylation of CPLA2 in both the membrane and cytosolic fractions. 30|iM LPA 
did not affect the phosphorylation state at 30 seconds stimulation, whereas lOOnM 
thrombin caused a marked increase in phosphorylated enzyme in the membrane 
fraction (Figure 6.3(b)). Whether this phosphorylated enzyme is due to the 
phosphorylation of enzyme already located at the membrane, or to a translocation of 
phosphorylated enzyme from the cytosoHc fraction is unclear. The phosphorylation of 
CPLA2 by estradiol-stimulated MAP kinase activation appeared to determine the 
localisation of the enzyme visualised by confocal microscopy. In untreated Rat-1 Raf 
ER4 fibroblasts, CPLA2 was detected mainly in an intranuclear location (Figure 
6.4(a)), however, following a 1 hour treatment with l}iM (3-estradiol, there was a 
concentration of the enzyme to a extranuclear compartment (Figure 6.4(b)). There
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appeared to be a distinct structural element to which the enzyme localised in estradiol- 
stimulated cells, rather than being diffusely distributed within the cytosol (Figure 6.5). 
The identity of the region to which the enzyme became associated remains to be 
elucidated.
Quantitation of extra- and intra-nuclear CPLA2 localisation was performed by 
using propidium iodide to stain the nucleus and subtracting the nuclear-associated 
fluorescence from the total fluorescence attributable to CPLA2 (Table 6.1). This 
demonstrated that in Swiss 3T3 fibroblasts quiesced in 2% (v/v) NBCS, the majority 
of CPLA2 was extranuclear and following a 1 minute stimulation of l(X)nM bombesin, 
there was translocation of the enzyme into the nucleus. In cells quiesced in 10% (v/v) 
NBCS, there was a more even distribution between extra- and intra-nuclear 
compartments, with lOOnM bombesin stimulating a translocation of the enzyme into 
the extranuclear compartment. In Rat-1 Raf ER4 fibroblasts CPLA2 was evenly 
distributed between the extra- and intra-nuclear compartments, however, estradiol 
treatment stimulated relocation of the enzyme into an extranuclear location.
As discussed earlier, there was a distinct localisation of the enzyme in the 
extranuclear compartment in estradiol-treated Rat-1 Raf ER4 fibroblasts (Figure 6.5). 
To examine this further, a z-series was taken of estradiol-treated Rat-1 Raf ER4 
fibroblasts (Figure 6.6). In this procedure, latitudinal sections were taken through the 
cell, to determine the localisation. This demonstrates, that as well as a concentration 
of the enzyme to a perinuclear fraction, there is also a polarity to the localisation. It 
was apparent that the enzyme was concentrated on the upper section of the nucleus and 
is not detected on the adherent surface of the cell.
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6 . 2 . 2  Localisation and phosphorylation state of cytosolic
phospholipase in acutely primed 5 day DMSO- 
differentiated HL60 cells and other human cells.
When the phosphorylation state of cPLAg in 5 day DMSO-differentiated HL60 
cells was examined, only the phosphorylated form of the enzyme could be detected 
(Figure 6.7(a)). Therefore, priming by cytochalasin B and perhydrovanadate had no 
apparent effect on the phosphorylation of CPLA2 , since the enzyme was already in the 
fully phosphorylated form. Both priming agents stimulated a translocation of CPLA2 
from the cytosolic fraction to the membrane fraction (Figure 6.7(b)), which would I
explain the higher sensitivity of the enzyme to subsequent fMLP stimulation.
However, fMLP alone stimulated translocation of the enzyme to the membrane 
fraction suggesting that an agonist-stimulated factor was involved. This factor could 
possibly be calcium, which has been shown to stimulate the translocation of CPLA2 
(Channon & Leslie, 1990) and intracellular calcium concentrations have been shown 
to increase upon fMLP stimulation (Figure 5.7(a)). To determine the localisation of 
the enzyme in more detail, confocal microscopy was utilised, however, specific c;
staining could not be detected using the conditions developed for the fibroblastic cells.
This inability to detect specific staining in 5 day DMSO-differentiated cells appeared to 
be a phenomenon of human cells, including human tonsil germinal centres. These 
human cells contained cytosolic phospholipase A2 (Figure 6.8(a)), but the localisation 
of the enzyme in both the isolated cells and tonsil sections could not be determined 
directly by confocal microscopy, due to very high non-specific staining.
Examination of the germinal centre B-cells and cell lines derived from different 
stages of the B- and T-cell maturation pathway demonstrated that cytosolic 
phospholipase A2 was not detectable in the more mature B- and T-cell lines, 
suggesting that there is a difference in the requirements of these cells for cytosolic 
phospholipase A2 activity (Figure 6.8(b)).
5
Figure 6.1(a) Localisation of cytosolic phospholipase A% (CPLA2 )
by western bloting in Swiss 3T3 fibroblasts 
quiesced in DMEM containing either 2% (v/v) or 
10% (v/v) NBCS.
Swiss 3T3 fibroblasts were seeded in 75cm^ flasks in DMEM containing 10% (v/v) 
newborn calf serum (NBCS) until 80-90% confluent when medium was replaced with 
DMEM containing either 2% or 10% (v/v) NBCS for 24 hours. Quiesced cells were 
washed and stimulated for the times shown with either DBG alone or lOOnM bombesin. 
Reaction was terminated by washing with ice-cold phosphate buffered saline (PBS) and 
placing on ice. Membrane and cytosolic fractions were prepared as described in Materials 
and methods. 30|Ltg total protein was loaded onto 12.5% (w/v) polyacrylamide gels and 
SDS-PAGE carried out. Proteins were transferred to nitrocellulose and western blotting 
was carried out using an anti-peptide anti-cPLA2 antibody as described in Chapter 2. 
Detected proteins were visualised using ECL and result is representative of 3 individual 
experiments.
F igure 6.1(b) Localisation and phosphorylation state of CPLA2 in
Swiss 3T3 fibroblasts quiesced in DMEM containing 
either 2% or 10% (v/v) NBCS 
Lysates were prepared as described for Figure 6.1(a). 5|ig total protein was loaded and 
SDS-PAGE carried out, allowing the dye front to run off for 3 hours prior to transfer 
onto nitrocellulose. Transferred proteins were identified as described in Chapter 2 and 
visualised using ECL. Result is representative of 7 individual experiments.
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Figure 6.2(a) Localisation of cPLAi in Swiss 3T3 fibroblasts 
quiesced in DMEM containing 2% (v/v) NBCS by 
confocal microscopy.
Swiss 3T3 fibroblasts were seeded onto microspot microscope slides at 2x10^ cells per 
ml in DMEM containing 10% (v/v) NBCS until 80-90% confluent when medium was 
replaced with DMEM containing 2% (v/v) NBCS for 24 hours. Quiesced cells were 
washed with DBG and reactions terminated by washing with ice-cold PBS. Cells were 
then fixed and stained for confocal microscopy as described in Materials and methods. 
Result is representative of 3 individual experiments. The top panel represents the visible 
staining observed down the microscope and the lower panel is selected cells from the 
visible field. These selected cells are magnified and 'banded' by the software available, 
with red indicating the strongest staining and blue indicating the weakest staining. The 
bar code shown highlights the colours used for the staining intensities.
Figure 6 .2 (b) Localisation of CPLA2 in Swiss 3T3 fibroblasts
quiesced in DMEM containing 10% (v/v) NBCS by 
confocal microscopy.
Swiss 3T3 fibroblasts were seeded onto microspot microscope slides at 2x10^ cells per 
ml in DMEM containing 10% (v/v) NBCS until 80-90% confluent when the medium was 
replaced with fresh culture medium for 24 hours. Quiesced cells were washed with DBG 
prior to the reaction being terminated by washing thouroughly with ice-cold PBS. Cells 
were fixed and stained for confocal microscopy as described in Materials and methods. 
Result is representaive of 3 individual experiments, carried out on freshly prepared cells. 
The upper panel demonstrates the visible staining as observed down the microscope and 
the lower panel showns an alternative 'banding' pattern available, with the brightest areas 
corresponding to the highest amount of staining.
a »
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Figure 6.3(a) Phosphorylation state of CPLA2 in estradiol-treated
and -untreated Rat-1 Raf ER4 fibroblasts.
Rat-1 Raf ER4 fibroblasts were seeded at 2x10^ cell/ml in DMEM containing 10% (v/v) 
NBCS and 400|ig/ml geneticin until 80-90% confluent when medium was replaced with 
DMEM alone for 24 hours. Quiesced cells were washed with DBG and then treated with 
DBG alone or IjiM p-estradiol for 1 hour at 37°C. Treated cells were then stimulated 
with either DBG alone or 30|iM lysophosphatidic acid (LPA) for 30 seconds at 37®C. 
Reactions were terminated by washing with ice-cold PBS. Lysates were prepared as 
described for MAP kinase in vitro assay in Materials and methods. lOjig total protein 
was loaded onto 12.5% (w/v) polyacrylamide gels and SDS-PAGE carried out as 
described in Chapter 2. Result is representative of 2 individual experiments.
Figure 6.3(b) Localisation and phosphorylation state of CPLA2 in
estradiol-treated and -untreated Rat-1 Raf ER4 
fibroblasts by western blotting.
Rat-1 Raf ER4 fibroblasts were seeded in 75cm^ flasks in DMEM containing 10% (v/v) 
NBCS and 400|ag/ml geneticin until 80-90% confluent when medium was replaced with 
DMEM alone for 24 hours. Quiesced cells were then washed with DBG and incubated at 
37°C for 1 hour with either DBG alone or IfiM p-estradiol. Pretreated cells were then 
stimulated for 30 seconds at 37®C with either 30|xM LPA, lOOnM endothelin-1 or lOOnM 
thrombin. Reactions were terminated by washing with ice-cold PBS and placing on ice. 
Membrane and cytosolic fractions were prepared as described in Materials and methods, 
lOfig total protein was loaded onto 12.5% (w/v) polyacrylamide gels and SDS-PAGE 
carried out as described in Chapter 2. Proteins were transferred onto nitrocellulose and 
western blotting carried out as described in Materials and methods. Detected proteins 
were visualised using ECL and result is representative of 3 individual experiments using 
freshly cultured fibroblasts.
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Figure 6.4(a) Localisation of CPLA2 in Rat-1 Raf ER4 fibroblasts 
by confocal microscopy.
Rat-1 Raf ER4 fibroblasts were seeded at 2x10^ cells/ml onto microspot microscope 
slides in DMEM containing 10% (v/v) NBCS and 400jig/ml geneticin until 80-90% 
confluent when medium was replaced with DMEM alone for 24 hours. Cells were 
washed for a total of 30 minutes at 37°C with DBG and then incubated for 1 hour at 
37^C with DBG. Reaction was terminated by washing with ice-cold PBS and placing on 
ice. Slides were fixed and stainined for confocal microscopy as described in Materials 
and methods. Result is representative of 4 individual experiments. The upper panel 
demonstrates the visible staining observed under the microscope and the lower panel 
represents 'banding' of magnified, selected cells from the visible field. The banding 
adopted is presented and explained in Figure 6.4(b).
Figure 6.4(b) Localisation of CPLA2 in estradiol-treated Rat-1 Raf 
ER4 fibroblasts by confocal microscopy
Rat-1 Raf ER4 fibroblasts were seeded at 2x10^ cells per ml onto microspot microscope 
slides in DMEM containing 10% (v/v) NBCS and 400p.g/ml geneticin until 80-90% 
confluent when medium was replaced by DMEM alone for 24 hours. Quiesced cells 
were washed with DBG for 30 minutes at 37°C and then incubated at 37°C for 1 hour 
with DBG containing IjiM p-estradiol. Reaction was terminated by washing with ice- 
cold PBS and placing on ice. Slides were fixed and stained for confocal microscopy as 
described in Materials and methods. Result is representative of 3 individual experiments 
which utilised freshly set up slides and cell batches. The upper and lower panels 
correspond to the conditions described in Fig.6.4(a) and the 'banding' utilised is 
demonstrated with red corresponding to the most highly stained areas and blue for the 
weakest stained.
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Table 6.1 Quantitative analysis of fluorescence attributed to
CPLA2 localisation extra- and intra-nuclear in Swiss 
3T3 and Rat-1 Raf ER4 fibroblasts.
Swiss 3T3 fibroblasts were seeded at 2x10^ cells/ml onto microspot microscope slides in 
DMEM containing 10% (v/v) NBCS until 80-90% confluent when medium was replaced 
with DMEM containing either 2% or 10% (v/v) NBCS for 24 hours. Quiesced cells were 
washed for 30 minutes with DBG at 37°C and then stimulated for 30 seconds at 37°C 
with either DBG alone or lOOnM bombesin. Rat-1 Raf ER4 fibroblasts were seeded at 
2x10^ cells/ml onto microspot microscope slides in DMEM containing 10% (v/v) NBCS 
and 400|ig/ml geneticin until 80-90% confluent when medium was replaced with DMEM 
alone for 24 hours. Quiesced cells were washed with DBG for 30 minutes at 37°C and 
then incubated for 1 hour at 37°C with either DBG alone or IjiM p-estradiol. Reaction 
was terminated by washing with ice-cold PBS and placing on ice.
All slides were fixed and stained as described in Materials and methods with the nucleus 
being stainined using propidium iodide (10p.g/ml). The nucleus could then be isolated 
and thus, the fluorescence attributed to intranuclear CPLA2 could be subtracted from the 
total cell fluorescence, by the software used. Result is representative of 2 individual 
experiments and presented as % total fluorescence attributed to cPLAz detection.
Table 6.1
Swiss 3T3 fibroblasts
2 % control 
2 % stimulation 
1 0 % control 
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Control
P-estradiol treated
45
29
55
71
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Figure 6.5 Qualitative measurement of CPLA2 fluorescence in
relation to location within estradiol-treated Rat-1 
Raf ER4 fibroblasts.
Rat-1 Raf ER4 fibroblasts were seeded at 2x10^ cells per ml onto microspot microscope 
slides in DMEM containing 10% (v/v) NBCS and 400jig/ml geneticin until 80-90% 
confluent when medium was replaced with DMEM alone for 24 hows. Cells were 
washed with DBG for 30 minutes at 37°C and then incubated for 1 hour at 3n^C with 
DBG containing lp,M p-estradiol. Reaction was terminated by washing with ice-cold 
PBS and placing on ice. Slides were fixed and stained as described in Materials and 
methods, with the nucleus being stained using propidium iodide. Confocal microscopy 
was carried out and pixel measurements taken longitudinally through the cell. Result is 
representative of 2 individual experiments.
r iX E L  IN T E K S ir V  P B O r iL C  9% U tH C IN
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Figure 6 . 6  Polarity of cPLA% localisation in estradiol-treated
Rat-1 Raf ER4 fibrobalsts.
Slides of estradiol-treated Rat-1 Raf ER4 fibroblasts were prepared exactly as described 
in Figure 6.5. Latitudinal, or z-sections were taken through the cell, starting at the 
exposed cell area working down to the basal lateral membrane. There are 4 sections 
presented here which run from left to right, top to bottom, going further towards the 
basal lateral membrane. This result is representative of 2 individual experiments.
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Figure 6.7(a) Phosphorylation state of cPLAz in 5 day DMSO-
differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium containing 15% 
(v/v) heat-inactivated foetal calf serum and 1.3% (v/v) DMSO for 5 days. Differentiated 
cells were washed in RBG and resuspended at 2x10^ cells/ml in RBG. 10  ^cells were 
used per sample and preincubated with either RBG alone, 5p.M cytochalasin B for 5 
minutes or 0.5mM perhydrovanadate for 2 minutes at 37°C. Pretreated cells were then 
stimulated with either RBG alone, lOOnM fMLP or 0.5mM perhydrovanadate for 5 
minutes at 37°C. Reaction was terminated by washing twice with ice-cold PBS and 
storing on ice. Lysates were prepared as described for MAP kinase in vitro assay and 
lOjuig total protein was loaded onto 12.5% (w/v) polyacrylamide gels and SDS-PAGE 
carried out as described in Materials and methods. Proteins were transferred to 
nitrocellulose and western blotting carried out as described in Chapter 2 using 
baculovirus expressed cPLA2 as the standard. Result is representative of 3 individual 
experiments.
Figure 6.7(b) Localisation of cPLA% as determined by western
blotting in 5 day DMSO-differentiated HL60 cells.
HL60 cells were seeded at 5x10^ cells per ml in RPMI 1640 medium containing 15% 
(v/v) heat-inactivated foetal calf serum and 1.3% (v/v) DMSO for 5 days. Differentiated 
cells were washed twice with RBG and resuspended at 2x10^ cells per ml in RBG. 10  ^
cells were used per sample and preincubated at 37°C with either RBG or 5|iM 
cytochalasin B for 5 minutes or 0.5mM perhydrovanadate for 2 minutes. Preincubated 
cells were then stimulated with either RBG or lOOnM fMLP for 5 minutes at 37°C. 
Reaction was terminated by washing twice with ice-cold PBS and cytosolic and 
membrane fractions prepared as described in Materials and methods. 10p.g total protein 
was loaded onto 12.5% (w/v) polyacrylamide gels and SDS-PAGE carried out. Proteins 
were transferred to nitrocellulose and western blotting carried out as described in Chapter 
2. Detected proteins were visualised using ECL and result is representative of 3 
individual experiments, which utilised freshly prepared lysates.
A
Phosphorylation of cytosolic phospholipasc In HL60 cells
Phos.-
non .P hos.-
llOkDa
I i
B
tx)cat:oH of cytosolic phospholipasc A% (CPLA2) in 5 day DMSO-dilTcrcntiated
IIL60 cells
110-
Mcin. cyto. mem. cyto.mem.cyto. mem. cyto. 
control cyt.B perv fMLP
+ cyt.ll
178
Figure 6.8(a) Detection of cPLAa in human germinal centres by
western blotting.
Germinal centres were isolated from human tonsils by I.MacDonald, Department of 
Immunology, University of Birmingham. Lysates were prepared as described in MAP 
kinase in vitro assay and 20|ig total protein was loaded onto 12.5% (w/v) polyacrylamide 
gels and SDS-PAGE carried out. Proteins were transferred to nitrocellulose and western 
blotting carried out as described in Chapter 2. Detected proteins were visualised using 
ECL and result is representative of 3 individual experiments. By = B-heavy cells from 
germinal centre mantle; Gc\/2 = Germinal centre 1/2 .
Figure 6.8(b) Detection of cPLA] in human B- and T-lymphocyte
cell lines by western blottting.
Jurkat, Daudi, HL60 and Ramos cells were kindly cultured by Dr.M.M.Harnett, 
Department of Biochemistry, University of Glasgow and lysates were prepared as 
described for MAP kinase in vitro assay in the Materials and methods chapter. Primary 
T-lymphocytes and resting B-lymphocytes were isolated by Dr.B.Cushley, Department 
of Biochemistry, University of Glasgow. 20|ig total protein was loaded onto 12.5% 
(w/v) polyacrylamide gels and SDS-PAGE carried out. Proteins were transferred onto 
nitrocellulose and western blotting carried out as described in Chapter 2. Detected 
proteins were visualised using ECL and result is representative of 3 individual 
experiments.
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6 .3  D IS C U S S IO N
6 . 3 . 1  Localisation and phosphorylation state of cytosolic
phospholipasc A% (CPLA2 ) in chronically primed Swiss 
3T3 and Rat-1 Raf ER4 fibroblasts.
Cytosolic phospholipasc A2 was so named, because it was first purified from 
the cytosol of U937 cells (Clark et aL, 1990). In work carried out on the regulation 
and activation of cytosolic phospholipasc A2 (CPLA2), evidence has been presented 
which suggests that for maximum responsiveness and activity, CPLA2 has to be 
associated with the plasma membrane (Diez et aL, 1992). This would be the obvious 
location for the enzyme, since it is the source of its substrate and regulatory moieties, 
such as GTP-binding proteins. It has also been shown that it is the phosphorylated 
form of the enzyme which is the more active form (Kramer et aL, 1993(a)).
Therefore, to determine the phosphorylation state and the localisation of the enzyme is 
of prime importance in elucidating its regulation.
In previous Chapters, it has been shown that Swiss 3T3 fibroblasts quiesced 
in DMEM containing 10% (v/v) NBCS, CPLA2 was more sensitive to bombesin 
stimulation, resulting in a quicker onset of arachidonate release (Figure 3.5(a)). This I
priming of CPLA2 , may have involved tyrosine phosphorylation and GTP-binding 
proteins, but also manifested itself in a higher proportion of phosphorylated CPLA2 
being located in a membrane fraction, prior to agonist stimulation, compared to cells 
quiesced in 2% (v/v) NBCS (Figure 6.1(b)). This work could not determine whether |
CPLA2 was phosphorylated in the cytosol or when attached to the membrane. 'i-
However, it is more probable that the enzyme is phosphorylated when attached to the 
membrane, or in transit, as no phosphorylated CPLA2 has ever been detected in the 
cytosolic fraction, whereas both phosphorylated and non-phosphorylated enzyme has 
been visible in the membrane fraction. The occurence of phosphorylated enzyme in 
the membrane fraction in response to priming, did not increase the basal levels of 
arachidonate release (Chapter 3). However, it could explain the increased 
responsiveness to bombesin stimulation, since the enzyme is already in its active form
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and in close proximity to both its substrate and potential regulatory moieties. This 
association with a membrane fraction, did indeed appear to have a role in the activation 
of cPLA2 , as the appearance of phosphorylated enzyme in the membrane fraction in 
response to bombesin stimulation, correlated with the kinetics observed for bombesin- 
stimulated arachidonate release in cells quiesced in both 2% and 10% (v/v) NBCS 
(Figure 6.1(b)). However, it has always been suggested that the membrane fraction 
with which the activated form of CPLA2 associates, is the plasma membrane. This 
would be the immediate choice of location of a receptor-regulated signalling enzyme, 
since it is here that the stimulatory elements such as the receptor and GTP-binding 
proteins are situated. This is not the case in Swiss 3T3 fibroblasts quiesced in either 
2% or 10% (v/v) NBCS. Confocal microscopy demonstrated that under both 
quiescing conditions, there was no detectable levels of CPLA2 at the plasma membrane 
(Figure 6.2(a) and (b)). This was not due to inaccessibility of the epitope for the 
antibody, as a second polyclonal antibody raised to an internal sequence of CPLA2 also 
failed to recognise any enzyme at the plasma membrane (result not shown). In cells 
quiesced in 2% NBCS, the majority of the enzyme was in the extranuclear area of the 
cell, whereas in cells quiesced in 10% serum, there was an even distribution between I
the extranuclear and intranuclear compartments. Upon bombesin stimulation, there 
was a translocation of the enzyme into the intranuclear compartment in cells quiesced
Iin 2% serum, whereas in cells quiesced in 10%, this translocation was into the 
extranuclear compartment (Table 6.1). As the cells quiesced in 10% NBCS are 
primed to bombesin stimulation, this localisation would suggest that CPLA2 is j
maximally active when situated in the nucleus. This is substantiated by the
Iintranuclear location of CPLA2 quiesced in 2% NBCS, after 30 seconds bombesin |
I’stimulation as quantified in Table 6.1, which was the time required for maximum 
arachidonate release in cells quiesced under these conditions (Figure 3.5(a)).
The distribution of CPLA2 between the intra- and extra-nuclear compartments 
in Raf ER4 cells at basal levels was very similar to that quantified for Swiss 3T3 
fibroblasts quiesced in 10% (v/v) NBCS (Table 6.1 and Figure 6.4(a)). However, the
enhanced responsiveness seen after estradiol treatment, corresponded to a 
translocation of the enzyme to a membrane fraction (Figure 6.3) in the extranuclear 
compartment. This membrane fraction appeared to be a defined structure, which 
remains to be identified (Figure 6.4(b)). This demonstrated that priming of CPLA2 in 
Swiss 3T3 fibroblasts by some serum factor and the priming of CPLA2 by estradiol- 
stimulated MAP kinase activity in Rat-1 Raf ER4 fibroblasts resulted in a different 
location of the enzyme within the cell. This could be explained by the location of the 
CPLA2 regulatory elements under both conditions. It has been shown that MAP 
kinase translocates to the nuclear membrane upon activation (Lenormand et aL, 1993), 
therefore in estradiol-treated Rat-1 Raf E.R4 fibroblasts, the CPLA2 could be recruited 
to the nuclear membrane by the activated MAP kinase. In the case of Swiss 3T3 
fibroblasts, upon bombesin stimulation a similar localisation was seen, around the 
perinuclear area, which could suggest a recruitment by activated MAP kinase. 
However, the intranuclear location observed at basal levels in Swiss 3T3 fibroblasts 
quiesced in DMEM containing 10% (v/v) NBCS cannot be explained as easily. Work 
carried out has shown that there is a high arachidonate content in the nuclear lipids and 
that the small molecular weight, secretory phospholipasc A2 (SPLA2) isozymes can 
associate with membrane structures within the nucleus, as demonstrated by 
ultrastructural cytochemistry (Maraldi et aL, 1992), making it highly probable that 
cytosolic phospholipasc A2 could do the same. One possibility that must be 
addressed, is that the location of CPLA2 in both basal and primed Swiss 3T3 and Rat-1 
Raf ER4 fibroblasts, could be the same membraneous structure, which interlaces 
within the nucleus and the extranuclear compartment. From electron microscopy 
studies, it has been shown that the golgi and the endoplasmic reticulum, do in fact 
intersperse between the cytosol and the nucleus through pores in the nuclear 
membrane (Kessel, 1983). Therefore, CPLA2 may move to areas within this 
membrane structure, which contain the desired elements required for maximal activity, 
such as MAP kinase. It would, therefore, be the affinity of association of CPLA2 with 
the membrane, both intra- and -extranuclear, that would determine whether or not the
1 8 2
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enzyme could be detected in a membrane or cytosolic fraction, due to the procedure !used to differentiate between cytosol and membrane fractions. The affinity of 
association with the membrane could be determined by the phosphorylation state of the 
enzyme, as it was mainly phosphorylated CPLA2 detected in the membrane fraction.
The polarity of the localisation visualised (Figure 6 .6 ) in estradiol-treated Rat-1 
Raf ER4 fibroblasts, could be explained by the position of the factors which stimulate 
CPLA2 activity. Lysophosphatidic acid has been suggested to bind to a 7 membrane- 
spanning, G-protein linked, plasma membrane receptor, therefore, LPA-stimulated 
arachidonate release is initiated at the plasma membrane of the cell, but the enzyme 
was shown to be located in and around the nucleus. As estradiol-mediated priming of 
CPLA2 did not increase the basal levels of arachidonate and LPA-stimulated 
arachidonate release had an absolute requirement for increased intracellular calcium 
concentrations, it could be advocated that it was the increase in intracellular calcium 
concentrations that mediated the activation of nuclear-associated CPLA2 activity. The 
response to increased calcium concentrations could be immediate as LPA-stimulated 
intracellular calcium release was detectable instantaneously and it has been documented 
that IP3-sensitive calcium pools are present within the endoplasmic reticulum (Gill et 
aL, 1989), the possible location for CPLA2 .
6 . 3 . 2  Localisation and phosphorylation state of cPLAa in acutely
primed 5 day DMSO-differentiated HL60 cells and other 
human cells.
It was shown that in 5 day-DMSO differentiated HL60 cells the cytosolic 
phospholipasc A2 was already in a fully phosphorylated form (Figure 6.7(a)). This 
was not a consequence of differentiation, as it was the same in undifferentiated HL60 
cells (results not shown), but could be due to the high concentration of serum used to 
culture these cells. As shown in Swiss 3T3 fibroblasts (Chapter 3 & 4), serum factors 
can prime CPLA2 , resulting in a higher proportion of phosphorylated enzyme being 
detected, therefore, this could be responsible for the complete phosphorylation of
cPL A 2 in HL60 cells. The hyperphosphorylation of ERKl observed for 
perhydrovanadate-primed DMSO-differentiated HL60 cells, did not appear to affect 
the phosphorylation state of CPLA2 under the same conditions. As with ERKl in 
these cells (Chapter 5), cytochalasin B and fMLP did not increase the phosphorylation
arachidonate release was also observed in various B- and T-lymphocyte cell lines 
(results not shown), however, in this case, there was no detectable cytosolic
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state of cytosolic phospholipasc A2 , suggesting that the highly neutrophil-like state of 
these cells or the culture serum concentration, fully phosphorylated both ERKl and 
CPLA2 , therefore, fully priming these enzymes for subsequent agonist stimulation, 
such as fMLP, which produces an additional intracellular signal, leading to full 
activation of CPLA2 . However, priming by cytochalasin B and perhydrovanadate, did 
induce a translocation of the phosphorylated CPLA2 from the cytosol to a membrane 
fraction (Figure 6.7(b)), suggesting that the role of the priming agent was to induce a 
translocation event, placing the enzyme in a cell location advantageous to the 
production of maximal activity upon agonist stimulation. Therefore, priming appears 
to be due to an effect upon the structural location of CPLA2 , as it requires the 
translocation of the enzyme from the cytosolic fraction to a membrane structure. It has 
been suggested that both calcium and MAP kinase-stimulated phosphorylation of 
CPLA2 is responsible for this translocation, however, in the work carried out here, it 
has been shown that these factors are only involved in the regulation of agonist- 
stimulated CPLA2 activity. All priming agents studied stimulate tyrosine 
phosphorylation, therefore, a possible cytoskeletally-associated protein could be 
tyrosine phosphorylated, leading to a manipulation of the cytoskeleton, which allows
CPLA2 to associate with its substrate and regulatory moitiés more advantageously.
The location of CPLA2 may have a role to play in other human haemopoietic 
cell, such as germinal centres (for review see MacLennan et aL, 1992). These primary 
B-lymphocytes isolated from human tonsils had cytosolic phospholipasc A2 present 
(Figure 6.8(a)), however, a CD40- or IgM-stimulated arachidonate release, could not 
be detected within these cells (results not shown). This lack of agonist-stimulated
phospholipasc A2 present (Figure 6.8(b)). This was very interesting as these cell 
lines, including HL60 cells, were derived from cells further down the maturation 
pathway of haemopoietic cells, suggesting that somewhere along the maturation 
process, there is a loss of CPLA2 in some cell types but not others. Why this is the 
case would be a very interesting future project.
In conclusion, it was shown that in the fibroblastic cell types studied, cytosolic 
phospholipasc A2 was not located at the plasma membrane as had been suggested. 
The location was in and around the nuclear area of the cell, depending on the activation 
state of the enzyme. Priming by serum in Swiss 3T3 fibroblasts produces a different 
location of the enzyme, compared to rdz/-f-stimulated MAP kinase activation in Rat-1 
Raf ER4 fibroblasts. However, the location under both priming conditions, maybe 
due to the position of substrate and regulatory elements within the same membrane 
structure. Acute priming of 5 day DMSO-differentiated HL60 cells, also resulted in 
the translocation of the enzyme to a membrane fraction, the nature of which could not 
be elucidated. In all the priming conditions, it appeared that it was the appearance of 
phosphorylated CPLA2 the membrane which directed activation.
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The work presented in this thesis supported proposals presented in the 
literature regarding the regulation of cytosolic phospholipasc A2 , however it also 
demonstrated that the regulation cannot be related to an assumed plasma membrane 
location of the enzyme.
7 .1  The implications of the nuclear location of cytosolic
phospholipasc A2
In Chapter 6 , confocal microscopy clearly demonstrated that the enzyme was 
not detectable at the plasma membrane under any condition studied in the fibroblastic 
cell lines utilised. Western blot analysis did show that CPLA2 could be detected as a 
llOkDa protein in both the cytosol and membrane fractions of Swiss 3T3 and Rat-1 
Raf ER4 fibroblasts. However, the membrane fraction contained all cellular 
membranes, including the plasma membrane. In published work the membrane 
location of CPLA2 had been assumed to be the plasma membrane, however from 
Chapter 6 , it was demonstrated that CPLA2 was-associated with a membrane structure
'Î;which appeared to be located in both the extra- and intra-nuclear compartments. If the 
'dogma' of signalling enzymes can be put to one side, this 'nuclear' location of CPLA2 
can be shown to be highly beneficial to the cell.
When the first studies demonstarted that CPLA2 was located in both the cytosol 
and membrane fractions prepared from cell fractionation, (Rehfeldt et aL, 1991;
Krause et aL, 1991) it was assumed that the membrane in question was the plasma 
membrane. This assumption was due to various pieces of evidence that suggested that 
CPLA2 was regulated by receptor-coupled heterotrimeric G-proteins (Cockcroft,
1992). The involvement of G-proteins in the regulation of CPLA2 has been widely 
studied and depending upon the cell and agonist used, a pertussis toxin-sensitive and - 
insensitive G-protein has been implicated (Cockcroft & Stutchfield, 1989; Fischer & 
Schonbrunn, 1988). Pertussis toxin ADP-ribosylates Gi and Go a  subunits, 
preventing association with the effector (for review see McDonald & Moss, 1994), 
which could include PIC. This is of importance due to the activation of CPLA2 by an
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increase in intracellular calcium concentrations (Bonventre et aL, 1988), which can be 
stimulated by calcium release from Ins-1,4,5 -P3-sensitive pools located within the 
endoplasmic reticulum (for review see Gill et aL, 1989). Therefore, the sensitivity of 
CPLA2 to pertussis toxin, could be due to the sensitivity of the PIC-associated G- 
protein, therefore inhibiting arachidonate release indirectly. The involvement of a 
pertussis toxin-insensitive G-protein in agonist-stimulated CPLA2 activity can also be 
explained by an indirect effect upon Ins-1,4,5-P3-stimulated intracellular calcium 
release, as the pertussis toxin insensitive G-protein, Gq, has also been shown to be 
associated with PIC (Conklin et aL, 1992). However, this cannot be the complete 
story as Gi2-stimulated arachidonate release has been shown to be independent of 
PIC-stimulated calcium release (Winitz et aL, 1994). In Swiss 3T3 fibroblasts, the 
attenuation of bombesin-stimulated arachidonate release by GTPyS, was only 
observed in cells quiesced by serum deprivation, i.e. in DMEM containing 2% (v/v)
NBCS (Figure 3.9(a)). Under both quiesing conditions, however, bombesin- 
stimulated arachidonate release was completely inhibited by GTPpS (Figure 3.10(b)), ,1suggesting that a GTP-binding protein was indeed involved in the response.
However, it appeared that some other factor restricts the activation of CPLA2 by
187
.:,y
.J:
GTPyS, which maybe due to the activation of a GTP binding protein-mediated 
inhibitory pathway, such as adenylyl cyclase or that CPLA2 has a finite capacity for 
that particular regulatory molecule enhanced by GTPyS stimulation, for example 
calcium. Therefore, Gq could be activated by GTPyS, resulting in elevated intracellular 
calcium concentrations, but CPLA2 would be saturated after a very short time and 
conversely, CPLA2 would be totally inhibited by GTPpS-mediated inhibition of both 
Gq and Gi G-proteins. Finally, GTPyS-stimulated arachidonate release may involve 
the small molecular weight GTP-binding proteins, as in various studies, including the 
work presented here, a GTP-dependence has been shown, which cannot be mimicked 
by the heterotrimeric G-protein activator aluminum fluoride, which is unable to 
activate the small molecular weight G-proteins (Kahn, 1991). These small molecular 
weight GTP-binding proteins were first shown to be involved in vesicular transport
I(for review see Glomset & Farnsworth, 1994), raising the possibility that the GTP- 
dependence of agonist-stimulated arachidonate release could be due to a cellular 
location factor. Perhaps the activation of these raj-like proteins, stimulates the 
translocation of CPLA2 to a more favourable enviroment or membrane compartment. 
This could explain the attenuation of bombesin-stimulated arachidonate release in 2% 
quiesced cells, as it has been shown by confocal microscopy, that the location of 
CPLA2 in these cells differs to that observed in the more agonist-responsive 10% 
quiesced cells (Figure 6.2). As these small molecular weight GTP-binding proteins 
are located within the cytosol, their mediation in the translocation of CPLA2 is 
possible, as upon activation they have been shown to translocate to various membrane 
compartments. The best characterised member of this protein family is p 2F ^ , which 
has been shown to mediate various kinase pathways, by direct receptor coupling (for 
review see Grand & Owen, 1991). One such pathway is the MAP kinase cascade, 
which coincides with increased tyrosine phosphorylation of various proteins (Worthen 
et aL, 1994). Therefore, GTPyS-stimulated ras activity would explain the pertussis 
toxin insensitive activation of CPLA2 and the total inhibition with GTPpS. Another 
member of this family, rac, has been shown to associate with CPLA2 in the NADPH- 
oxidase complex and is essential for maximal superoxide generation (Abo et aL, 
1991). Therefore, it could be responsible for positioning CPLA2 within the active 
complex. Therefore, both heterotrimeric, via either direct coupling to CPLA2 or 
indirect manipulation of PIC-mediated increased intracellular calcium concentrations 
and small molecular weight GTP-binding proteins play a role in the regulation of 
CPLA2 . However, in aU the cases presented, activation of a nuclear-associated CPLA2 
would be possible.
It was shown that the CPLA2 isoform present in Swiss 3T3 fibroblasts had a 
preference for phosphatidylcholine containing arachidonic acid (20:4) at the sn-2 
position of the diacylglycerol backbone (Currie et aL, 1992). This arachidonyl- 
specific cytosolic phospholipasc A2 has been detected in many cell types, mainly by 
biasing in vitro systems utilising a PC micelle (Diez et aL, 1992; Kramer et aL, 1988).
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However, it has been clearly shown that arachidonate was abundant within the nuclear 
phospholipids, especially within phosphatidylcholine and phosphatidylethanolamine
'g(Tasca & Galis, 1988). Therefore, the substrate for the enzyme was in plentiful 
supply within the peri- and nuclear areas. Arachidonate released upon CPLA2 
activation may be a second messenger alone, as it has been shown to release calcium 
from Ins-l,4,5-P3-insensitive pools (Currie et aL, 1992). The possible location of 
these pools could indeed be the nuclear area, as both Ins-l,4,5-P3-sensitive and - I':
insensitive pools have been identified there (Miyazaki, 1995). However, the main role 
of arachidonate is in the production of eicosanoids via the lipoxygenase and |
cyclooxygenase pathways, with enzymes involved in both arachidonate-metabolising 
pathways being located at the nuclear membrane (Rollins & Smith, 1980; Woods et 
aL, 1995).
Known regulatory enzymes of CPLA2 , including MAP kinase and some 
isoforms of protein kinase C (PKC), have also been shown to translocate from the 
cytosol to the nuclear membrane upon agonist stimulation. Both kinase pathways are 
regulated by receptor associated GTP-binding proteins with many of the components 
of the kinase cascade being distributed within the cytosol, therefore allowing the 
transduction of the signal from the plasma membrane to the nucleus (for review see 
Nishizuka, 1995 and Lenormand gf a/., 1993)
Therefore, a nuclear location for CPLA2 is possible and advantageous in both 
regulation and cellular responses involving arachidonate [for a possible scheme see 
Figure 7.1],
7 .2  The possible protein kinase C ’loop'
In the case of protein kinase C, CPLA2 activation may play a role in the 
regulation of various PKC isoforms. CPLA2 does not only hydrolyse arachidonate at 
the sn-2 position of the diacylglycerol backbone, but contains a lysophospholipase 
activity, resulting in the hydrolysis of the mainly saturated fatty acids at the sn-l 
position (Leslie, 1991). In Chapter 3, it was shown that endothelin stimulated a dose-
Figure 7.1 Possible regulation of nuclear-associated cytosolic
phospholipase A2.
This is a schematic diagram of the possible regulation of nuclear-associated 
cytosolic phospholipase A2  by extracellular stimuli. The components outlined
include: Q  ^  G-protein-linked receptors Hetrotrimeric
GTP-binding 
QQ Tyrosine kinase receptors proteins
MAPK=Microtubule-associated protein kinase 
PKC=Protein kinase C
ras = 21kDa small molecular weight G-protein 
PIC = Phosphatinositidase C
PtdIns-4,5-P2= phosphatidylinositol-4,5-bisphosphate
Ins-1,4 .5 -P3 = inositol-1.4,5-trisphosphate 
DAG = Diacylglycerol 
Ca-+ = calcium
I a n y  a - i d  j > > s s i h k M a r g e t s  —  —  —  - ►
All arrows represent the possible effectors of the component in question.
Figure 7.1
j Ins-1,4,5-P3
DAG
Fatty acids
R
Nucleus
r? m n i  = pnmed cPLA] 
; iSSm  = active cPLA?
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and time-dependent release of oleic acid (18:1) in Rat-1 fibroblasts and GC mass 
spectrometry demonstrated that many saturated and monounsaturated fatty acids were 
released upon bombesin-stimulation in Swiss 3T3 fibroblasts, which could be due to 
the lysophospholipase activity of cPLA2 - Evidence has shown that this 
lysophospholipase activity can hydrolyse any fatty acid at the sn~l position of 
lysophosphatidylcholine (lysoPtdCho) and oleate at the same position in lysoPtdEth 
and LysoPtdSer (She et aL, 1994). This is of interest as it has been shown that there 
is a requirement for free fatty acids in the maximum activation of certain PKC 
isoforms (McPhail et aL, 1984) and oleate has been implicated in the activation of one 
form of phospholipase D (PLD) (Chalifa et al., 1990), As many agonists have been 
shown to produce biphasic cPLA^ activity (Currie et al., 1992), it can be proposed 
that the initial transient phase of fatty acid release could be responsible for producing 
maximal activity of such enzymes as PLD and PKC. The cellular location of PLD has 
still to be elucidated, however, it has been shown that certain PKC isoforms 
translocate to the nucleus when free fatty acids, diacylglycerol (DAG) and calcium are 
available (for review see Nishizuka, 1995). Since many agonists stimulate both I
cPLA% and PIC (Takuwa et al,, 1987), the factors required for this translocation 
would be available. Therefore, PKC would come into contact with the nuclear 
associated cPLA^ and then regulate the activity of this enzyme by phosphorylation.
This proposition would explain the phorbol-ester-stimulated arachidonate release, 
which corresponds kinetically with the second sustained phase of CPLA2 activity 
produced by many agonists. The only drawback of this arguement is the supply of 
DAG required. One possibility is the involvement of the fatty acid- and DAG- 
insensitive PKC isofbrms, the regulation of which has still to be elucidated. An other k
exciting possibility, is the involvement of PLD, which has been shown to produce a 
sustained phase of PtdCho-derived DAG in response to phorbol esters and bombesin 
(Cook & Wakelam, 1989), with very similar kinetics to those seen for arachidonate 
release. Therefore, this raises the possibility that PLD-mediated DAG production is 
used to produce the chronic stimulation of PKC required for the chronic activation of
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cPLA2 and therefore, eicosanoid production, one of which prostaglandin E2 (PGE2) 
was detectable in Swiss 3T3 fibroblasts after a 10 minute bombesin stimulation 
(Currie, 1991). It also raises the possibility of a regulatory loop for both PKC and 
PLD by cPLA2-stimulated fatty acid release, resulting in the enhancement of activity of 
all 3 enzymes, as outlined in Figure 7.2. However, this analogy depends upon the 
initial, rapid release of fatty acids upon agonist stimulation.
7 .3  Role of phosphorylation in the priming and translocation of
CPLA2
In both the chronic priming of CPLA2 by serum in Swiss 3T3 fibroblasts and 
the acute priming of the enzyme by cytochalasin B in differentiated HL60 cells, there 
was an increase in the level of tyrosine phosphorylation (Figure 4.1), but this did not 
result in an increased MAP kinase activity (Table 5.1) or arachidonate release (Chapter 
5), compared to the unprimed cells. This increased tyrosine phosphorylation may 
have increased the sensitivity of CPLA2 to subsequent agonist stimulation, by perhaps 
modulating the enzyme into a more active configuration or location. In 5 day DMSO- 
differentiated HL60 cells, MAP kinase is in a highly phosphorylated state, perhaps 
due to priming by the high concentration of serum in which the cells are cultured 
(Figure 5.5). However, this phosphorylated MAP kinase did not stimulate the 
translocation of CPLA2 from the cytosol to the membrane, as shown by western 
blotting (Figure 6.7). Only the addition of the priming agents, perhydrovanadate or 
cytochalasin B, stimulated translocation (Figure 6.7). Both these priming agents 
increased tyrosine phosphorylation (Figure 4.1) with only perhyrdrovanadate
f'stimulating any additional in vitro MAP kinase activity (Table 5.1). Therefore, the 
translocation is perhaps via the enhanced tyrosine phosphorylation of a protein 
involved directly or indirectly in the structural alignment of CPLA2 , much in the same 
way rac has been suggested to do in the NADPH-oxidase complex (Abo et aL, 1991).
A readjustment of the cytoskeleton has been shown for cytochalasin B priming 
(Cooper, 1987) and has been suggested to be mediated via an increase in tyrosine
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Figure 7.2 The possible protein kinase C (PKC) 'loop'
This a schematic diagram of a possible cytosolic phospholipase A2 (CPLA2)
and protein kinase C (PKC) ‘loop’. The components described include:
PIP2 = phosphatidylinositol-4,5-bisphosphate
PtdCho = Phosphatidylcholine 
DAG = Diacylglycerol 
Ca2+ = calcium 
PLD = Phospholipase D
MAP kinase = microtubule-associated protein kinase
All arrows show the possible targets of the component of interest.
Figure 7.2
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phosphorylation (Ridley & Hall, 1994). The association of the cytoskeleton with the 
nucleus has been shown, therefore, the structural moiety with which CPLA2 is 
associated with could be the cytoskeleton (Eamshaw & MacKay, 1994). In these 
cells, MAP kinase is so highly phosphorylated that it may have consigned a definite 
localisation of CPLA2 prior to priming, however, confocal studies are not available at 
this moment in time to confirm this.
This definite MAP kinase-stimulated localisation of CPLA2 was observed in 
Rat-1 Raf ER4 fibrobasts. Confocal microscopy demonstrated that in Rat-1 Raf ER4 
fibroblasts CPLA2 is evenly distributed between the extra- and intra-nuclear 
compartments, with a relocation to a structure in the extranuclear compartment upon 
estradiol-mediated raf-1 activity (Figure 6.4). However, this MAP kinase activity
only phosphorylated and did not activate CPLA2 (Figure 5.3(a)). Of interest was the k
'1fact that in both 5 day DMSO-differentiated HL60 cells and estradiol-treated Rat-1 Raf 
ER4 fibroblasts, phosphorylated CPLA2 was detected within the cytosol. In the cell 
fractionation carried out, any weakly membrane associated CPLA2 would appear in the 
cytosolic fraction, along with any true cytosolic enzyme, whereas CPLA2 which has a 
high membrane affinity, will be detected only in the membrane fraction. Work carried 
out in serum-primed Swiss 3T3 fibroblasts showed that only non-phosphorylated 
CPLA2 was ever found in the cytosol, suggesting that weakly associated membrane- 
bound and free cytosolic CPLA2 , were in the non-phosphoylated state (Figure 6.1).
This led to the suggestion that it was phosphorylation of CPLA2 which enhanced the 
affinity of the enzyme for the membrane. However, in many experiments, both 
phosphorylated and non-phosphorylated CPLA2 was found in the membrane fraction 
and as discussed above, phosphorylated enzyme was found in the cytosol of both 
DMSO-differentiated HL60 cells and estradiol-treated Rat-1 Raf ER4 fibroblasts,
'.,4:Therefore, phosphorylation of CPLA2 does not confer high affinity with membranes, 
but may only regulate activity as it has been demonstrated in vitro that phosphorylated 
CPLA2 is the more active form (Kramer et aL, 1993(a)).
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This increased affinity for membrane upon priming appears therefore, to be 
due to an additional factor, which may or may not be mediated via the common factor 
in all the priming models studied, namely increased tyrosine phosphorylation. With 
cPLA2 containing so many as yet unassigned phosphorylation sites, it is possible that
!■the enzyme maybe phosphorylated by some factor, to such an extent that the mobility 
of the enzyme would be unaffected upon SDS-PAGE, but would confer some 
possible conformational change upon the enzyme which results in enhanced membrane 
affinity.
Figure 7.3 demonstrates the possible mechanisms involved in priming in the 
fibroblast models studied, combining both western blotting and confocal microscopy.
In this model it is suggested that for the initial phase of agonist-stimulated CPLA2 
activity, the enzyme has to be located within the nucleus and tightly associated with a 
membrane fraction. Activity is only seen when there is an increase in intracellular 
calcium concentrations. In serum-primed Swiss 3T3 fibroblasts, both MAP kinase 
and PIC appear to be primed, producing a small biphasic MAP kinase activity and 
enhanced calcium release in comparison to serum-deprived cells, which would 
produce the signals required for maximum CPLA2 activity. At later time points of 
agonist stimulation, there is a chronic stimulation of both MAP kinase and 
arachidonate release. The former could mediate the translocation of CPLA2 to the 
perinuclear region as demonstrated in estradiol-treated Raf ER4 fibroblasts, where it 
can be regulated by the activated protein kinase C isoforms, as discussed in section 
7.2.
In conclusion, the work presented in this thesis highlights the need to be 
flexible in the visualisation of the physiological localisation of signalling enzymes and 
to question the 'dogma' which can arise from isolated pieces of investigation. These 
thorough investigations are correct in their own right, however, the conclusions drawn 
are perhaps ambigious. As shown, the absence of CPLA2 from the plasma membrane, 
which was assumed to be the cellular location of activated cytosolic phospholipase A2, 
does not affect its regulation by PKC and MAP kinase as these enzymes are
s
Figure 7,3 Possible mechanism for priming
This is a diagram of the possible mechanism of priming, derived from the data 
presented in this Thesis.
The abbreviations used are: = = phosphorylated CPLA2
P-ser505 = phosphorylated on serine 505 
CPLA2 = cytosolic phospholipase A2
( Li2+ = calcium
M APK = microtubule-associated protein kinase 
The arrows represent the possible targets of the component in question. The 
differences in the shape of cPLAa depends upon the regulatory factors which 
have acted upon it.
Figure 7.3
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translocated to the nuclear membrane upon activation. It does not affect the 
metabolism of the CPLA2 product, free arachidonic acid, as the lipoxygenase and
:cyclo-oxygenase enzymes involved have also been shown to be located at the nuclear 
membrane. Finally, the reported GTP-binding protein involvement can be explained 
by the effect on both inhibitory and stimulatory regulators of CPLA2 , such as cAMP 
and PIC-mediated increased intracellular calcium concentrations, respectively. Both of 
these pathways also supply the link from the plasma membrane-associated agonist 
receptor and the intracellular localisation of CPLA2.
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